0001144204-17-041557.txt : 20170809 0001144204-17-041557.hdr.sgml : 20170809 20170809140625 ACCESSION NUMBER: 0001144204-17-041557 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170809 DATE AS OF CHANGE: 20170809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cryoport, Inc. CENTRAL INDEX KEY: 0001124524 STANDARD INDUSTRIAL CLASSIFICATION: ARRANGEMENT OF TRANSPORTATION OF FREIGHT & CARGO [4731] IRS NUMBER: 880313393 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34632 FILM NUMBER: 171017373 BUSINESS ADDRESS: STREET 1: 17305 DAIMLER STREET CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: (949) 232-1900 MAIL ADDRESS: STREET 1: 17305 DAIMLER STREET CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: CRYOPORT SYSTEMS LLC DATE OF NAME CHANGE: 20010614 FORMER COMPANY: FORMER CONFORMED NAME: CRYOPORT SYSTEMS INC DATE OF NAME CHANGE: 20000923 10-Q 1 v472238_10q.htm 10-Q

 

 
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 10-Q

 

 

 

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

 

For the quarterly period ended June 30, 2017

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-34632

 

 

 

 

CRYOPORT, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Nevada 88-0313393

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

17305 Daimler St.

Irvine, CA 92614

(Address of principal executive offices)

 

(949) 470-2300

(Registrant’s telephone number, including area code)

 

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨ Accelerated filer ¨
       
Non-accelerated filer ¨  (Do not check if a smaller reporting company) Smaller reporting company x
       
Emerging growth company   ¨      

  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ¨

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No   x

 

As of July 31, 2017 there were 24,674,432 shares of the registrant’s common stock outstanding.  

 

 

 

 

 

 

TABLE OF CONTENTS

 

  Page
   
PART I. FINANCIAL INFORMATION 3
   
ITEM 1. Financial Statements 3
   
Condensed Consolidated Balance Sheets at June 30, 2017 (Unaudited) and December 31, 2016 3
   
Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2017 and 2016 4
   
Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2017 and 2016 5
   
Notes to Condensed Consolidated Financial Statements (Unaudited) 6
   
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
   
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 24
   
ITEM 4. Controls and Procedures 24
   
PART II. OTHER INFORMATION 24
   
ITEM 1. Legal Proceedings 24
   
ITEM 1A. Risk Factors 24
   
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
   
ITEM 3. Defaults Upon Senior Securities 25
   
ITEM 4. Mine Safety Disclosures 25
   
ITEM 5. Other Information 25
   
ITEM 6. Exhibits 25
   
SIGNATURES 26

 

 2 

 

 

Cryoport, Inc. and Subsidiary

Condensed Consolidated Balance Sheets

 

   June 30,   December 31, 
  

2017

  

2016

 
   (unaudited)     
ASSETS
Current Assets:          
Cash and cash equivalents  $12,854,526   $4,524,529 
Accounts receivable, net of allowance for doubtful accounts of $60,000 and $75,000, respectively   1,250,731    1,195,479 
Inventories   72,621    89,499 
Prepaid expenses and other current assets   308,929    286,919 
Total current assets   14,486,807    6,096,426 
Property and equipment, net   2,311,680    1,647,104 
Intangible assets, net   29,728    5,000 
Deposits   363,403    363,403 
Total assets  $17,191,618   $8,111,933 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:          
Accounts payable and other accrued expenses  $1,369,223   $1,160,299 
Accrued compensation and related expenses   598,325    419,034 
Related-party notes payable and accrued interest, net of discount of $0 and $6,100, respectively   —    651,934 
Total current liabilities   1,967,548    2,231,267 
Deferred rent liability   196,973    200,264 
Total liabilities   2,164,521    2,431,531 
           
Commitments and contingencies          
Stockholders’ Equity:          
Preferred stock, $0.001 par value; 2,500,000 shares authorized:          
Class A convertible preferred stock — $0.001 par value; 800,000 shares authorized; none issued and outstanding   —    — 
Class B convertible preferred stock — $0.001 par value; 585,000 shares authorized; none issued and outstanding   —    — 
Common stock, $0.001 par value; 50,000,000 shares authorized; 23,992,510 and 17,604,283 issued and outstanding at June 30, 2017 and December 31, 2016, respectively   23,993    17,604 
Additional paid-in capital   142,186,654    129,196,680 
Accumulated deficit   (127,183,550)   (123,533,882)
Total stockholders’ equity   15,027,097    5,680,402 
Total liabilities and stockholders’ equity  $17,191,618   $8,111,933 

  

See accompanying notes to condensed consolidated financial statements.

 

 3 

 

 

Cryoport, Inc. and Subsidiary

Condensed Consolidated Statements of Operations

(unaudited)

 

  

Three Months Ended
June 30,

  

Six Months Ended
June 30,

 
  

2017

  

2016

  

2017

  

2016

 
Revenues  $2,917,378   $1,917,566   $5,629,612   $3,473,111 
Cost of revenues   1,524,189    1,135,616    2,982,926    2,109,354 
Gross margin   1,393,189    781,950    2,646,686    1,363,757 
Operating costs and expenses:                    
     General and administrative   1,789,514    1,429,768    3,492,546    3,244,189 
     Sales and marketing   1,236,833    1,195,638    2,306,768    2,442,664 
     Engineering and development   230,736    135,799    480,579    280,277 
     Total operating costs and expenses   3,257,083    2,761,205    6,279,893    5,967,130 
Loss from operations   (1,863,894)   (1,979,255)   (3,633,207)   (4,603,373)
Other income (expense):                    
   Interest expense   (26)   (21,242)   (15,693)   (102,436)
   Warrant repricing expense   —    (1,929,818)   —    (1,929,818)
   Other income (expense), net   3,463    (1,915)   3,463    (6,787)
Loss before provision for income taxes   (1,860,457)   (3,932,230)   (3,645,437)   (6,642,414)
Provision for income taxes   —    (2,484)   (4,231)   (2,484)
Net loss   (1,860,457)   (3,934,714)   (3,649,668)   (6,644,898)
Undeclared cumulative preferred dividends   —    —    —    (75,460)
Net loss attributable to common stockholders  $(1,860,457)  $(3,934,714)  $(3,649,668)  $(6,720,358)
Net loss per share attributable to common stockholders – basic and diluted  $(0.08)  $(0.28)  $(0.18)  $(0.54)
Weighted average shares outstanding – basic and diluted   23,965,825    14,199,742    20,802,628    12,428,991 

 

See accompanying notes to condensed consolidated financial statements.

 

 4 

 

 

Cryoport, Inc. and Subsidiary

Condensed Consolidated Statements of Cash Flows

(unaudited)

 

  

For the Six Months Ended

June 30,

 
   2017   2016 
Cash Flows From Operating Activities:          
Net loss  $(3,649,668)  $(6,644,898)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   307,905    170,751 
Amortization of debt discounts and deferred financing costs   6,130    72,252 
Stock-based compensation expense   1,565,001    1,538,139 
Warrant repricing expense   —    1,929,818 
Loss on disposal of property and equipment   49,840    140,588 
Provision for bad debt   1,636    2,503 
Changes in operating assets and liabilities:          
Accounts receivable   (56,888)   (400,983)
Inventories   16,878    (68,940)
Prepaid expenses and other current assets   (22,010)   10 
Accounts payable and other accrued expenses   205,633    57,300 
Accrued compensation and related expenses   179,291    (269)
Accrued interest   (1,843)   15,045 
Net cash used in operating activities   (1,398,095)   (3,188,684)
Cash Flows From Investing Activities:          
Purchases of property and equipment   (1,022,321)   (599,115)
Trademark costs   (24,728)   — 
Net cash used in investing activities   (1,047,049)   (599,115)
Cash Flows From Financing Activities:          
Proceeds from the common stock offering, net of offering costs   11,405,924    — 
Proceeds from April 2016 tender offer, net of offering costs   —    2,244,247 
Proceeds from the rights offering, net of offering costs   —    1,000,678 
Proceeds from exercise of stock options and warrants   25,438    — 
Repayment of related-party notes payable   (656,221)   (178,831)
Net cash provided by financing activities   10,775,141    3,066,094 
Net change in cash and cash equivalents   8,329,997    (721,705)
Cash and cash equivalents — beginning of period   4,524,529    5,247,425 
Cash and cash equivalents — end of period  $12,854,526   $4,525,720 
Supplemental Disclosure of Non-Cash Financing Activities:          
Cumulative undeclared preferred dividends recorded upon conversion of Class A convertible preferred stock and Class B convertible preferred stock into common  $—   $1,068,055 
Reclassification of shipper inventory to fixed assets  $—   $38,276 
Leasehold improvements paid by tenant allowance included in accounts payable and other accrued expenses  $—   $200,000 
Issuance of common stock for accrued board of director compensation  $—   $26,901 

  

See accompanying notes to condensed consolidated financial statements.  

 

 5 

 

 

Cryoport, Inc. and Subsidiary

Notes to Condensed Consolidated Financial Statements

For the Three and Six Months Ended June 30, 2017 and 2016

(Unaudited)

 

Note 1. Management’s Representation and Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared by Cryoport, Inc. (the “Company”, “our” or “we”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. However, the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included.

 

Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Transition Report on Form 10-K for the period ended December 31, 2016.

 

The Company has evaluated subsequent events through the date of this filing, and determined that no subsequent events have occurred that would require recognition in the unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.

 

Note 2. Nature of the Business

 

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material. Cryoport actively supports points-of-care, contract research organizations, central laboratories, pharmaceutical and biotechnology companies, contract manufacturers and university researchers.

 

The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”

 

Note 3. Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiary, Cryoport Systems, Inc. All intercompany accounts and transactions have been eliminated. In June 2017, the Company established Cryoport Europe Limited, an English company, as a wholly-owned subsidiary of Cryoport Systems, Inc.

 

Use of Estimates

 

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, related-party notes payable, accounts payable and accrued expenses. The carrying value for all such instruments, except for related-party notes payable, approximates fair value at June 30, 2017 and December 31, 2016 due to their short-term nature. The difference between the fair value and recorded values of the related-party notes payable is not significant.

 

 6 

 

 

Cash and Cash Equivalents

 

The Company considers highly liquid investments with original maturities of 90 days or less to be cash equivalents.

  

Customers

 

The Company grants credit to customers within the United States and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at June 30, 2017 and December 31, 2016 are net of reserves for doubtful accounts of $60,000 and $75,000, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.

 

The Company’s customers are in the biotechnology, pharmaceutical and life sciences industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. There were no customers that accounted for more than 10% of net accounts receivable at June 30, 2017 and December 31, 2016.

 

The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During the six months ended June 30, 2017 and 2016, the Company had revenues from foreign customers of approximately $714,600 and $508,400, respectively, which constituted approximately 12.7% and 14.6%, respectively, of total revenues. For the six months ended June 30, 2016, there was one customer that accounted for 10.9% of total revenues. No other single customer generated over 10% of total revenues during the six months ended June 30, 2017 and 2016.

 

Inventories

 

The Company’s inventories consist of packaging materials and accessories that are used as part of the solutions provided by the Company to its customers or are sold to customers directly. Inventories are stated at the lower of cost and net realizable value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.

 

Property and Equipment

 

The Company provides shipping containers, the Cryoport Express® Shippers, to its customers and charges a fee in exchange for the use of the container. The Company’s arrangements are similar to the accounting standard for leases since they convey the right to use the container over a period of time. The Company retains the title to the containers and provides its customers the use of the container for a specific shipping cycle. At the culmination of the customer’s shipping cycle, the container is returned to the Company. As a result, the Company classifies the containers as property and equipment for the per-use container program.

 

Property and equipment are recorded at cost. Cryoport Express® Shippers and data loggers, used as part of the Company’s SmartPak Condition Monitoring Systems, which comprise 52% and 44% of the Company’s net property and equipment balance at June 30, 2017 and December 31, 2016, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Equipment acquired under capital leases is amortized over the estimated useful life of the assets or term of the lease, whichever is shorter and included in depreciation and amortization expense.

 

 7 

 

 

Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the condensed consolidated statements of operations.

 

Intangible Assets

 

Intangible assets are comprised of patents and trademarks and software development costs. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The Company capitalizes certain costs related to software developed for internal use. Software development costs incurred during the preliminary or maintenance project stages are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized using the straight-line method over the estimated useful life of the software, which is five years. Capitalized costs include purchased materials and costs of services including the valuation of warrants issued to consultants.

 

Long-lived Assets

 

If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through June 30, 2017.

 

Deferred Financing Costs

 

Deferred financing costs represent costs incurred in connection with the issuance of notes payable and equity financings. Deferred financing costs related to the issuance of debt are reported as a direct deduction from the face amount of the related debt, and are amortized over the term of the financing instrument using the effective interest method. Offering costs from equity financings are netted against the gross proceeds received from the related equity financing.

 

Income Taxes

 

The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes, or ASC 740. As of June 30, 2017 and December 31, 2016, there were no unrecognized tax benefits included in the accompanying condensed consolidated balance sheets that would, if recognized, affect the effective tax rates.

 

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company’s income tax provision consists of state minimum taxes.

 

The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its condensed consolidated balance sheets at June 30, 2017 and December 31, 2016 and has not recognized interest and/or penalties in the condensed consolidated statements of operations for the three months ended June 30, 2017 and 2016. The Company is subject to taxation in the U.S. and various state jurisdictions. As of June 30, 2017, the Company is no longer subject to U.S. federal examinations for years before 2012 and for California franchise and income tax examinations for years before 2011. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by United States federal or state jurisdictions.

  

Revenue Recognition

 

The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company’s arrangements are similar to the accounting standard for leases since they convey the right to use the containers over a period of time. The Company retains title to the containers and provides its customers the use of the container for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the container is returned to the Company.

 

 8 

 

 

The Company recognizes revenue for the use of the shipper at the time of the delivery of the shipper to the end user of the enclosed materials, and at the time that collectability is reasonably certain. Revenue is based on gross amounts, net of discounts and allowances.

 

The Company also provides logistics support and management to some customers, which may include onsite logistics personnel. Revenue is recognized for these services as services are rendered and at the time that collectability is reasonably certain.

 

Accounting for Shipping and Handling Revenue, Fees and Costs

 

The Company classifies amounts billed for shipping and handling as revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.

 

Engineering and Development Expenses

 

Expenditures relating to engineering and development are expensed in the period incurred.

 

Stock-Based Compensation

 

The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.

 

The Company accounts for forfeitures of unvested awards as they occur. The Company’s stock-based compensation plans are discussed further in Note 7.

 

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

 

Issuances of the Company’s common stock for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.

  

Basic and Diluted Net Income (Loss) Per Share

 

We calculate basic and diluted net income (loss) per share attributable to common stockholders using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for deemed preferred stock dividends and cumulative preferred stock dividends, whether they are earned or not during the period. In periods of a net loss position, basic and diluted weighted average shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt and convertible preferred stock outstanding during the periods. As of June 30, 2017 and December 31, 2016, the Company had no cumulative, undeclared, dividends that have not been accrued related to its preferred stock. During the six months ended June 30, 2017 and 2016, undeclared dividends totaling $0 and $75,460, respectively, were added to the net loss on the condensed consolidated statements of operations in order to calculate net loss per share attributable to common stockholders.

 

 9 

 

 

The following shows the amounts used in computing net loss per share for the six months ended June 30, 2017 and 2016:

 

   Six Months Ended June 30, 
   2017   2016 
Net loss  $(3,649,668)  $(6,644,898)
Add:          
Undeclared cumulative preferred dividends   —    (75,460)
Net loss attributable to common stockholders  $(3,649,668)  $(6,720,358)
Weighted average common shares issued and outstanding - basic and diluted   20,802,628    12,428,991 
Basic and diluted net loss per shareattributable to common stockholders  $(0.18)  $(0.54)

  

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

 

   Six Months Ended June 30, 
  

2017

  

2016

 
Stock options    513,746    58,269 
Warrants    875,947    2,495,464 
    1,389,693    2,553,733 

 

Segment Reporting

 

We currently operate in one reportable segment and our Chief Executive Officer is the chief operating decision maker.

 

Fair Value Measurements

 

We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:

 

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.

 

Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

 

 In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.

 

We have no assets or liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016.

 

Foreign Currency Transactions

 

We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any of the periods presented.

 

 10 

 

 

Balance Sheet Arrangements

 

We do not currently have any off balance sheet arrangements.

 

Recent Accounting Pronouncements

 

In May 2014, the FASB issued Accounting Standard Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 supersedes the revenue recognition requirements in FASB Topic 605, “Revenue Recognition”. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. In August 2015, the FASB issued ASU No. 2015-14 which deferred the effective date by one year for public entities and others. The amendments in this ASU are effective for interim and annual periods beginning after December 15, 2017 for public business entities, certain not-for-profit entities, and certain employee benefit plans. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Management has not selected a transition method and is currently assessing the impact the adoption of ASU 2014-09 will have on our consolidated financial statements.

 

 In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory”. The amendments in this update apply to inventory that is measured using first-in, first-out (FIFO) or average cost. They do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. Other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost and net realizable value for inventory within the scope of this update, there are no other substantive changes to the guidance on measurement of inventory. The amendments in this update more closely align the measurement of inventory in International Financial Reporting Standards (IFRS) and are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2015-11 did not have an impact on our consolidated financial statements.

 

In February 2016, the FASB issued ASU 2016-02, “Leases”, which provides for a comprehensive change to lease accounting. The new standard requires that a lessee recognize a lease obligation liability and a right-to-use asset for virtually all leases of property, plant and equipment, subsequently amortized over the lease term. The new standard is effective for fiscal years beginning after December 15, 2018, with a modified retrospective transition. Management is currently evaluating the impact this standard will have on our consolidated financial statements.

 

In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amendments in this ASU are effective for the reporting periods beginning after December 15, 2016 and early application is permitted. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2016-09 did not have an impact on our consolidated financial statements.

 

Note 4. Related-Party Transactions

 

As of June 30, 2017 and December 31, 2016, the Company had aggregate principal balances of $0 and $646,700, respectively, in outstanding unsecured indebtedness owed to three related parties, including former members of the Board of Directors, representing working capital advances made to the Company from February 2001 through March 2005.

 

Related-Party Notes Payable

 

On March 1, 2016, we entered into definitive agreements with Patrick Mullens, M.D., Maryl Petreccia and Jeffrey Dell, M.D. to amend and restate the outstanding notes pursuant to certain Second Amended and Restated Promissory Notes dated as of February 29, 2016 (the “Amended and Restated Notes”). As of March 31, 2017, the three note holders had outstanding principal balances of $268,900, $160,000 and $125,400, respectively. The Amended and Restated Notes increased the interest rate to 7% per annum, extended the term to April 1, 2017, and modified the repayment provisions to provide for (i) repayment on March 1, 2016 of the outstanding amount of interest accrued through February 29, 2016, (ii) repayment of 10% of the original principal balance and accrued interest of such notes on a quarterly basis commencing April 1, 2016, and (iii) payment of the remaining outstanding balance on April 1, 2017. In addition, we issued such note holders warrants for the purchase of 11,910, 7,088, and 5,553 shares, respectively, of our common stock at an exercise price of $1.88 per share, immediately exercisable and expiring on April 1, 2019. The Company also agreed to reimburse up to $5,000 of legal fees incurred by the note holders. The relative fair value of the warrants issued in March 2016 of $26,900 was recorded as a debt discount and was amortized to interest expense using the straight-line method which approximated the effective interest method over the term of the related-party notes. During the six months ended June 30, 2017 and 2016, $6,100 and $8,200 of the debt discount was amortized to interest expense. The notes were repaid in full in April 2017.

 

 11 

 

 

Related-party interest expense under these notes was $9,600 and $30,183 for the six months ended June 30, 2017 and 2016, respectively. Accrued interest, which is included in related-party notes payable in the accompanying condensed consolidated balance sheets, amounted to $0 and $11,400 as of June 30, 2017 and December 31, 2016, respectively.

 

Note 5. Commitments and Contingencies

 

Facility and Equipment Leases

 

We lease 27,600 square feet of corporate, engineering and development, and warehouse facilities in Irvine, California under an operating lease expiring February 28, 2023, subject to our option to extend the lease for two additional five-year periods. The initial base rent is approximately $24,700 per month. This lease agreement contains certain scheduled annual rent increases which are accounted for on a straight-line basis. We also lease certain office equipment which expires in March 2018.

 

Employment Agreements

 

We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.

 

Consulting and Engineering Services

 

On September 16, 2015, the Company entered into the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), by and between KLATU Networks, LLC (“KLATU”) and the Company. Pursuant to the Purchase and Sale Agreement, the Company purchased from KLATU certain intellectual property and intellectual property rights related to the Company’s CryoportalTM logistics management platform (the “Developed Technology”), which KLATU previously developed for and licensed to the Company pursuant to the Master Consulting and Engineering Services Agreement, by and between KLATU and the Company, dated October 9, 2007 (as amended, the “Master Consulting and Engineering Services Agreement”). As full compensation for the sale and assignment of the Developed Technology from KLATU to the Company, the Company paid KLATU an aggregate amount of $400,000 in two equal installments of $200,000.

 

Concurrently with entering into the Purchase and Sale Agreement, on September 16, 2015, the Company and KLATU entered into the Amended and Restated Master Consulting and Engineering Services Agreement (the “Amended and Restated Master Consulting and Engineering Services Agreement”) to amend and restate the Master Consulting and Engineering Services Agreement. The Amended and Restated Master Consulting and Engineering Services Agreement provides a framework for KLATU to perform certain consulting, software and hardware engineering development services as mutually agreed upon and further set forth in one or more Statements of Work (as defined in the Amended and Restated Master Consulting and Engineering Services Agreement). To ensure the availability of KLATU personnel to perform services pursuant to the Amended and Restated Master Consulting and Engineering Services Agreement, the Company agreed to pay KLATU a minimum of $25,000 per month for services fees, which may be carried forward as advance payment for future services under certain conditions. The initial term of the agreement is until December 31, 2017 and will thereafter automatically renew for subsequent one year terms, unless notice of termination is given.

 

Consulting fees for services provided by KLATU were $115,500 and $157,270 for the six months ended June 30, 2017 and 2016, respectively.

 

Litigation

 

The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. In the opinion of management, there are no legal matters involving the Company that would have a material adverse effect upon the Company’s consolidated financial condition or results of operations.

 

Indemnities and Guarantees

 

The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying condensed consolidated balance sheets.

 

 12 

 

 

The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility lease, the Company has indemnified its lessor for certain claims arising from the use of the facility. The duration of the guarantees and indemnities varies, and is generally tied to the life of the agreement.

 

Note 6. Stockholders’ Equity

 

Authorized Stock

 

The Company has 50,000,000 authorized shares of common stock with a par value of $0.001 per share which were increased in November 2015 upon approval from our stockholders from 20,833,333 authorized shares. In September 2011, our stockholders approved an amendment to the Amended and Restated Articles of Incorporation to authorize a class of undesignated or “blank check” preferred stock, consisting of 2,500,000 shares at $0.001 par value per share. Shares of preferred stock may be issued in one or more series, with such rights, preferences, privileges and restrictions to be fixed by the Board of Directors. In May 2014, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation which designated 800,000 shares of the Company’s previously authorized preferred stock, par value $0.001, as Class A Convertible Preferred Stock. In February 2015, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation which designated 400,000 shares of the Company’s previously authorized preferred stock, par value $0.001, as Class B Convertible Preferred Stock. In April 2015, the Company filed with the Secretary of State of the State of Nevada an Amendment to the Certificate of Designation to increase the number shares of Class B Convertible Preferred Stock from 400,000 shares to 585,000 shares.

 

Common Stock Issued for Services

 

During the six months ended June 30, 2017, 12,113 shares of common stock with a fair value of $35,000 were issued to two members of the board of directors as compensation for services.

 

Common Stock Reserved for Future Issuance

 

As of June 30, 2017, approximately 12.1 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options and warrants, as follows:

 

Exercise of stock options    5,338,559 
Exercise of warrants    6,730,427 
Total shares of common stock reserved for future issuances    12,068,986 

 

Common Stock Offering

 

On March 31, 2017, we completed an underwritten public offering (the “Offering”) for gross proceeds of $12.7 million for 6,325,000 shares of our common stock (the “Shares”) pursuant to a registration statement on Form S-3 that was previously filed and declared effective by the SEC. The Shares were issued and sold pursuant to an underwriting agreement (the “Underwriting Agreement”), dated March 28, 2017, by and among the Company and Cowen and Company, LLC and Needham & Company, LLC, as Representatives of the underwriters, at a public offering price per share of $2.00. The Shares include 825,000 shares issued and sold pursuant to the Underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the Underwriting Agreement. The Company received net proceeds of approximately $11.4 million from the Offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with this offering, the Company incurred $170,300 in offering costs which were offset against the proceeds from this offering.

 

 13 

 

 

Note 7. Stock-Based Compensation

 

Warrant Activity

 

We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Our outstanding warrants expire on varying dates through November 2021. A summary of warrant activity is as follows:

 

  

Number of
Shares

  

Weighted-
Average
Exercise
Price/Share

  

Weighted-
Average
Remaining
Contractual
Term (Years)

  

Aggregate
Intrinsic
Value (1)

 
Outstanding — December 31, 2016   7,447,478   $4.29           
Issued    —    —           
Exercised    (90,000)   2.04           
Expired    (627,051)   8.36           
Outstanding — June 30, 2017    6,730,427   $3.94    2.7   $8,419,800 
Vested (exercisable) — June 30, 2017    6,730,427   $3.94    2.7   $8,419,800 

 

(1)Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of our common stock on June 30, 2017, which was $4.92 per share.

 

During the six months ended June 30, 2017, the Company issued 37,989 shares of common stock in connection with the cashless exercise of warrants to purchase 90,000 shares of common stock. The total intrinsic value of warrants exercised during the six months ended June 30, 2017 was $134,100.

  

 Stock Options

 

We have four stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”) and the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, and the 2011 Plan (collectively the “Prior Plans”) have been superseded by the 2015 Plan. In October 2015, the stockholders approved the 2015 Plan for 5,000,000 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2015 Plan. As of June 30, 2017, the Company had 1,490,638 shares available for future awards under the 2015 Plan.

 

During the six months ended June 30, 2017, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:

 

Expected life (years) 5.3 – 6.6
Risk-free interest rate 1.8% - 2.1%
Volatility 112% – 115%  
Dividend yield 0%

  

The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the historical volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.

 

We recognize stock-based compensation expense over the vesting period using the straight-line single option method. Stock-based compensation expense is recognized only for those awards that vest. We account for the forfeitures of unvested awards as they occur.

 

 14 

 

 

Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:

 

   Six Months Ended June 30,   Six Months Ended June 30, 
   2017   2016 
         
Cost of revenues  $18,523   $9,567 
General and administrative   1,217,109    1,209,591 
Sales and marketing   321,075    312,558 
Engineering and development   8,294    6,423 
   $1,565,001   $1,538,139 

 

A summary of stock option activity is as follows:  

 

  

Number of
Shares

 
  

Weighted-
Average
Exercise
Price/Share

 
  

Weighted-
Average
Remaining
Contractual
Term (Years)

 
  

Aggregate
Intrinsic
Value (1)

 
 
Outstanding — December 31, 2016   4,512,550   $4.01           
Granted (weighted-average fair value of $2.98 per share)    908,500    3.56           
Exercised    (13,125)   1.94           
Forfeited    (17,212)   2.28           
Expired    (52,154)   8.03           
Outstanding — June 30, 2017    5,338,559   $3.90    8.1   $6,901,200 
Vested (exercisable) — June 30, 2017    2,420,322   $4.10    7.3   $2,805,900 
Expected to vest after June 30, 2017 (unexercisable)   2,918,237   $3.74    2.4   $4,095,300 

 

(1)Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on June 30, 2017, which was $4.92 per share.

 

The total intrinsic value of options exercised during the six months ended June 30, 2017 was $34,200.

 

As of June 30, 2017, there was unrecognized compensation expense of $7.8 million related to unvested stock options, which we expect to recognize over a weighted average period of 2.4 years.

 

Note 8. Subsequent Event

 

In July 2017, the Company received proceeds of $1.8 million from the exercise of 605,114 supplemental warrants which were issued in connection with the October 2016 tender offer. The warrants were exercisable upon issuance and expired on the earlier of (i) October 28, 2019 and (ii) the thirtieth (30th) day after the date that the closing price of the Company’s common stock equals or exceeds $4.50 for ten consecutive trading days.

 

As of June 27, 2017, the closing price of the Company’s common stock was equal to or exceeded $4.50 for ten consecutive trading days. As a result, the supplemental warrants expiration date was accelerated to July 27, 2017 unless exercised prior to that date.

 

 15 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

In this Form 10-Q, the terms “Cryoport”, “Company” and similar terms refer to Cryoport, Inc., and its wholly owned subsidiary, Cryoport Systems, Inc.

 

SAFE HARBOR FOR FORWARD LOOKING STATEMENTS:

 

This Quarterly Report on Form 10-Q contains forward-looking statements that have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. In some cases, you can identify these statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words which are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable as of the date of this Quarterly Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Quarterly Report. You should be aware that these statements are projections or estimates as to future events and are subject to a number of factors that may tend to influence the accuracy of the statements. These forward-looking statements should not be regarded as a representation by the Company or any other person that the events or plans of the Company will be achieved. You should not unduly rely on these forward-looking statements, which speak only as of the date of this Quarterly Report. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this Quarterly Report or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the reports we file from time to time with the Securities and Exchange Commission (“SEC”), including those contained in our Transition Report on Form 10-K for the nine months ended December 31, 2016, as filed with the SEC on March 13, 2017 and those reports filed after the date of this Quarterly Report. Actual results may differ materially from any forward looking statement.

 

The following management’s discussion and analysis of the Company’s financial condition and results of operations (“MD&A”) should be read in conjunction with the condensed consolidated balance sheet as of June 30, 2017 (unaudited) and the consolidated balance sheet as of December 31, 2016 (audited) and the related unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2017 and 2016, and condensed consolidated statements of cash flows for the six months ended June 30, 2017 and 2016 and the related notes thereto (see Item 1. Financial Statements), as well as the audited consolidated financial statements of the Company for the nine month period ended December 31, 2016 and the year ended March 31, 2016 included in the Company’s Transition Report on Form 10-K for the nine months ended December 31, 2016.

 

General Overview

 

Overview

 

We provide cryogenic logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. We view our solutions as disruptive to the “older technologies” of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our client’s requirements. We provide comprehensive, reliable, economic alternatives to all existing logistics solutions and services utilized for frozen shipping in the life sciences industry (e.g., personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). As part of our services we provide the ability to monitor, record and archive crucial information for each shipment that can be used for scientific and regulatory purposes.

 

Our Cryoport Express® Solutions include a sophisticated cloud-based logistics operating platform, which is branded as the Cryoportal™. The Cryoportal™ supports the management of the entire shipment and logistics process through a single interface, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. In addition, it provides unique and incisive information dashboards and validation documentation for every shipment. The Cryoportal™ records and retains a fully documented “chain-of-custody” and, at the client’s option, “chain-of-condition” for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities are maintained throughout the process. This recorded and archived information allows our clients to meet exacting requirements necessary for scientific work and for proof of regulatory compliance during the logistics phase.

 

The branded packaging for our Cryoport Express® Solutions includes our liquid nitrogen dry vapor shippers, the Cryoport Express® Shippers. The Cryoport Express® Shippers are engineered shippers that can consist of cost-effective and reusable cryogenic transport shippers, which utilize an innovative application of “dry vapor” liquid nitrogen (“LN2”) technology and SmartPak Condition Monitoring Systems. Cryoport Express® Shippers are International Air Transport Association (“IATA”) certified and validated to maintain stable temperatures of minus 150° Celsius and below for a 10-day dynamic shipment period. The Company currently features three Cryoport Express® Shippers: the Standard Dry Shipper (holding up to 75 2.0 ml vials), the High Volume Dry Shipper (holding up to 500 2.0 ml vials) and Cryoport Express® CXVC1 Shipper (holding up to 1,500 2.0 ml vials). In addition, we assist clients with internal secondary packaging (e.g., vials, canes, straws and plates).

 

 16 

 

 

Our most used solution is the “turnkey” solution, which can be accessed directly through our cloud-based Cryoportal™ or by contacting Cryoport Client Care for order entry. Once an order is placed and cleared, we ship a fully charged Cryoport Express® Shipper to the client who conveniently loads its frozen commodity into the inner chamber of the Cryoport Express® Shipper. The customer then closes the shipper package and reseals the shipping box displaying the next recipient’s address (“Flap A”) for pre-arranged carrier pick up. Cryoport arranges for the pick-up of the parcel by a shipping service provider, which is designated by the client or chosen by Cryoport, for delivery to the client’s intended recipient. The recipient simply opens the shipper package and removes the frozen commodity that has been shipped. The recipient then reseals the package, displaying the nearest Cryoport Staging Center address, making it ready for pre-arranged carrier pick-up. When the Cryoport Staging Center receives the Cryoport Express® Shipper, it is cleaned, put through quality assurance testing, and returned to inventory for reuse.

 

In late 2012, we shifted our focus to become a comprehensive cryogenic logistics solutions provider. Recognizing that clients in the life sciences industry have varying requirements, we unbundled our technologies, established customer facing solutions and took a consultative approach to the market. Today, in addition to our standard turn-key solution, described above, we also provide the following customer facing, value-added solutions to address our various clients’ needs:

 

  · “Integrated Solution,” which is our total outsource solution. It is our most comprehensive solution and involves our management of the entire cryogenic logistics process for our client, including Cryoport employees at the client’s site to manage the client’s cryogenic logistics function in total.
     
  · “Regenerative Medicine Point-of-Care Repository Solution,” designed for allogeneic therapies. In this solution we supply our Cryoport Express® Shipper to ship and store cryogenically preserved life science products for up to six days (or longer periods with supplementary shippers) at a point-of-care site, with the Cryoport Express® Shipper serving as a temporary freezer/repository enabling the efficient and effective distribution of temperature sensitive allogeneic cell-based therapies without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device.
     
  · “Personalized Medicine and Cell-based Immunotherapy Solution,” designed for autologous therapies.  In this solution our Cryoport Express® Shipper serves as an enabling technology for the safe transportation of manufactured autologous cellular-based immunotherapy market by providing a comprehensive logistics solution for the verified chain of custody and condition transport from, (a) the collection of the patient’s cells in a hospital setting, to (b) a central processing facility where they are manufactured into a personalized medicine, to (c) the safe, cryogenically preserved return of these irreplaceable cells to a point-of-care treatment facility.  If required, the Cryoport Express® Shipper can then serve as a temporary freezer/repository to allow the efficient distribution of this personalized medicine to the patient when and where the medical provider needs it most without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device.
     
  · “Customer Staged Solution,” designed for clients making 50 or more shipments per month. Under this solution, we supply an inventory of our Cryoport Express® Shippers to our customer, in an uncharged state, enabling our customer (after training/certification) to charge them with liquid nitrogen and use our Cryoportal™ to enter orders with shipping and delivery service providers for the transportation of the package.

 

  · “Customer Managed Solution,” a limited customer implemented solution, whereby we supply our Cryoport Express® Shippers to clients in a fully charged state, but leaving it to the client to manage the shipping, including the selection of the shipping and delivery service provider and the return of the shipper to us.

 

·“powered by CryoportSM,” available to providers of shipping and delivery services who seek to offer a “branded” cryogenic logistics solution as part of their service offerings, with “powered by CryoportSM” appearing prominently on the offering software interface and packaging. This solution can also be private labeled upon meeting certain requirements, such as minimum required shipping volumes.

 

Cryoport is continuously expanding its solutions offerings in response to its customers’ needs.

 

In April 2016, Cryoport launched its Temperature Controlled Logistics Consulting Division to assist life sciences companies in developing strategies for global cold chain logistics management and contingency options to protect their valuable, and often irreplaceable, biological commodities. The launch of Cryoport’s Temperature Controlled Logistics Consulting Division addresses the demand created by the worldwide advances in cellular based therapies, including immunotherapies, stem cells and CAR T-cells. Cell-based immunotherapies are causing broad shifts and challenges for the life sciences industry, including how to obtain, properly store and transport the growing number of new, individualized, temperature sensitive therapies. Improper temperature maintenance or temperature excursions during any portion of a logistics cycle can adversely affect the viability of these biologically based commodities. Consequently, strategic, global logistics planning for cryogenic cold chain solutions has taken on a strategic importance to the life sciences industry and a rapidly growing demand for consulting expertise.

 

 17 

 

 

In June 2016, Cryoport further broadened its capabilities and solutions offerings beyond cryogenic logistics and transportation services to include temperature-controlled storage solutions that include cGMP compliant biorepositories at controlled temperatures and climatized systems. Cryoport Biostorage services feature extensive management and monitoring, including controlled access to commodities, periodic temperature and activity reports, as well as 21 CFR, Part II compliant monitoring with 24/7/365 alarm response.

 

Also in June 2016, Cryoport announced a new Laboratory Relocation Service, for transport of complete laboratories. The Laboratory Relocation Service manages the safe, secure and proper transportation of materials that are stored in labs as well as lab equipment and instruments. Relocation projects can range in size from the relocation of a fully equipped lab to the move of a single freezer.

 

Strategic Logistics Alliances

 

We have established strategic alliances to market our solutions to the life sciences industry. We have focused our efforts on leading companies in the logistics services industry as well as participants in the life sciences industry. In connection with our alliances with providers of shipping services, we refer to their offerings as “powered by CryoportSM” to reflect our solutions being integrated into our alliance partner’s services.

 

Cryoport now serves and supports the three largest integrators in the world, responsible for over 85% of worldwide airfreight, with its advanced cryogenic logistics solutions for life sciences. We operate with each independently and confidentially in support of their respective market and sales strategies. In addition, we plan to establish additional strategic partnerships with integrators and freight forwarders.

 

FedEx. In January 2013, we entered into a master agreement with Federal Express Corporation (“FedEx”) (the “FedEx Agreement”) renewing these services and providing FedEx with a non-exclusive license and right to use a customized version of our CryoportalTM for the management of shipments made by FedEx customers. The FedEx Agreement became effective on January 1, 2013 and was amended in December 2015 to extend the initial term for an additional three years, expiring on December 31, 2018. FedEx has the right to terminate this agreement at any time for convenience upon 180 days’ notice.

 

Under our FedEx Agreement, we provide frozen shipping logistics services through the combination of our purpose-built proprietary technologies and turnkey management processes. FedEx markets and sells Cryoport’s services for frozen temperature-controlled cold chain transportation as its FedEx® Deep Frozen Shipping Solution on a non-exclusive basis and at its sole expense. As part of the solution, Cryoport has developed a FedEx branded version of the CryoportalTM software platform, which is “powered by CryoportSM” for use by FedEx and its customers, giving them access to the full capabilities of our cloud-based logistics management software platform.

 

DHL. In June 2014, we entered into a master agreement with LifeConEx, a part of DHL Global Forwarding (“DHL”). DHL has enhanced its cold chain logistics offerings to its life sciences and healthcare customers with Cryoport’s validated cryogenic solutions. DHL offers Cryoport’s cryogenic solutions through its worldwide Thermonet network of Certified Life Sciences Stations under the DHL brands as “powered by CryoportSM”. In addition, DHL’s customers have direct access to our cloud-based order entry and tracking portal to order Cryoport Express® Solutions and receive preferred DHL shipping rates and discounts. Our proprietary logistics management operating platform, the CryoportalTM, is integrated with DHL’s tracking and billing systems to provide DHL life sciences and healthcare customers with a seamless way of accessing critical information regarding shipments of biological material worldwide.

 

UPS. In October 2014, we added United Parcel Services, Inc. (“UPS”) as our third major distributor by entering into an agreement with UPS Oasis Supply Corporation, a part of UPS, whereby UPS offers our validated and comprehensive cryogenic solutions to its life sciences and healthcare customers on a global basis. Over the course of rolling out our new relationship with UPS, UPS customers will have direct access to our cloud-based order entry and tracking portal to order Cryoport Express® Solutions and gain access to UPS’s broad array of domestic and international shipping and logistics solutions at competitive prices. Our proprietary logistics management operating platform, the CryoportalTM, is integrated with UPS’s tracking and billing systems to provide UPS life sciences and healthcare customers with a seamless way of accessing critical information regarding shipments of biological material worldwide.

 

 18 

 

 

Cryoport has and continues to build strategic relationships with leaders supporting the life sciences industry, in areas of cGMP compliant climate- and temperature controlled biorepositories as well as in the design and manufacture of biostorage and logistics equipment. This enables us to further advance and expand our cold chain solutions to meet the growing and varied demands in the life sciences market. This provides us with additional opportunities to increases our revenues as well as enables us to rapidly scale our capabilities in support our client’s commercialization activities.

 

 Cryoport’s Positioning in the Life Sciences Industry

 

Life sciences technologies are expected to have a significant impact on global society over the next 25 years. In the United States alone, the life sciences industry is made up of 6,000 identifiable establishments. However, the industry is growing globally in a way where research and manufacturing pipelines span across the globe, which increases the need to mitigate logistics risk.

 

The total cold chain logistics market has historically grown 70% faster per annum than the total logistics market. For 2011, global cold chain logistics transportation costs were reported to be $7.2 billion; about $1.5 billion within the cryogenic range of requirements. By 2017, transportation cost alone, for global life sciences cold chain logistics, is forecasted to grow to $9.3 billion, a 41% increase, and twice the growth of the overall market.

 

In addition, with the recent advancements in the development of biologics and cell-based therapies, scientists, intermediaries, and manufacturers require the means for cryogenically transporting their work. Temperatures must be maintained below the “glass point” (generally, minus 136ºC) while shipping these therapies to ensure that the shipped specimens are not subject to degradation that could impact the characteristics and efficacy of those specimens.

 

While we estimate that our solutions currently offer comprehensive and technology-based monitoring and tracking for a potential of six to seven million deep frozen shipments globally on an annual basis, we also believe that with investment in our services, adaptations of our solutions can be applied to a large portion of an additional fifty-five to sixty million annual shipments requiring ambient (between 20° and 25°C), chilled (between 2° and 8°C) or frozen (minus 10°C or less) temperatures.

 

Cryoport’s clients include companies and institutions that require reliable cryogenic logistics solutions such as therapy developers for personalized medicine, bio-pharmaceuticals, research, contract research organizations, diagnostic laboratories, contract manufacturers, cord blood repositories, vaccine manufacturers, animal husbandry related companies, and in-vitro fertilization clinics.

 

Life Sciences Agreements

 

Zoetis. In December 2012, we signed an agreement with Pfizer Inc. relating to Zoetis Inc. (formerly the animal health business unit of Pfizer Inc.) pursuant to which we were engaged to manage frozen shipments of a key poultry vaccine. Under this arrangement, Cryoport provides on-site logistics personnel and its logistics management operating platform, the CryoportalTM to manage shipments from the Zoetis manufacturing site in the United States to domestic customers as well as various international distribution centers. As part of our logistics management services, Cryoport is constantly analyzing logistics data and processes to further introduce economies and reliability throughout the network, ensuring products arrive at their destinations in specified conditions, on-time and with the optimum utilization of resources. The Company manages Zoetis’ total fleet of dewar flask shippers used for this purpose, including liquid nitrogen shippers. In July 2013 the agreement was amended to expand Cryoport’s scope to manage all logistics of Zoetis’ key frozen poultry vaccine to all Zoetis’ international distribution centers as well as all domestic shipments. In October 2013, the agreement was further amended to further expand Cryoport’s role to include the logistics management for a second poultry vaccine. In September 2015, the agreement was further amended and extended through September 2018, subject to certain termination and extension provisions.

 

In summary, we serve the life sciences industry with cryogenic logistics solutions that are advanced, comprehensive, reliable, validated, and efficient. Our clients include those companies and institutions that have logistics requirements for personalized medicine, immunotherapies, stem cells, cell lines, tissue, vaccines, in-vitro fertilization, cord blood and other temperature sensitive commodities of life sciences.

 

Recent Developments

 

Common Stock Offering

 

On March 31, 2017, we completed an underwritten public offering (the “Offering”) for gross proceeds of $12.7 million for 6,325,000 shares of our common stock (the “Shares”) pursuant to a registration statement on Form S-3 that was previously filed and declared effective by the SEC. The Shares were issued and sold pursuant to an underwriting agreement (the “Underwriting Agreement”), dated March 28, 2017, by and among the Company and Cowen and Company, LLC and Needham & Company, LLC, as Representatives of the underwriters, at a public offering price per share of $2.00. The Shares include 825,000 shares issued and sold pursuant to the Underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the Underwriting Agreement. The Company received net proceeds of approximately $11.4 million from the Offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with this offering, the Company incurred $170,300 in offering costs which were offset against the proceeds from this offering.

 

 19 

 

 

Results of Operations

 

Three months ended June 30, 2017 compared to three months ended June 30, 2016:

 

The following table summarizes certain information derived from our condensed consolidated statements of operations:

 

   Three Months Ended June 30,         
   2017   2016   $ Change   % Change 
       ($ in 000’s)         
                 
Revenues  $2,917   $1,918   $999    52.1%
Cost of revenues   (1,524)   (1,136)   (388)   34.2%
                     
Gross margin   1,393    782    611    78.2%
General and administrative   (1,789)   (1,430)   (359)   25.2%
Sales and marketing   (1,237)   (1,196)   (41)   3.4%
Engineering and development   (231)   (136)   (95)   69.99%
Interest expense   —    (21)   21    (100)%
Warrant repricing expense   —    (1,930)   1,930    (100)%
Other income (expense), net   4    (2)   6    (280.8)%
Provision for income taxes   —    (2)   2    (100)%
                     
Net loss  $(1,860)  $(3,935)  $(2,075)   (52.7)%

 

Total revenues

 

   Three Months Ended June 30,         
   2017   2016   $ Change   % Change 
   ($ in 000’s)         
                 
Biopharmaceutical  $2,229   $1,319   $910    69.0%
Reproductive medicine   426    370    56    15.2%
Animal health   262    229    33    14.6%
                     
Total revenues  $2,917   $1,918   $999    52.1%

 

Revenues. We generated revenues from customers in all of our target life sciences markets, such as biopharma, animal health and reproductive medicine. Revenues increased $1.0 million or 52.1% to $2.9 million for the three months ended June 30, 2017, as compared to $1.9 million for the three months ended June 30, 2016. This increase was primarily driven by the continuing increase in the number of biopharmaceutical customers utilizing our services and frequency of shipments compared to the prior year. Biopharmaceutical revenue increased $910,300 or 69.0%, to $2.2 million for the quarter compared to $1.3 million in the same quarter last year. During the three months ended June 30, 2017, we added approximately 19 new biopharma clients and supported 172 clinical trials, of which 17 trials were in Phase III. This increased activity in the clinical trial space is expected to drive future revenue growth as these clinical trials advance and resulting therapies are commercialized. Revenues in the reproductive medicine market increased by 15.2% for the three months ended June 30, 2017, as compared to the same period in 2016. This increase was driven by a 57.0% increase in revenues in the U.S. market through continued success of our targeted marketing campaigns and was partially offset by a 33.0% decrease in revenues in the international markets as a result of regulatory uncertainties. Our revenues from animal health increased 14.6% for the three months ended June 30, 2017, as compared to the same period in 2016 driven by the onboarding of several new clients in this market.

 

Gross margin and cost of revenues. Gross margin for the three months ended June 30, 2017 was 47.8% of revenues, as compared to 40.8% of revenues for the three months ended June 30, 2016. The increase in gross margin by almost seven percentage points is primarily due to the increased business volume and pricing adjustments combined with a reduction in freight as a percentage of revenues and a decrease of fixed manufacturing costs. Our cost of revenues are primarily comprised of freight charges, payroll and related expenses related to our operations center in California, third-party charges for our European and Asian staging centers in Holland and Singapore, depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions. Cost of revenues increased $388,600, or 34.2%, to $1.5 million for the three months ended June 30, 2017, as compared to $1.1 million in the same period in 2016. The increase in cost of revenues was primarily due to freight charges from the increased volume of shipments.

 

 20 

 

 

General and administrative expenses. General and administrative expenses increased $359,700 for the three months ended June 30, 2017 or 25.2% as compared to the three months ended June 30, 2016. This increase is primarily due to an increase of $125,800 for legal settlements, an increase in salaries and associated employee costs of $82,200, public company related expenses in the amount of $57,500, including legal fees, patent legal fees of $32,100, implementation costs for a new ERP system of $21,800, an increase of $15,200 for insurance premiums and an increase in stock-based compensation expense of $13,900.

 

Sales and marketing. Sales and marketing expenses increased $41,200 or 3.4% for the three months ended June 30, 2017 as compared to the three months ended June 30, 2016. This increase is primarily due to recruiting fees and related relocation costs of $84,900 incurred to expand our sales force, an increase in stock based compensation expense of $22,000 and an increase in marketing trade shows of $9,700. These increases were partially offset by a reduction in outsourced marketing consulting of $117,100 as a result of bringing this function in-house.

 

Engineering and development expenses. Engineering and development expenses increased $94,900 or 69.9% for the three months ended June 30, 2017, as compared to the three months ended June 30, 2016. The increase was primarily due to $49,700 in salary adjustments, recruiting and associated employee costs to add a software development product manager, $52,700 in testing expenses, facility expenses of $21,400 and an increase of $3,100 in stock-based compensation expense. These increases were partially offset by a reduction of $36,200 in web portal development expenses. We continually strive to improve and expand the features of our Cryoport Express® Solutions. Our developments are directed towards facilitating the safe, reliable and efficient shipment of life science commodities through innovative and technology-based solutions. We also incurred costs to design and validate additional new primary and secondary packaging solutions and accessories in response to requests from our customers. We supplement our internal engineering and development resources with subject matter experts and consultants.

 

Interest expense. Interest expense decreased $21,200 for the three months ended June 30, 2017, as compared to the three months ended June 30, 2016. There was no interest expense during the three months ended June 30, 2017 as the related party notes were paid in full April 1, 2017. Interest expense for the three months ended June 30, 2016 included amortization of the debt discount on the related-party notes of $6,200 and the stated interest expense of $15,000.

 

Warrant repricing expense. Warrant repricing expense for the three months ended June 30, 2016 was due to the repricing of certain warrants for the tender offer that was completed April 7, 2016.

 

Other income (expense), net. The other expense, net for the three months ended June 30, 2017 increased $5,400 as compared to the three months ended June 30, 2016 primarily due to an increase in interest income on larger cash balances and foreign exchange gains on accounts receivable and payable invoices partially offset by bank administrative charges.

 

 21 

 

 

Six months ended June 30, 2017 compared to six months ended June 30, 2016:

 

The following table summarizes certain information derived from our condensed consolidated statements of operations:

 

   Six Months Ended June 30,         
   2017   2016   $ Change   % Change 
       ($ in 000’s)         
                 
Revenues  $5,630   $3,473   $2,157    62.1%
Cost of revenues   (2,983)   (2,109)   (874)   41.4%
                     
Gross margin   2,647    1,364    1,283    94.1%
General and administrative   (3,493)   (3,244)   (249)   7.7%
Sales and marketing   (2,307)   (2,443)   136    (5.6)%
Engineering and development   (481)   (280)   (201)   71.5%
Interest expense   (16)   (103)   87    (84.7)%
Warrant repricing expense   —    (1,930)   1,930    (100)%
Other income (expense), net   4    (7)   11    (151)%
Provision for income taxes   (4)   (2)   (2)   70.3%
                     
Net loss  $(3,650)  $(6,645)  $2,995    (45.1)%

 

Total revenues

 

   Six Months Ended June 30,         
   2017   2016   $ Change   % Change 
   ($ in 000’s)         
                 
Biopharmaceutical  $4,252   $2,332   $1,920    82.3%
Reproductive medicine   844    701    143    20.5%
Animal health   534    440    94    21.2%
                     
Total revenues  $5,630   $3,473   $2,157    62.1%

 

Revenues. We generated revenues from customers in all of our target life sciences markets, such as biopharma, animal health and reproductive medicine. Revenues increased $2.2 million or 62.1% to $5.6 million for the six months ended June 30, 2017, as compared to $3.5 million for the six months ended June 30, 2016. This increase was primarily driven by the continuing increase in the number of biopharmaceutical customers utilizing our services and frequency of shipments compared to the prior year. Biopharmaceutical revenue increased $1.9 million or 82.3%, to $4.3 million for the six months ended June 30, 2017 as compared to $2.3 million in the same period last year. During the six months ended June 30, 2017, we added approximately 46 new biopharma clients and supported 172 clinical trials, of which 17 trials were in Phase III. This increased activity in the clinical trial space is expected to drive future revenue growth as these clinical trials advance and resulting therapies are commercialized. Revenues in the reproductive medicine market increased by 20.5% for the six months ended June 30, 2017, as compared to the same period in 2016. This increase was driven by a 54.2% increase in revenues in the U.S. market through continued success of our targeted marketing campaigns and was partially offset by a 24.0% decrease in revenues in the international markets as a result of regulatory uncertainties. Our revenues from animal health increased 21.2% for the six months ended June 30, 2017, as compared to the same period in 2016 driven by the onboarding of several new clients in this market.

 

Gross margin and cost of revenues. Gross margin for the six months ended June 30, 2017 was 47.0% of revenues, as compared to 39.3% of revenues for the six months ended June 30, 2016. The increase in gross margin by almost eight percentage points is primarily due to the increased business volume and pricing adjustments combined with a reduction in freight as a percentage of revenues and a decrease of fixed manufacturing costs. Our cost of revenues are primarily comprised of freight charges, payroll and related expenses related to our operations center in California, third-party charges for our European and Asian staging centers in Holland and Singapore, and depreciation expenses of our Cryoport Express® Shippers and supplies and consumables used for our solutions. Cost of revenues increased $873,600, or 41.4%, to $3.0 million for the six months ended June 30, 2017, as compared to $2.1 million in the same period in 2016. The increase in cost of revenues was primarily due to freight charges from the increased volume of shipments.

 

 22 

 

 

General and administrative expenses. General and administrative expenses increased $248,400 for the six months ended June 30, 2017 or 7.7% as compared to the six months ended June 30, 2016. This increase is primarily due to an increase of $125,800 for legal settlements, an increase in salaries and associated employee costs of $43,000, patent legal fees of $28,200, implementation costs for a new ERP system of $63,200, an increase of $66,800 for insurance premiums, facility expenses of $41,500 and an increase in stock-based compensation expense of $35,400. These increases were partially offset by a decrease in public company related expenses in the amount of $17,500, including legal fees, a decrease in moving expenses incurred in 2016 of $10,000 and the 2016 disposal of components used to manufacture our shippers in the amount of $121,700 due to our decision to co-develop and outsource the manufacturing of our shippers that was not incurred in 2017.

 

Sales and marketing. Sales and marketing expenses decreased $135,900 or 5.6% for the six months ended June 30, 2017 as compared to the six months ended June 30, 2016. This decrease is primarily due to a reduction in outsourced marketing consulting of $241,900 as a result of bringing this function in-house and a decrease in salaries and associated employee costs of $29,100. These decreases were partially offset by an increase in facility expenses of $29,000, an increase in marketing trade shows of $30,300, an increase in travel and lodging expense of $18,400, implementation costs for a new ERP system of $33,300 and an increase in stock-based compensation expense of $9,200.

 

Engineering and development expenses. Engineering and development expenses increased $200,300 or 71.5% for the six months ended June 30, 2017, as compared to the six months ended June 30, 2016. We continually strive to improve and expand the features of our Cryoport Express® Solutions. Our developments are directed towards facilitating the safe, reliable and efficient shipment of life science commodities through innovative and technology-based solutions. During the six months ended June 30, 2017, we tested and upgraded the firmware and software of our SmartPak II™ Condition Monitoring System that tracks the key aspects of each shipment that could affect the quality and/or timing of delivery of the commodities shipped to its intended destination. We also incurred costs to design, qualify, and test additional new primary and secondary packaging solutions and accessories in response to requests from our customers. We incurred a total of $177,300 for these testing and qualification activities for the six months ended June 30, 2017 as compared to $4,300 for the same period in the prior year. We supplement our internal engineering and development resources with subject matter experts and consultants.

 

Interest expense. Interest expense decreased $86,700 for the six months ended June 30, 2017, as compared to the six months ended June 30, 2016. Interest expense for the six months ended June 30, 2017 included amortization of the debt discount on the related-party notes of $6,100 and the stated interest expense of $9,600. Interest expense for the six months ended June 30, 2016 included amortization of the debt discount on the related-party notes of $72,300 and the stated interest expense of $30,200.

 

Warrant repricing expense. Warrant repricing expense for the six months ended June 30, 2016 was due to the repricing of certain warrants for the tender offer that was completed April 7, 2016.

 

Other income (expense), net. The other expense, net for the six months ended June 30, 2017 increased $10,200, as compared to the six months ended June 30, 2016 primarily due to an increase in interest income on larger cash balances and foreign exchange gains on accounts receivable and payable invoices partially offset by bank administrative charges.

 

Liquidity and Capital Resources

 

As of June 30, 2017, the Company had cash and cash equivalents of $12.9 million and working capital of $12.5 million. Historically, we have financed our operations primarily through sales of our debt and equity securities.

 

For the six months ended June 30, 2017, we used $1.4 million of cash for operations primarily as a result of the net loss of $3.6 million offset by non-cash expenses of $1.9 million primarily comprised of depreciation and amortization, stock-based compensation expense, and loss on disposal of fixed assets. Also contributing to the cash impact of our net operating loss (excluding non-cash items) was an increase in accounts receivable of $56,900 as a result of an increase in sales offset by an increase in accounts payable and other accrued expenses and accrued compensation of $383,000.  

 

Net cash used in investing activities of $1.0 million during the six months ended June 30, 2017 was primarily due to the purchase of Cryoport Express® CXVC1 Shippers, Smart Pak IITM Condition Monitoring Systems and computer equipment as well as legal expenses incurred for trademark applications.

 

Net cash provided by financing activities totaled $10.8 million during the six months ended June 30, 2017, and resulted from net proceeds of $11.4 million from the March 2017 common stock offering, proceeds from the exercise of stock options and warrants of $25,400, which were partially offset by the repayment of related party notes payable of $656,200. 

 

The Company’s management believes that, based on its current plans and assumptions, the current cash on hand, together with projected cash flows, will satisfy our operational and capital for at least the next twelve months. The Company’s management recognizes that the Company may need to obtain additional capital to fund its operations until sustained profitable operations are achieved. Additional funding plans may include obtaining additional capital through equity and/or debt funding sources. No assurance can be given that additional capital, if needed, will be available when required or upon terms acceptable to the Company.

 

 23 

 

 

Off-Balance Sheet Arrangements

 

We do not currently have any off balance sheet arrangements.

     

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures.

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

As required by Securities and Exchange Commission Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Principal Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Principal Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2017 at the reasonable assurance level.

 

Changes in internal control over financial reporting.

 

There were no changes in our internal controls over financial reporting during the fiscal quarter ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II — OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None

 

ITEM 1A. RISK FACTORS

 

The risks described in Part I, Item 1A, Risk Factors, in our Transition Report on Form 10-K for the nine months ended December 31, 2016, could materially and adversely affect our business, financial condition and results of operations. These risk factors do not identify all of the risks that we face. Our business, financial condition and results of operations could also be affected by factors that are not presently known to us or that we currently consider to be immaterial. There have been no material changes to the “Risk Factors” section included in our Transition Report on Form 10-K for the nine months ended December 31, 2016.

 

 24 

 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable

 

ITEM 5. OTHER INFORMATION

 

None

 

ITEM 6. EXHIBITS

 

Exhibit    
Index    
     
31.1+   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2+   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1+   Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS+   XBRL Instance Document.
     
101.SCH+   XBRL Taxonomy Extension Schema Document.
     
101.CAL+   XBRL Taxonomy Extension Calculation Linkbase Document.
     
101.DEF+   XBRL Taxonomy Extension Definition Linkbase Document.
     
101.LAB+   XBRL Taxonomy Extension Label Linkbase Document.
     
101.PRE+   XBRL Taxonomy Extension Presentation Linkbase Document.

 

 

  + Filed herewith.    

 

 25 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Cryoport, Inc.
   
Dated: August 9, 2017    
     
  By: /s/ Jerrell W. Shelton
    Jerrell W. Shelton
    Chief Executive Officer
     
Dated: August 9, 2017    
     
  By: /s/ Robert S. Stefanovich
    Robert S. Stefanovich
    Chief Financial Officer

 

 26 

 

 EX-31.1 2 v472238_ex31-1.htm EXHIBIT 31.1

 

EXHIBIT 31.1

 

CERTIFICATION

CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jerrell W. Shelton, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Cryoport, Inc.

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: August 9, 2017

 

/s/ Jerrell W. Shelton  
   
JERRELL W. SHELTON  

Chief Executive Officer

(Principal Executive Officer)

  

 

 

 

 EX-31.2 3 v472238_ex31-2.htm EXHIBIT 31.2

 

EXHIBIT 31.2

CERTIFICATION

CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Robert S. Stefanovich, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Cryoport, Inc.

 

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

 

4.

The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules

13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

 

  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

 

  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Date: August 9, 2017

 

/s/ Robert S. Stefanovich  
   
ROBERT S. STEFANOVICH  

Chief Financial Officer

(Principal Financial Officer)

  

 

 

 

 EX-32.1 4 v472238_ex32-1.htm EXHIBIT 32.1

 

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Cryoport, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jerrell W. Shelton, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

 

(1)

The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act

of 1934; and

 

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Jerrell W. Shelton
 
JERRELL W. SHELTON
President and Chief Executive Officer
 
August 9, 2017

 

In connection with the Quarterly Report of Cryoport, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert S. Stefanovich, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:

 

(1)

The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act

of 1934; and

 

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Robert S. Stefanovich
 
ROBERT S. STEFANOVICH
Chief Financial Officer
 
August 9, 2017

 

A signed original of this written statement required by Section 906 has been provided to Cryoport, Inc. and will be retained by Cryoport, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

This Certification is being furnished pursuant to Rule 15(d) and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act (15 U.S.C. 78r), or otherwise subject to the liability of that section. This Certification shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference. 

 

 

 

 GRAPHIC 5 v472238_img1.jpg GRAPHIC begin 644 v472238_img1.jpg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�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end EX-101.INS 6 cyrx-20170630.xml XBRL INSTANCE DOCUMENT 0001124524 2016-01-01 2016-06-30 0001124524 2017-01-01 2017-03-31 0001124524 2017-01-01 2017-06-30 0001124524 2017-03-31 0001124524 2016-04-01 2016-06-30 0001124524 2017-04-01 2017-06-30 0001124524 2017-06-30 0001124524 2017-07-01 2017-07-31 0001124524 2017-07-31 0001124524 2016-12-31 0001124524 2015-12-31 0001124524 2016-06-30 0001124524 us-gaap:ConvertiblePreferredStockMember 2016-12-31 0001124524 cyrx:ClassBConvertiblePreferredStockMember 2016-12-31 0001124524 us-gaap:ConvertiblePreferredStockMember 2017-06-30 0001124524 cyrx:ClassBConvertiblePreferredStockMember 2017-06-30 0001124524 us-gaap:AccountsReceivableMember 2017-01-01 2017-06-30 0001124524 cyrx:ForeignCustomersMember 2017-01-01 2017-06-30 0001124524 cyrx:ForeignCustomersMember 2016-01-01 2016-06-30 0001124524 us-gaap:SalesRevenueNetMember cyrx:ForeignCustomersMember 2017-01-01 2017-06-30 0001124524 us-gaap:SalesRevenueNetMember cyrx:ForeignCustomersMember 2016-01-01 2016-06-30 0001124524 us-gaap:SalesRevenueNetMember 2017-01-01 2017-06-30 0001124524 us-gaap:SalesRevenueNetMember cyrx:CustomerOneMember 2016-01-01 2016-06-30 0001124524 cyrx:CryogenicShippersMember 2017-06-30 0001124524 cyrx:DataLoggersMember 2016-12-31 0001124524 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001124524 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001124524 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001124524 us-gaap:WarrantMember 2016-01-01 2016-06-30 0001124524 cyrx:PatrickMullinsMdMember 2017-03-31 0001124524 cyrx:MarylPetrecciaMember 2017-03-31 0001124524 cyrx:JeffreyDellMdMember 2017-03-31 0001124524 cyrx:AmendedAndRestatedNotesMember 2016-03-31 0001124524 cyrx:AmendedAndRestatedNotesMember 2017-01-01 2017-06-30 0001124524 cyrx:AmendedAndRestatedNotesMember 2016-01-01 2016-06-30 0001124524 cyrx:IrvineCaliforniaFacilityMember 2017-01-01 2017-06-30 0001124524 cyrx:IrvineCaliforniaFacilityMember 2017-06-30 0001124524 cyrx:PurchaseAndSaleAgreementMember cyrx:KlatuNetworksLlcMember 2015-09-01 2015-09-16 0001124524 cyrx:KlatuNetworksLlcMember us-gaap:MinimumMember 2015-09-01 2015-09-16 0001124524 us-gaap:MinimumMember 2015-11-30 0001124524 cyrx:ClassBConvertiblePreferredStockMember 2015-02-28 0001124524 cyrx:ClassBConvertiblePreferredStockMember us-gaap:MaximumMember 2015-04-30 0001124524 us-gaap:ConvertiblePreferredStockMember 2014-05-31 0001124524 cyrx:ClassBConvertiblePreferredStockMember us-gaap:MinimumMember 2015-04-30 0001124524 us-gaap:DirectorMember 2017-01-01 2017-06-30 0001124524 us-gaap:WarrantMember 2017-06-30 0001124524 cyrx:WarrantsMember 2017-01-01 2017-06-30 0001124524 cyrx:WarrantsMember 2017-06-30 0001124524 cyrx:WarrantsMember 2016-12-31 0001124524 cyrx:Plan2015Member us-gaap:EmployeeStockOptionMember 2015-10-31 0001124524 cyrx:Plan2015Member us-gaap:EmployeeStockOptionMember 2017-06-30 0001124524 us-gaap:CostOfSalesMember 2017-01-01 2017-06-30 0001124524 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001124524 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-06-30 0001124524 cyrx:EngineeringAndDevelopmentMember 2017-01-01 2017-06-30 0001124524 us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001124524 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001124524 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0001124524 cyrx:EngineeringAndDevelopmentMember 2016-01-01 2016-06-30 0001124524 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001124524 us-gaap:EmployeeStockOptionMember 2017-06-30 0001124524 us-gaap:EmployeeStockOptionMember 2016-12-31 0001124524 cyrx:RelatedPartyNotesPayableOtherPayableMember 2017-06-30 0001124524 cyrx:RelatedPartyNotesPayableOtherPayableMember 2016-12-31 0001124524 us-gaap:EmployeeStockOptionMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001124524 us-gaap:EmployeeStockOptionMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001124524 cyrx:ClassBConvertiblePreferresStockMember 2017-06-30 0001124524 cyrx:ClassBConvertiblePreferresStockMember 2016-12-31 0001124524 cyrx:UnderwrittenPublicOfferingMember 2017-01-01 2017-03-31 0001124524 cyrx:UnderwrittenPublicOfferingMember 2017-03-31 0001124524 us-gaap:OverAllotmentOptionMember 2017-01-01 2017-03-31 0001124524 cyrx:PublicOfferingMember 2017-01-01 2017-03-31 0001124524 us-gaap:AccountsReceivableMember 2016-01-01 2016-12-31 0001124524 us-gaap:SalesRevenueNetMember 2016-01-01 2016-06-30 0001124524 us-gaap:SubsequentEventMember 2017-07-01 2017-07-31 0001124524 us-gaap:WarrantMember 2017-01-01 2017-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares utr:sqft xbrli:pure 10-Q false 2017-06-30 2017 Q2 Cryoport, Inc. 0001124524 --12-31 Smaller Reporting Company CYRX 24674432 4524529 1195479 89499 6096426 1647104 5000 363403 8111933 1160299 419034 651934 2231267 2431531 0 0 17604 129196680 -123533882 5680402 8111933 12854526 1250731 72621 14486807 2311680 29728 363403 17191618 1369223 598325 0 1967548 2164521 0 0 23993 142186654 -127183550 15027097 17191618 308929 286919 196973 200264 2917378 1917566 1524189 1135616 1393189 781950 3257083 2761205 -1863894 -1979255 26 21242 3463 -1915 -1860457 -3932230 0 2484 -1860457 -3934714 0 0 -1860457 -3934714 -0.08 -0.28 23965825 14199742 1789514 1429768 1236833 1195638 5629612 3473111 2982926 2109354 2646686 1363757 6279893 5967130 -3633207 -4603373 15693 102436 3463 -6787 -3645437 -6642414 4231 2484 -3649668 -6644898 0 75460 -3649668 -6720358 -0.18 -0.54 20802628 12428991 3492546 3244189 2306768 2442664 307905 170751 6130 72252 1565001 1538139 -49840 -140588 1636 2503 56888 400983 -16878 68940 205633 57300 179291 -269 -1843 15045 -1398095 -3188684 1022321 599115 -1047049 -599115 656221 178831 10775141 3066094 8329997 -721705 5247425 4525720 0 26901 24728 0 22010 -10 0 1068055 11405924 0 P90D 75000 60000 0.1 714600 508400 0.127 0.109 0.1 0.146 0.52 0.44 513746 875947 58269 2495464 0 646700 1.88 11910 7088 5553 26900 6100 5000 8200 9600 30183 0 11400 24700 2023-02-28 27600 400000 200000 25000 115500 157270 50000000 2500000 0.001 20833333 400000 585000 800000 0.001 400000 0.001 0.001 12113 35000 12068986 6730427 P2Y8M12D 8419800 P2Y8M12D 8419800 6730427 6730427 3.94 3.94 7447478 0 90000 627051 4.29 0 2.04 8.36 5000000 1490638 18523 1217109 321075 8294 9567 1209591 312558 6423 P8Y1M6D P7Y3M18D 2805900 6901200 5338559 2420322 3.90 4.10 2918237 3.74 P2Y4M24D 4095300 4512550 908500 13125 17212 52154 4.01 3.56 1.94 2.28 8.03 4.92 7800000 P2Y4M24D <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 8.&#160;Subsequent Event</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2017, the Company received proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million from the exercise of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 605,114</font> supplemental warrants which were issued in connection with the October 2016 tender offer. The warrants were exercisable upon issuance and expired on the earlier of&#160; <font style="FONT-SIZE: 10pt">(i) October 28, 2019 and (ii) the thirtieth (30th) day after the date that the closing price of the Company&#8217;s common stock equals or exceeds $4.50 for ten consecutive trading days.</font></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of June 27, 2017, the closing price of the Company&#8217;s common stock was equal to or exceeded $4.50 for ten consecutive trading days. As a result, the supplemental warrants expiration date was accelerated to July 27, 2017 unless exercised prior to that date.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 6100 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>5.3 &#150; 6.6</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>1.8% - 2.1%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>112% &#150; 115%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>0%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Six&#160;Months&#160;Ended June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Six&#160;Months&#160;Ended June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Cost of revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,523</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,567</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,217,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,209,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>321,075</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>312,558</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Engineering and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,294</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,423</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,565,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,538,139</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">A summary of stock option activity is as follows: &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price/Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Term&#160;(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value&#160;(1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding &#151; December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,512,550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted (weighted-average fair value of $2.98 per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>908,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(13,125)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(17,212)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(52,154)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding &#151; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,338,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,901,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested (exercisable) &#151; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2,420,322</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>7.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2,805,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expected to vest after June 30, 2017 (unexercisable)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2,918,237</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>3.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4,095,300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.45pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 24.5pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="33"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;TEXT-INDENT: 0in; MARGIN: 0in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on June 30, 2017, which was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.92</font> per share.</font></div> </div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.001 0.001 0.001 P5Y3M18D 2500000 P6Y7M6D 0.018 0.021 1.12 800000 1.15 800000 0 0 0 0 0 0.001 0.001 585000 585000 0 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of June 30, 2017, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12.1</font>&#160;million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options and warrants, as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Exercise of stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>5,338,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Exercise of warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div>6,730,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="65%"> <div>Total shares of common stock reserved for future issuances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div>12,068,986</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0 0 5338559 0.001 50000000 23992510 23992510 17604283 17604283 12700000 6325000 2.00 825000 11400000 170300 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 5.&#160;Commitments and Contingencies</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Facility and Equipment Leases</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We lease <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 27,600</font> square feet of corporate, engineering and development, and warehouse facilities in Irvine, California under an operating lease expiring <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">February 28, 2023</font>, subject to our option to extend the lease for two additional five-year periods. The initial base rent is approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,700</font> per month. This lease agreement contains certain scheduled annual rent increases which are accounted for on a straight-line basis. We also lease certain office equipment which expires in March 2018.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Employment Agreements</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 12.2pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 12.2pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Consulting and Engineering Services</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 16, 2015, the Company entered into the Purchase and Sale Agreement (the &#8220;Purchase and Sale Agreement&#8221;), by and between KLATU Networks, LLC (&#8220;KLATU&#8221;) and the Company. Pursuant to the Purchase and Sale Agreement, the Company purchased from KLATU certain intellectual property and intellectual property rights related to the Company&#8217;s Cryoportal<sup style="font-style:normal">TM</sup> logistics management platform (the &#8220;Developed Technology&#8221;), which KLATU previously developed for and licensed to the Company pursuant to the Master Consulting and Engineering Services Agreement, by and between KLATU and the Company, dated October 9, 2007 (as amended, the &#8220;Master Consulting and Engineering Services Agreement&#8221;). As full compensation for the sale and assignment of the Developed Technology from KLATU to the Company, the Company paid KLATU an aggregate amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">400,000</font> in two equal installments of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">200,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Concurrently with entering into the Purchase and Sale Agreement, on September 16, 2015, the Company and KLATU entered into the Amended and Restated Master Consulting and Engineering Services Agreement (the &#8220;Amended and Restated Master Consulting and Engineering Services Agreement&#8221;) to amend and restate the Master Consulting and Engineering Services Agreement. The Amended and Restated Master Consulting and Engineering Services Agreement provides a framework for KLATU to perform certain consulting, software and hardware engineering development services as mutually agreed upon and further set forth in one or more Statements of Work (as defined in the Amended and Restated Master Consulting and Engineering Services Agreement). To ensure the availability of KLATU personnel to perform services pursuant to the Amended and Restated Master Consulting and Engineering Services Agreement, the Company agreed to pay KLATU a minimum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font> per month for services fees, which may be carried forward as advance payment for future services under certain conditions. The initial term of the agreement is until December 31, 2017 and will thereafter automatically renew for subsequent one year terms, unless notice of termination is given.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Consulting fees for services provided by KLATU were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115,500</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">157,270</font> for the six months ended June 30, 2017 and 2016, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Litigation</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. In the opinion of management, there are no legal matters involving the Company that would have a material adverse effect upon the Company&#8217;s consolidated financial condition or results of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">&#160;</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Indemnities and Guarantees</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying condensed consolidated balance sheets.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility lease, the Company has indemnified its lessor for certain claims arising from the use of the facility. The duration of the guarantees and indemnities varies, and is generally tied to the life of the agreement.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 230736 135799 480579 280277 0 1929818 0 1929818 0 2244247 0 -1000678 25438 0 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Note 1. Management&#8217;s Representation and Basis of Presentation</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared by Cryoport, Inc. (the &#8220;Company&#8221;, &#8220;our&#8221; or &#8220;we&#8221;) in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information, and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. However, the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2017. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company&#8217;s Transition Report on Form 10-K for the period ended December 31, 2016.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has evaluated subsequent events through the date of this filing, and determined that no subsequent events have occurred that would require recognition in the unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 2.&#160;Nature of the Business</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.38in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material. &#160;Cryoport actively&#160;supports points-of-care, contract research organizations, central laboratories, pharmaceutical and biotechnology companies, contract manufacturers and university researchers.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.38in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol &#8220;CYRX.&#8221;</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><i>Use of Estimates</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company&#8217;s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><i>Fair Value of Financial Instruments</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, related-party notes payable, accounts payable and accrued expenses. The carrying value for all such instruments, except for related-party notes payable, approximates fair value at June 30, 2017 and December 31, 2016 due to their short-term nature. The difference between the fair value and recorded values of the related-party notes payable is not significant.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Cash and Cash Equivalents</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company considers highly liquid investments with original maturities of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90</font> days or less to be cash equivalents.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i> Customers</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company grants credit to customers within the United States and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company&#8217;s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at June 30, 2017 and December 31, 2016 are net of reserves for doubtful accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font>, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s customers are in the biotechnology, pharmaceutical and life sciences industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. There were no customers that accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net accounts receivable at June 30, 2017 and December 31, 2016.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During the six months ended June 30, 2017 and 2016, the Company had revenues from foreign customers of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">714,600</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">508,400</font>, respectively, which constituted approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12.7</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14.6</font>%, respectively, of total revenues. For the six months ended June 30, 2016, there was one customer that accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10.9</font>% of total revenues. No other single customer generated over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of total revenues during the six months ended June 30, 2017 and 2016.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i> Inventories</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s inventories consist of packaging materials and accessories that are used as part of the solutions provided by the Company to its customers or are sold to customers directly. Inventories are stated at the lower of cost and net realizable value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company&#8217;s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company&#8217;s forecasts of market conditions, industry trends, competition and other factors.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><i> Property and Equipment</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company provides shipping containers, the Cryoport Express<sup style="font-style:normal">&#174;</sup> Shippers, to its customers and charges a fee in exchange for the use of the container. The Company&#8217;s arrangements are similar to the accounting standard for leases since they convey the right to use the container over a period of time. The Company retains the title to the containers and provides its customers the use of the container for a specific shipping cycle. At the culmination of the customer&#8217;s shipping cycle, the container is returned to the Company. As a result, the Company classifies the containers as property and equipment for the per-use container program.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Property and equipment are recorded at cost. Cryoport Express<sup style="font-style:normal">&#174;</sup> Shippers and data loggers, used as part of the Company&#8217;s SmartPak Condition Monitoring Systems, which comprise <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 52</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 44</font>% of the Company&#8217;s net property and equipment balance at June 30, 2017 and December 31, 2016, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Equipment acquired under capital leases is amortized over the estimated useful life of the assets or term of the lease, whichever is shorter and included in depreciation and amortization expense.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the condensed consolidated statements of operations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><i> <strong>Intangible Assets</strong></i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Intangible assets are comprised of patents and trademarks and software development costs. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The Company capitalizes certain costs related to software developed for internal use. Software development costs incurred during the preliminary or maintenance project stages are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized using the straight-line method over the estimated useful life of the software, which is five years. Capitalized costs include purchased materials and costs of services including the valuation of warrants issued to consultants.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Long-lived Assets</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets&#8217; carrying value, and accordingly, we have not recognized any impairment losses through June 30, 2017.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Deferred Financing Costs</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Deferred financing costs represent costs incurred in connection with the issuance of notes payable and equity financings. Deferred financing costs related to the issuance of debt are reported as a direct deduction from the face amount of the related debt, and are amortized over the term of the financing instrument using the effective interest method. Offering costs from equity financings are netted against the gross proceeds received from the related equity financing.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Income Taxes</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 740, Income Taxes, or ASC 740. As of June 30, 2017 and December 31, 2016, there were no unrecognized tax benefits included in the accompanying condensed consolidated balance sheets that would, if recognized, affect the effective tax rates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company&#8217;s management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company&#8217;s income tax provision consists of state minimum taxes.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its condensed consolidated balance sheets at June 30, 2017 and December 31, 2016 and has not recognized interest and/or penalties in the condensed consolidated statements of operations for the three months ended June 30, 2017 and 2016. The Company is subject to taxation in the U.S. and various state jurisdictions. As of June 30, 2017, the Company is no longer subject to U.S. federal examinations for years before 2012 and for California franchise and income tax examinations for years before 2011. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by United States federal or state jurisdictions.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Revenue Recognition</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company&#8217;s arrangements are similar to the accounting standard for leases since they convey the right to use the containers over a period of time. The Company retains title to the containers and provides its customers the use of the container for a specified shipping cycle. At the culmination of the customer&#8217;s shipping cycle, the container is returned to the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue for the use of the shipper at the time of the delivery of the shipper to the end user of the enclosed materials, and at the time that collectability is reasonably certain. Revenue is based on gross amounts, net of discounts and allowances.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company also provides logistics support and management to some customers, which may include onsite logistics personnel. Revenue is recognized for these services as services are rendered and at the time that collectability is reasonably certain.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><i> Accounting for Shipping and Handling Revenue, Fees and Costs</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company classifies amounts billed for shipping and handling as revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Engineering and Development Expenses</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Expenditures relating to engineering and development are expensed in the period incurred.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Stock-Based Compensation</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (&#8220;Black-Scholes&#8221;) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The determination of fair value using Black-Scholes is affected by the Company&#8217;s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for forfeitures of unvested awards as they occur. The Company&#8217;s stock-based compensation plans are discussed further in Note 7.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Equity Instruments Issued to Non-Employees for Acquiring Goods or Services</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Issuances of the Company&#8217;s common stock for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i)&#160;the date at which a commitment for performance to earn the equity instruments is reached (a &#8220;performance commitment&#8221; which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii)&#160;the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Basic and Diluted Net Income (Loss) Per Share</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We calculate basic and diluted net income (loss) per share attributable to common stockholders using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for deemed preferred stock dividends and cumulative preferred stock dividends, whether they are earned or not during the period. In periods of a net loss position, basic and diluted weighted average shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt and convertible preferred stock outstanding during the periods. As of June 30, 2017 and December 31, 2016, the Company had no cumulative, undeclared, dividends that have not been accrued related to its preferred stock. During the six months ended June 30, 2017 and 2016, undeclared dividends totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,460</font>, respectively, were added to the net loss on the condensed consolidated statements of operations in order to calculate net loss per share attributable to common stockholders.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> The following shows the amounts used in computing net loss per share for the six months ended June 30, 2017 and 2016: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> <font style="FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.34in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(3,649,668)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(6,644,898)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Add:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Undeclared cumulative preferred dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(75,460)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Net loss attributable to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(3,649,668)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(6,720,358)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Weighted average common shares issued and outstanding - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>20,802,628</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>12,428,991</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Basic and diluted net loss per shareattributable to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>(0.18)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>(0.54)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.34in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>513,746</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>58,269</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>875,947</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,495,464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>1,389,693</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>2,553,733</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 13.5pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Segment Reporting</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We currently operate in one reportable segment and our Chief Executive Officer is the chief operating decision maker.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 12.2pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"></font></i></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <strong><i><strong><font style="FONT-SIZE: 10pt"><i>Fair Value Measurements</i></font></strong></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Level&#160;1:&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Level&#160;2:&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Level&#160;3:&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We have no assets or liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Foreign Currency Transactions</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any of the periods presented.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><i>Balance Sheet Arrangements</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 13.5pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We do not currently have any off balance sheet arrangements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><i><font style="FONT-SIZE: 10pt"><i>Recent Accounting Pronouncements</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the FASB issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221;. ASU 2014-09 supersedes the revenue recognition requirements in FASB Topic 605, &#8220;Revenue Recognition&#8221;. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. In August 2015, the FASB issued ASU No. 2015-14 which deferred the effective date by one year for public entities and others. The amendments in this ASU are effective for interim and annual periods beginning after December 15, 2017 for public business entities, certain not-for-profit entities, and certain employee benefit plans. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Management has not selected a transition method and is currently assessing the impact the adoption of ASU 2014-09 will have on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2015, the FASB issued ASU No. 2015-11, &#8220;Simplifying the Measurement of Inventory&#8221;. The amendments in this update apply to inventory that is measured using first-in, first-out (FIFO) or average cost. They do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. Other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost and net realizable value for inventory within the scope of this update, there are no other substantive changes to the guidance on measurement of inventory. The amendments in this update more closely align the measurement of inventory in International Financial Reporting Standards (IFRS) and are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2015-11 did not have an impact on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases&#8221;, which provides for a comprehensive change to lease accounting. The new standard requires that a lessee recognize a lease obligation liability and a right-to-use asset for virtually all leases of property, plant and equipment, subsequently amortized over the lease term. The new standard is effective for fiscal years beginning after December 15, 2018, with a modified retrospective transition. Management is currently evaluating the impact this standard will have on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, &#8220;Improvements to Employee Share-Based Payment Accounting&#8221; which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amendments in this ASU are effective for the reporting periods beginning after December 15, 2016 and early application is permitted. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2016-09 did not have an impact on our consolidated financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> The following shows the amounts used in computing net loss per share for the six months ended June 30, 2017 and 2016: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> <font style="FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.34in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(3,649,668)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(6,644,898)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Add:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Undeclared cumulative preferred dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(75,460)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Net loss attributable to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(3,649,668)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(6,720,358)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Weighted average common shares issued and outstanding - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>20,802,628</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>12,428,991</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Basic and diluted net loss per shareattributable to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>(0.18)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>(0.54)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.34in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>513,746</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>58,269</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>875,947</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,495,464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>1,389,693</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>2,553,733</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 1389693 2553733 0.1 0.1 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 4. Related-Party Transactions</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of June 30, 2017 and December 31, 2016, the Company had aggregate principal balances of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">646,700</font>, respectively, in outstanding unsecured indebtedness owed to three related parties, including former members of the Board of Directors, representing working capital advances made to the Company from February 2001 through March 2005.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font><b><i><font style="FONT-SIZE: 10pt">Related-Party Notes Payable</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 1, 2016, we entered into definitive agreements with Patrick Mullens, M.D., Maryl Petreccia and Jeffrey Dell, M.D. to amend and restate the outstanding notes pursuant to certain Second Amended and Restated Promissory Notes dated as of February 29, 2016 (the &#8220;Amended and Restated Notes&#8221;). As of March 31, 2017, the three note holders had outstanding principal balances of $268,900, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">125,400</font>, respectively. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Amended and Restated Notes increased the interest rate to 7% per annum, extended the term to April 1, 2017, and modified the repayment provisions to provide for (i) repayment on March 1, 2016 of the outstanding amount of interest accrued through February 29, 2016, (ii) repayment of 10% of the original principal balance and accrued interest of such notes on a quarterly basis commencing April 1, 2016, and (iii) payment of the remaining outstanding balance on April 1, 2017.</font> In addition, we issued such note holders warrants for the purchase of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,910</font>, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 7,088</font>, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,553</font> shares, respectively, of our common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.88</font> per share, immediately exercisable and expiring on April 1, 2019. The Company also agreed to reimburse up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,000</font> of legal fees incurred by the note holders. The relative fair value of the warrants issued in March 2016 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">26,900</font> was recorded as a debt discount and was amortized to interest expense using the straight-line method which approximated the effective interest method over the term of the related-party notes. During the six months ended June 30, 2017 and 2016, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,100</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">8,200</font> of the debt discount was amortized to interest expense. The notes were repaid in full in April 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Related-party interest expense under these notes was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,600</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">30,183</font> for the six months ended June 30, 2017 and 2016, respectively. Accrued interest, which is included in related-party notes payable in the accompanying condensed consolidated balance sheets, amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,400</font> as of June 30, 2017 and December 31, 2016, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> The Amended and Restated Notes increased the interest rate to 7% per annum, extended the term to April 1, 2017, and modified the repayment provisions to provide for (i) repayment on March 1, 2016 of the outstanding amount of interest accrued through February 29, 2016, (ii) repayment of 10% of the original principal balance and accrued interest of such notes on a quarterly basis commencing April 1, 2016, and (iii) payment of the remaining outstanding balance on April 1, 2017. 160000 125400 268900 1800000 605114 (i) October 28, 2019 and (ii) the thirtieth (30th) day after the date that the closing price of the Company&#8217;s common stock equals or exceeds $4.50 for ten consecutive trading days. 2.98 0 38276 0 200000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Principles of Consolidation</i></font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The condensed consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiary, Cryoport Systems, Inc. All intercompany accounts and transactions have been eliminated.&#160;In June 2017, the Company established Cryoport Europe Limited, an English company, as a wholly-owned subsidiary of Cryoport Systems, Inc.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">A summary of warrant activity is as follows:</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price/Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Term&#160;(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value&#160;(1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding &#151; December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,447,478</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(90,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(627,051)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding &#151; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,730,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,419,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested (exercisable) &#151; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>6,730,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>3.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>8,419,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-stretch: normal; font-size-adjust: none" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div>(1)</div> </td> <td style="TEXT-ALIGN: justify"> <div>Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of our common stock on June 30, 2017, which was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.92</font> per share.</div> </td> </tr> </table> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 37989 90000 4.92 134100 34200 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Note 6.&#160;Stockholders&#8217; Equity</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><i> &#160;</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><i> Authorized Stock</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000,000</font> authorized shares of common stock with a par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share which were increased in November 2015 upon approval from our stockholders from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,833,333</font> authorized shares. In September 2011, our stockholders approved an amendment to the Amended and Restated Articles of Incorporation to authorize a class of undesignated or &#8220;blank check&#8221;&#160;preferred stock, consisting of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,500,000</font> shares at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> par value per share. Shares of preferred stock may be issued in one or more series, with such rights, preferences, privileges and restrictions to be fixed by the Board of Directors. In May 2014, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation which designated <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 800,000</font> shares of the Company&#8217;s&#160;previously authorized preferred stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font>, as Class A Convertible Preferred Stock. In February 2015, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation which designated <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400,000</font> shares of the Company&#8217;s previously authorized preferred stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font>, as Class B Convertible Preferred Stock. In April 2015, the Company filed with the Secretary of State of the State of Nevada an Amendment to the Certificate of Designation to increase the number shares of Class B Convertible Preferred Stock from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 400,000</font> shares to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 585,000</font> shares.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <strong><font style="FONT-SIZE: 10pt"><i>Common Stock Issued for Services</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt">During the six months ended June 30, 2017, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12,113</font> shares of common stock with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">35,000</font> were issued to two members of the board of directors as compensation for services.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><i>Common Stock Reserved for Future Issuance</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of June 30, 2017, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12.1</font>&#160;million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options and warrants, as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="78%"> <div>Exercise of stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>5,338,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="78%"> <div>Exercise of warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,730,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="78%"> <div>Total shares of common stock reserved for future issuances</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>12,068,986</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><i>Common Stock Offering</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On March 31, 2017, we completed an underwritten public offering (the&#160;&#8220;Offering&#8221;) for gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12.7</font> million for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,325,000</font> shares of our common stock (the &#8220;Shares&#8221;) pursuant to a registration statement on Form S-3 that was previously filed and declared effective by the SEC. The Shares were issued and sold pursuant to an underwriting agreement (the &#8220;Underwriting Agreement&#8221;), dated March 28, 2017, by and among the Company and Cowen and Company, LLC and Needham &amp; Company, LLC, as Representatives of the underwriters, at a public offering price per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.00</font>. The Shares include <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 825,000</font> shares issued and sold pursuant to the Underwriters&#8217; exercise in full of their option to purchase additional shares of common stock pursuant to the Underwriting Agreement. The Company received net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11.4</font> million from the Offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with this offering, the Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">170,300</font> in offering costs which were offset against the proceeds from this offering.</font></div> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Note 7.&#160;Stock-Based Compensation</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><i> &#160;</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><i>Warrant Activity</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Our outstanding warrants expire on varying dates through November 2021.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of warrant activity is as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price/Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Term&#160;(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value&#160;(1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding &#151; December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>7,447,478</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.29</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(90,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.04</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(627,051)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.36</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding &#151; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,730,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8,419,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested (exercisable) &#151; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>6,730,427</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>3.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>8,419,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-stretch: normal; font-size-adjust: none" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"></td> <td style="WIDTH: 0.25in"> <div>(1)</div> </td> <td style="TEXT-ALIGN: justify"> <div>Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of our common stock on June 30, 2017, which was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.92</font> per share.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none" align="justify">During the six months ended June 30, 2017, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 37,989</font> shares of common stock in connection with the cashless exercise of warrants to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 90,000</font> shares of common stock. The total intrinsic value of warrants exercised during the six months ended June 30, 2017 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">134,100</font>. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><i>Stock Options</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We have four stock incentive plans: the 2002 Stock Incentive Plan (the &#8220;2002 Plan&#8221;), the 2009 Stock Incentive Plan (the &#8220;2009 Plan&#8221;), the 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;) and the 2015 Omnibus Equity Incentive Plan (the &#8220;2015 Plan&#8221;), (collectively, the &#8220;Plans&#8221;). The 2002 Plan, the 2009 Plan, and the 2011 Plan (collectively the &#8220;Prior Plans&#8221;) have been superseded by the 2015 Plan. In October 2015, the stockholders approved the 2015 Plan for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,000,000</font> shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2015 Plan. As of June 30, 2017, the Company had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,490,638</font> shares available for future awards under the 2015 Plan.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During the six months ended June 30, 2017, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Expected life (years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>5.3 &#150; 6.6</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>1.8% - 2.1%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Volatility</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>112% &#150; 115%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>0%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the historical volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We recognize stock-based compensation expense over the vesting period using the straight-line single option method. Stock-based compensation expense is recognized only for those awards that vest. We account for the forfeitures of unvested awards as they occur.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Six&#160;Months&#160;Ended June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Six&#160;Months&#160;Ended June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Cost of revenues</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,523</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>9,567</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>General and administrative</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,217,109</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,209,591</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Sales and marketing</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>321,075</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>312,558</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>Engineering and development</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,294</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6,423</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="75%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,565,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,538,139</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of stock option activity is as follows: &#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Weighted-</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Contractual</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price/Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Term&#160;(Years)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Value&#160;(1)</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding &#151; December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4,512,550</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>4.01</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Granted (weighted-average fair value of $2.98 per share)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>908,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3.56</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(13,125)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1.94</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(17,212)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(52,154)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8.03</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Outstanding &#151; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>5,338,559</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3.90</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>8.1</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>6,901,200</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Vested (exercisable) &#151; June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2,420,322</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4.10</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>7.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2,805,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Expected to vest after June 30, 2017 (unexercisable)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2,918,237</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>3.74</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>2.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>4,095,300</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -24.5pt; MARGIN: 0in 0in 0pt 24.45pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 24.5pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="33"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">(1)</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both;TEXT-INDENT: 0in; MARGIN: 0in; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on June 30, 2017, which was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.92</font> per share.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify">The total intrinsic value of options exercised during the six months ended June 30, 2017 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,200</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of June 30, 2017, there was unrecognized compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7.8</font>&#160;million related to unvested stock options, which we expect to recognize over a weighted average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.4</font>&#160;years.</font></div> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt">Note 3. Summary of Significant Accounting Policies</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><i> Principles of Consolidation</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The condensed consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiary, Cryoport Systems, Inc. All intercompany accounts and transactions have been eliminated.&#160;In June 2017, the Company established Cryoport Europe Limited, an English company, as a wholly-owned subsidiary of Cryoport Systems, Inc.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Use of Estimates</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company&#8217;s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Fair Value of Financial Instruments</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, related-party notes payable, accounts payable and accrued expenses. The carrying value for all such instruments, except for related-party notes payable, approximates fair value at June 30, 2017 and December 31, 2016 due to their short-term nature. The difference between the fair value and recorded values of the related-party notes payable is not significant.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Cash and Cash Equivalents</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company considers highly liquid investments with original maturities of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">90</font> days or less to be cash equivalents.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><strong> <font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Customers</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company grants credit to customers within the United States and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company&#8217;s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at June 30, 2017 and December 31, 2016 are net of reserves for doubtful accounts of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,000</font>, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s customers are in the biotechnology, pharmaceutical and life sciences industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. There were no customers that accounted for more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of net accounts receivable at June 30, 2017 and December 31, 2016.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During the six months ended June 30, 2017 and 2016, the Company had revenues from foreign customers of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">714,600</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">508,400</font>, respectively, which constituted approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12.7</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14.6</font>%, respectively, of total revenues. For the six months ended June 30, 2016, there was one customer that accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10.9</font>% of total revenues. No other single customer generated over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font></font>% of total revenues during the six months ended June 30, 2017 and 2016.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Inventories</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s inventories consist of packaging materials and accessories that are used as part of the solutions provided by the Company to its customers or are sold to customers directly. Inventories are stated at the lower of cost and net realizable value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company&#8217;s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company&#8217;s forecasts of market conditions, industry trends, competition and other factors.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Property and Equipment</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company provides shipping containers, the Cryoport Express<sup style="font-style:normal">&#174;</sup> Shippers, to its customers and charges a fee in exchange for the use of the container. The Company&#8217;s arrangements are similar to the accounting standard for leases since they convey the right to use the container over a period of time. The Company retains the title to the containers and provides its customers the use of the container for a specific shipping cycle. At the culmination of the customer&#8217;s shipping cycle, the container is returned to the Company. As a result, the Company classifies the containers as property and equipment for the per-use container program.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Property and equipment are recorded at cost. Cryoport Express<sup style="font-style:normal">&#174;</sup> Shippers and data loggers, used as part of the Company&#8217;s SmartPak Condition Monitoring Systems, which comprise <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 52</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 44</font>% of the Company&#8217;s net property and equipment balance at June 30, 2017 and December 31, 2016, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Equipment acquired under capital leases is amortized over the estimated useful life of the assets or term of the lease, whichever is shorter and included in depreciation and amortization expense.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the condensed consolidated statements of operations.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i><strong>Intangible Assets</strong></i></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Intangible assets are comprised of patents and trademarks and software development costs. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The Company capitalizes certain costs related to software developed for internal use. Software development costs incurred during the preliminary or maintenance project stages are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized using the straight-line method over the estimated useful life of the software, which is five years. Capitalized costs include purchased materials and costs of services including the valuation of warrants issued to consultants.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Long-lived Assets</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets&#8217; carrying value, and accordingly, we have not recognized any impairment losses through June 30, 2017.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Deferred Financing Costs</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Deferred financing costs represent costs incurred in connection with the issuance of notes payable and equity financings. Deferred financing costs related to the issuance of debt are reported as a direct deduction from the face amount of the related debt, and are amortized over the term of the financing instrument using the effective interest method. Offering costs from equity financings are netted against the gross proceeds received from the related equity financing.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Income Taxes</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 740, Income Taxes, or ASC 740. As of June 30, 2017 and December 31, 2016, there were no unrecognized tax benefits included in the accompanying condensed consolidated balance sheets that would, if recognized, affect the effective tax rates.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company&#8217;s management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company&#8217;s income tax provision consists of state minimum taxes.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company&#8217;s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its condensed consolidated balance sheets at June 30, 2017 and December 31, 2016 and has not recognized interest and/or penalties in the condensed consolidated statements of operations for the three months ended June 30, 2017 and 2016. The Company is subject to taxation in the U.S. and various state jurisdictions. As of June 30, 2017, the Company is no longer subject to U.S. federal examinations for years before 2012 and for California franchise and income tax examinations for years before 2011. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by United States federal or state jurisdictions.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Revenue Recognition</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.31in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company&#8217;s arrangements are similar to the accounting standard for leases since they convey the right to use the containers over a period of time. The Company retains title to the containers and provides its customers the use of the container for a specified shipping cycle. At the culmination of the customer&#8217;s shipping cycle, the container is returned to the Company.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes revenue for the use of the shipper at the time of the delivery of the shipper to the end user of the enclosed materials, and at the time that collectability is reasonably certain. Revenue is based on gross amounts, net of discounts and allowances.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company also provides logistics support and management to some customers, which may include onsite logistics personnel. Revenue is recognized for these services as services are rendered and at the time that collectability is reasonably certain.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Accounting for Shipping and Handling Revenue, Fees and Costs</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company classifies amounts billed for shipping and handling as revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Engineering and Development Expenses</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Expenditures relating to engineering and development are expensed in the period incurred.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Stock-Based Compensation</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (&#8220;Black-Scholes&#8221;) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The determination of fair value using Black-Scholes is affected by the Company&#8217;s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for forfeitures of unvested awards as they occur. The Company&#8217;s stock-based compensation plans are discussed further in Note 7.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Equity Instruments Issued to Non-Employees for Acquiring Goods or Services</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Issuances of the Company&#8217;s common stock for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i)&#160;the date at which a commitment for performance to earn the equity instruments is reached (a &#8220;performance commitment&#8221; which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii)&#160;the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Basic and Diluted Net Income (Loss) Per Share</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We calculate basic and diluted net income (loss) per share attributable to common stockholders using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for deemed preferred stock dividends and cumulative preferred stock dividends, whether they are earned or not during the period. In periods of a net loss position, basic and diluted weighted average shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt and convertible preferred stock outstanding during the periods. As of June 30, 2017 and December 31, 2016, the Company had no cumulative, undeclared, dividends that have not been accrued related to its preferred stock. During the six months ended June 30, 2017 and 2016, undeclared dividends totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">75,460</font>, respectively, were added to the net loss on the condensed consolidated statements of operations in order to calculate net loss per share attributable to common stockholders.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> The following shows the amounts used in computing net loss per share for the six months ended June 30, 2017 and 2016: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-stretch: normal; font-size-adjust: none"> <font style="FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.34in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Net loss</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(3,649,668)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(6,644,898)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Add:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Undeclared cumulative preferred dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(75,460)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Net loss attributable to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(3,649,668)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>(6,720,358)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Weighted average common shares issued and outstanding - basic and diluted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>20,802,628</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>12,428,991</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Basic and diluted net loss per shareattributable to common stockholders</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>(0.18)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>(0.54)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.34in; WIDTH: 95%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="22%" colspan="5"> <div>Six&#160;Months&#160;Ended&#160;June&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Stock options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>513,746</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>58,269</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>875,947</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>2,495,464</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="71%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>1,389,693</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>2,553,733</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 13.5pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Segment Reporting</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">We currently operate in one reportable segment and our Chief Executive Officer is the chief operating decision maker.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 12.2pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></font></strong> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><i>Fair Value Measurements</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Level&#160;1:&#160;Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Level&#160;2:&#160;Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Level&#160;3:&#160;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We have no assets or liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Foreign Currency Transactions</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any of the periods presented.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><i>Balance Sheet Arrangements</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 13.5pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We do not currently have any off balance sheet arrangements.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><i> Recent Accounting Pronouncements</i></font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the FASB issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221;. ASU 2014-09 supersedes the revenue recognition requirements in FASB Topic 605, &#8220;Revenue Recognition&#8221;. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. In August 2015, the FASB issued ASU No. 2015-14 which deferred the effective date by one year for public entities and others. The amendments in this ASU are effective for interim and annual periods beginning after December 15, 2017 for public business entities, certain not-for-profit entities, and certain employee benefit plans. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Management has not selected a transition method and is currently assessing the impact the adoption of ASU 2014-09 will have on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In July 2015, the FASB issued ASU No. 2015-11, &#8220;Simplifying the Measurement of Inventory&#8221;. The amendments in this update apply to inventory that is measured using first-in, first-out (FIFO) or average cost. They do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. Other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost and net realizable value for inventory within the scope of this update, there are no other substantive changes to the guidance on measurement of inventory. The amendments in this update more closely align the measurement of inventory in International Financial Reporting Standards (IFRS) and are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2015-11 did not have an impact on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In February 2016, the FASB issued ASU 2016-02, &#8220;Leases&#8221;, which provides for a comprehensive change to lease accounting. The new standard requires that a lessee recognize a lease obligation liability and a right-to-use asset for virtually all leases of property, plant and equipment, subsequently amortized over the lease term. The new standard is effective for fiscal years beginning after December 15, 2018, with a modified retrospective transition. Management is currently evaluating the impact this standard will have on our consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In March 2016, the FASB issued ASU 2016-09, &#8220;Improvements to Employee Share-Based Payment Accounting&#8221; which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amendments in this ASU are effective for the reporting periods beginning after December 15, 2016 and early application is permitted. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2016-09 did not have an impact on our consolidated financial statements.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of our common stock on June 30, 2017, which was $4.92 per share. Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on June 30, 2017, which was $4.92 per share. EX-101.SCH 7 cyrx-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 106 - Disclosure - Management's Representation and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Nature of the Business link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Related-Party Transactions link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Subsequent Event link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Summary of Significant Accounting Policies (Schedule of Earnings Per Share) (Details) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies (Schedule of Antidilutive Shares) (Details) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Related-Party Transactions (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Stockholders' Equity (Schedule of Common Stock Reserved for Future Issuance) (Details) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Stockholders' Equity (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Stock-Based Compensation (Summary of Warrant Activity) (Details) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used to Estimate Fair Value of Stock Options) (Details) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Stock-Based Compensation (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Subsequent Event (Narrative) (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 cyrx-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 cyrx-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 cyrx-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 cyrx-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document And Entity Information - shares
 6 Months Ended
Jun. 30, 2017
Jul. 31, 2017
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Jun. 30, 2017  
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q2  
Entity Registrant Name Cryoport, Inc.  
Entity Central Index Key 0001124524  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Trading Symbol CYRX  
Entity Common Stock, Shares Outstanding   24,674,432
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2017
Dec. 31, 2016
Current Assets:    
Cash and cash equivalents $ 12,854,526 $ 4,524,529
Accounts receivable, net of allowance for doubtful accounts of $60,000 and $75,000, respectively 1,250,731 1,195,479
Inventories 72,621 89,499
Prepaid expenses and other current assets 308,929 286,919
Total current assets 14,486,807 6,096,426
Property and equipment, net 2,311,680 1,647,104
Intangible assets, net 29,728 5,000
Deposits 363,403 363,403
Total assets 17,191,618 8,111,933
Current Liabilities:    
Accounts payable and other accrued expenses 1,369,223 1,160,299
Accrued compensation and related expenses 598,325 419,034
Related-party notes payable and accrued interest, net of discount of $0 and $6,100, respectively 0 651,934
Total current liabilities 1,967,548 2,231,267
Deferred rent liability 196,973 200,264
Total liabilities 2,164,521 2,431,531
Commitments and contingencies
Stockholders’ Equity:    
Common stock, $0.001 par value; 50,000,000 shares authorized; 23,992,510 and 17,604,283 issued and outstanding at June 30, 2017 and December 31, 2016, respectively 23,993 17,604
Additional paid-in capital 142,186,654 129,196,680
Accumulated deficit (127,183,550) (123,533,882)
Total stockholders’ equity 15,027,097 5,680,402
Total liabilities and stockholders’ equity 17,191,618 8,111,933
Class A convertible preferred stock [Member]    
Stockholders’ Equity:    
Preferred stock, $0.001 par value; 2,500,000 shares authorized: 0 0
Class B Convertible Preferred Stock [Member]    
Stockholders’ Equity:    
Preferred stock, $0.001 par value; 2,500,000 shares authorized: $ 0 $ 0
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Jun. 30, 2017
Dec. 31, 2016
Allowance for doubtful accounts receivable $ 60,000 $ 75,000
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 2,500,000 2,500,000
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 23,992,510 17,604,283
Common stock, shares outstanding 23,992,510 17,604,283
Related Party Notes payable, Other Payable [Member]    
Debt Instrument, Unamortized Discount $ 0 $ 6,100
Class A Convertible Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 800,000 800,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Class B Convertible Preferres Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 585,000 585,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Revenues $ 2,917,378 $ 1,917,566 $ 5,629,612 $ 3,473,111
Cost of revenues 1,524,189 1,135,616 2,982,926 2,109,354
Gross margin 1,393,189 781,950 2,646,686 1,363,757
Operating costs and expenses:        
General and administrative 1,789,514 1,429,768 3,492,546 3,244,189
Sales and marketing 1,236,833 1,195,638 2,306,768 2,442,664
Engineering and development 230,736 135,799 480,579 280,277
Total operating costs and expenses 3,257,083 2,761,205 6,279,893 5,967,130
Loss from operations (1,863,894) (1,979,255) (3,633,207) (4,603,373)
Other income (expense):        
Interest expense (26) (21,242) (15,693) (102,436)
Warrant repricing expense 0 (1,929,818) 0 (1,929,818)
Other income (expense), net 3,463 (1,915) 3,463 (6,787)
Loss before provision for income taxes (1,860,457) (3,932,230) (3,645,437) (6,642,414)
Provision for income taxes 0 (2,484) (4,231) (2,484)
Net loss (1,860,457) (3,934,714) (3,649,668) (6,644,898)
Undeclared cumulative preferred dividends 0 0 0 (75,460)
Net loss attributable to common stockholders $ (1,860,457) $ (3,934,714) $ (3,649,668) $ (6,720,358)
Net loss per share attributable to common stockholders - basic and diluted $ (0.08) $ (0.28) $ (0.18) $ (0.54)
Weighted average shares outstanding - basic and diluted 23,965,825 14,199,742 20,802,628 12,428,991
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash Flows From Operating Activities:    
Net loss $ (3,649,668) $ (6,644,898)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 307,905 170,751
Amortization of debt discounts and deferred financing costs 6,130 72,252
Stock-based compensation expense 1,565,001 1,538,139
Warrant repricing expense 0 1,929,818
Loss on disposal of property and equipment 49,840 140,588
Provision for bad debt 1,636 2,503
Changes in operating assets and liabilities:    
Accounts receivable (56,888) (400,983)
Inventories 16,878 (68,940)
Prepaid expenses and other current assets (22,010) 10
Accounts payable and other accrued expenses 205,633 57,300
Accrued compensation and related expenses 179,291 (269)
Accrued interest (1,843) 15,045
Net cash used in operating activities (1,398,095) (3,188,684)
Cash Flows From Investing Activities:    
Purchases of property and equipment (1,022,321) (599,115)
Trademark costs (24,728) 0
Net cash used in investing activities (1,047,049) (599,115)
Cash Flows From Financing Activities:    
Proceeds from the common stock offering, net of offering costs 11,405,924 0
Proceeds from April 2016 tender offer, net of offering costs 0 2,244,247
Proceeds from the rights offering, net of offering costs 0 1,000,678
Proceeds from exercise of stock options and warrants 25,438 0
Repayment of related-party notes payable (656,221) (178,831)
Net cash provided by financing activities 10,775,141 3,066,094
Net change in cash and cash equivalents 8,329,997 (721,705)
Cash and cash equivalents - beginning of period 4,524,529 5,247,425
Cash and cash equivalents - end of period 12,854,526 4,525,720
Supplemental Disclosure of Non-Cash Financing Activities:    
Cumulative undeclared preferred dividends recorded upon conversion of Class A convertible preferred stock and Class B convertible preferred stock into common 0 1,068,055
Reclassification of shipper inventory to fixed assets 0 38,276
Leasehold improvements paid by tenant allowance included in accounts payable and other accrued expenses 0 200,000
Issuance of common stock for accrued board of director compensation $ 0 $ 26,901
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Management's Representation and Basis of Presentation
 6 Months Ended
Jun. 30, 2017
Nature of the Business [Abstract]  
Management's Representation and Basis of Presentation
Note 1. Management’s Representation and Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements have been prepared by Cryoport, Inc. (the “Company”, “our” or “we”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statement presentation. However, the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of management, all adjustments (consisting primarily of normal recurring accruals) considered necessary for a fair presentation have been included.
 
Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Transition Report on Form 10-K for the period ended December 31, 2016.
 
The Company has evaluated subsequent events through the date of this filing, and determined that no subsequent events have occurred that would require recognition in the unaudited condensed consolidated financial statements or disclosure in the notes thereto other than as disclosed in the accompanying notes.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Nature of the Business
 6 Months Ended
Jun. 30, 2017
Nature of the Business [Abstract]  
Nature of Operations
Note 2. Nature of the Business
 
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells for clients worldwide. Leading global companies, such as FedEx, UPS and DHL have each separately selected Cryoport as the preferred cryogenic logistics provider for time- and temperature-sensitive biological material.  Cryoport actively supports points-of-care, contract research organizations, central laboratories, pharmaceutical and biotechnology companies, contract manufacturers and university researchers.
 
The Company is a Nevada corporation and its common stock is traded on the NASDAQ Capital Market exchange under the ticker symbol “CYRX.”
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2017
Summary of Significant Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 3. Summary of Significant Accounting Policies
 
Principles of Consolidation
 
The condensed consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiary, Cryoport Systems, Inc. All intercompany accounts and transactions have been eliminated. In June 2017, the Company established Cryoport Europe Limited, an English company, as a wholly-owned subsidiary of Cryoport Systems, Inc. 
 
Use of Estimates
 
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.
 
Fair Value of Financial Instruments
 
The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, related-party notes payable, accounts payable and accrued expenses. The carrying value for all such instruments, except for related-party notes payable, approximates fair value at June 30, 2017 and December 31, 2016 due to their short-term nature. The difference between the fair value and recorded values of the related-party notes payable is not significant.
 
Cash and Cash Equivalents
 
The Company considers highly liquid investments with original maturities of 90 days or less to be cash equivalents.
 
Customers
 
The Company grants credit to customers within the United States and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at June 30, 2017 and December 31, 2016 are net of reserves for doubtful accounts of $60,000 and $75,000, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.
 
The Company’s customers are in the biotechnology, pharmaceutical and life sciences industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. There were no customers that accounted for more than 10% of net accounts receivable at June 30, 2017 and December 31, 2016.
 
The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During the six months ended June 30, 2017 and 2016, the Company had revenues from foreign customers of approximately $714,600 and $508,400, respectively, which constituted approximately 12.7% and 14.6%, respectively, of total revenues. For the six months ended June 30, 2016, there was one customer that accounted for 10.9% of total revenues. No other single customer generated over 10% of total revenues during the six months ended June 30, 2017 and 2016.
 
Inventories
 
The Company’s inventories consist of packaging materials and accessories that are used as part of the solutions provided by the Company to its customers or are sold to customers directly. Inventories are stated at the lower of cost and net realizable value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.
 
Property and Equipment
 
The Company provides shipping containers, the Cryoport Express® Shippers, to its customers and charges a fee in exchange for the use of the container. The Company’s arrangements are similar to the accounting standard for leases since they convey the right to use the container over a period of time. The Company retains the title to the containers and provides its customers the use of the container for a specific shipping cycle. At the culmination of the customer’s shipping cycle, the container is returned to the Company. As a result, the Company classifies the containers as property and equipment for the per-use container program.
 
Property and equipment are recorded at cost. Cryoport Express® Shippers and data loggers, used as part of the Company’s SmartPak Condition Monitoring Systems, which comprise 52% and 44% of the Company’s net property and equipment balance at June 30, 2017 and December 31, 2016, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Equipment acquired under capital leases is amortized over the estimated useful life of the assets or term of the lease, whichever is shorter and included in depreciation and amortization expense.
 
Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the condensed consolidated statements of operations.
 
Intangible Assets
 
Intangible assets are comprised of patents and trademarks and software development costs. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The Company capitalizes certain costs related to software developed for internal use. Software development costs incurred during the preliminary or maintenance project stages are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized using the straight-line method over the estimated useful life of the software, which is five years. Capitalized costs include purchased materials and costs of services including the valuation of warrants issued to consultants.
 
Long-lived Assets
 
If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through June 30, 2017.
 
Deferred Financing Costs
 
Deferred financing costs represent costs incurred in connection with the issuance of notes payable and equity financings. Deferred financing costs related to the issuance of debt are reported as a direct deduction from the face amount of the related debt, and are amortized over the term of the financing instrument using the effective interest method. Offering costs from equity financings are netted against the gross proceeds received from the related equity financing.
 
Income Taxes
 
The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes, or ASC 740. As of June 30, 2017 and December 31, 2016, there were no unrecognized tax benefits included in the accompanying condensed consolidated balance sheets that would, if recognized, affect the effective tax rates.
 
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company’s income tax provision consists of state minimum taxes.
 
The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its condensed consolidated balance sheets at June 30, 2017 and December 31, 2016 and has not recognized interest and/or penalties in the condensed consolidated statements of operations for the three months ended June 30, 2017 and 2016. The Company is subject to taxation in the U.S. and various state jurisdictions. As of June 30, 2017, the Company is no longer subject to U.S. federal examinations for years before 2012 and for California franchise and income tax examinations for years before 2011. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by United States federal or state jurisdictions.
 
Revenue Recognition
 
The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company’s arrangements are similar to the accounting standard for leases since they convey the right to use the containers over a period of time. The Company retains title to the containers and provides its customers the use of the container for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the container is returned to the Company.
 
The Company recognizes revenue for the use of the shipper at the time of the delivery of the shipper to the end user of the enclosed materials, and at the time that collectability is reasonably certain. Revenue is based on gross amounts, net of discounts and allowances.
 
The Company also provides logistics support and management to some customers, which may include onsite logistics personnel. Revenue is recognized for these services as services are rendered and at the time that collectability is reasonably certain.
 
Accounting for Shipping and Handling Revenue, Fees and Costs
 
The Company classifies amounts billed for shipping and handling as revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.
 
Engineering and Development Expenses
 
Expenditures relating to engineering and development are expensed in the period incurred.
 
Stock-Based Compensation
 
The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.
 
The Company accounts for forfeitures of unvested awards as they occur. The Company’s stock-based compensation plans are discussed further in Note 7.
 
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services
 
Issuances of the Company’s common stock for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.
 
Basic and Diluted Net Income (Loss) Per Share
 
We calculate basic and diluted net income (loss) per share attributable to common stockholders using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for deemed preferred stock dividends and cumulative preferred stock dividends, whether they are earned or not during the period. In periods of a net loss position, basic and diluted weighted average shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt and convertible preferred stock outstanding during the periods. As of June 30, 2017 and December 31, 2016, the Company had no cumulative, undeclared, dividends that have not been accrued related to its preferred stock. During the six months ended June 30, 2017 and 2016, undeclared dividends totaling $0 and $75,460, respectively, were added to the net loss on the condensed consolidated statements of operations in order to calculate net loss per share attributable to common stockholders.
 
The following shows the amounts used in computing net loss per share for the six months ended June 30, 2017 and 2016:
 
 
 
 
Six Months Ended June 30,
 
 
 
2017
 
2016
 
Net loss
 
$
(3,649,668)
 
$
(6,644,898)
 
Add:
 
 
 
 
 
 
 
Undeclared cumulative preferred dividends
 
 
—
 
 
(75,460)
 
Net loss attributable to common stockholders
 
$
(3,649,668)
 
$
(6,720,358)
 
Weighted average common shares issued and outstanding - basic and diluted
 
 
20,802,628
 
 
12,428,991
 
Basic and diluted net loss per shareattributable to common stockholders
 
$
(0.18)
 
$
(0.54)
 
 
The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:
 
 
 
Six Months Ended June 30,
 
 
 
2017
 
2016
 
Stock options
 
 
513,746
 
 
58,269
 
Warrants
 
 
875,947
 
 
2,495,464
 
 
 
 
1,389,693
 
 
2,553,733
 
 
Segment Reporting
 
We currently operate in one reportable segment and our Chief Executive Officer is the chief operating decision maker.
 
Fair Value Measurements
 
We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
 
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.
 
Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
 
In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.
 
We have no assets or liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016.
 
Foreign Currency Transactions
 
We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any of the periods presented.
 
Balance Sheet Arrangements
 
We do not currently have any off balance sheet arrangements.
 
Recent Accounting Pronouncements
 
In May 2014, the FASB issued Accounting Standard Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 supersedes the revenue recognition requirements in FASB Topic 605, “Revenue Recognition”. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. In August 2015, the FASB issued ASU No. 2015-14 which deferred the effective date by one year for public entities and others. The amendments in this ASU are effective for interim and annual periods beginning after December 15, 2017 for public business entities, certain not-for-profit entities, and certain employee benefit plans. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Management has not selected a transition method and is currently assessing the impact the adoption of ASU 2014-09 will have on our consolidated financial statements.
 
In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory”. The amendments in this update apply to inventory that is measured using first-in, first-out (FIFO) or average cost. They do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. Other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost and net realizable value for inventory within the scope of this update, there are no other substantive changes to the guidance on measurement of inventory. The amendments in this update more closely align the measurement of inventory in International Financial Reporting Standards (IFRS) and are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2015-11 did not have an impact on our consolidated financial statements.
 
In February 2016, the FASB issued ASU 2016-02, “Leases”, which provides for a comprehensive change to lease accounting. The new standard requires that a lessee recognize a lease obligation liability and a right-to-use asset for virtually all leases of property, plant and equipment, subsequently amortized over the lease term. The new standard is effective for fiscal years beginning after December 15, 2018, with a modified retrospective transition. Management is currently evaluating the impact this standard will have on our consolidated financial statements.
 
In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amendments in this ASU are effective for the reporting periods beginning after December 15, 2016 and early application is permitted. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2016-09 did not have an impact on our consolidated financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related-Party Transactions
 6 Months Ended
Jun. 30, 2017
Related Party Transactions [Abstract]  
Related-Party Transactions
Note 4. Related-Party Transactions
 
As of June 30, 2017 and December 31, 2016, the Company had aggregate principal balances of $0 and $646,700, respectively, in outstanding unsecured indebtedness owed to three related parties, including former members of the Board of Directors, representing working capital advances made to the Company from February 2001 through March 2005.
 
Related-Party Notes Payable
 
On March 1, 2016, we entered into definitive agreements with Patrick Mullens, M.D., Maryl Petreccia and Jeffrey Dell, M.D. to amend and restate the outstanding notes pursuant to certain Second Amended and Restated Promissory Notes dated as of February 29, 2016 (the “Amended and Restated Notes”). As of March 31, 2017, the three note holders had outstanding principal balances of $268,900, $160,000 and $125,400, respectively. The Amended and Restated Notes increased the interest rate to 7% per annum, extended the term to April 1, 2017, and modified the repayment provisions to provide for (i) repayment on March 1, 2016 of the outstanding amount of interest accrued through February 29, 2016, (ii) repayment of 10% of the original principal balance and accrued interest of such notes on a quarterly basis commencing April 1, 2016, and (iii) payment of the remaining outstanding balance on April 1, 2017. In addition, we issued such note holders warrants for the purchase of 11,910, 7,088, and 5,553 shares, respectively, of our common stock at an exercise price of $1.88 per share, immediately exercisable and expiring on April 1, 2019. The Company also agreed to reimburse up to $5,000 of legal fees incurred by the note holders. The relative fair value of the warrants issued in March 2016 of $26,900 was recorded as a debt discount and was amortized to interest expense using the straight-line method which approximated the effective interest method over the term of the related-party notes. During the six months ended June 30, 2017 and 2016, $6,100 and $8,200 of the debt discount was amortized to interest expense. The notes were repaid in full in April 2017.
 
Related-party interest expense under these notes was $9,600 and $30,183 for the six months ended June 30, 2017 and 2016, respectively. Accrued interest, which is included in related-party notes payable in the accompanying condensed consolidated balance sheets, amounted to $0 and $11,400 as of June 30, 2017 and December 31, 2016, respectively.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 5. Commitments and Contingencies
 
Facility and Equipment Leases
 
We lease 27,600 square feet of corporate, engineering and development, and warehouse facilities in Irvine, California under an operating lease expiring February 28, 2023, subject to our option to extend the lease for two additional five-year periods. The initial base rent is approximately $24,700 per month. This lease agreement contains certain scheduled annual rent increases which are accounted for on a straight-line basis. We also lease certain office equipment which expires in March 2018.
 
Employment Agreements
 
We have entered into employment agreements with certain of our officers under which payment and benefits would become payable in the event of termination by us for any reason other than cause, or upon a change in control of our Company, or by the employee for good reason.
 
Consulting and Engineering Services
 
On September 16, 2015, the Company entered into the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), by and between KLATU Networks, LLC (“KLATU”) and the Company. Pursuant to the Purchase and Sale Agreement, the Company purchased from KLATU certain intellectual property and intellectual property rights related to the Company’s CryoportalTM logistics management platform (the “Developed Technology”), which KLATU previously developed for and licensed to the Company pursuant to the Master Consulting and Engineering Services Agreement, by and between KLATU and the Company, dated October 9, 2007 (as amended, the “Master Consulting and Engineering Services Agreement”). As full compensation for the sale and assignment of the Developed Technology from KLATU to the Company, the Company paid KLATU an aggregate amount of $400,000 in two equal installments of $200,000.
 
Concurrently with entering into the Purchase and Sale Agreement, on September 16, 2015, the Company and KLATU entered into the Amended and Restated Master Consulting and Engineering Services Agreement (the “Amended and Restated Master Consulting and Engineering Services Agreement”) to amend and restate the Master Consulting and Engineering Services Agreement. The Amended and Restated Master Consulting and Engineering Services Agreement provides a framework for KLATU to perform certain consulting, software and hardware engineering development services as mutually agreed upon and further set forth in one or more Statements of Work (as defined in the Amended and Restated Master Consulting and Engineering Services Agreement). To ensure the availability of KLATU personnel to perform services pursuant to the Amended and Restated Master Consulting and Engineering Services Agreement, the Company agreed to pay KLATU a minimum of $25,000 per month for services fees, which may be carried forward as advance payment for future services under certain conditions. The initial term of the agreement is until December 31, 2017 and will thereafter automatically renew for subsequent one year terms, unless notice of termination is given.
 
Consulting fees for services provided by KLATU were $115,500 and $157,270 for the six months ended June 30, 2017 and 2016, respectively.
 
Litigation
 
The Company may become a party to product litigation in the normal course of business. The Company accrues for open claims based on its historical experience and available insurance coverage. In the opinion of management, there are no legal matters involving the Company that would have a material adverse effect upon the Company’s consolidated financial condition or results of operations.
 
Indemnities and Guarantees
 
The Company has made certain indemnities and guarantees, under which it may be required to make payments to a guaranteed or indemnified party, in relation to certain actions or transactions. The guarantees and indemnities do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded for these indemnities and guarantees in the accompanying condensed consolidated balance sheets.
 
The Company indemnifies its directors, officers, employees and agents, as permitted under the laws of the States of California and Nevada. In connection with its facility lease, the Company has indemnified its lessor for certain claims arising from the use of the facility. The duration of the guarantees and indemnities varies, and is generally tied to the life of the agreement.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity
 6 Months Ended
Jun. 30, 2017
Stockholders' Equity [Abstract]  
Stockholders' Equity
Note 6. Stockholders’ Equity
 
Authorized Stock
 
The Company has 50,000,000 authorized shares of common stock with a par value of $0.001 per share which were increased in November 2015 upon approval from our stockholders from 20,833,333 authorized shares. In September 2011, our stockholders approved an amendment to the Amended and Restated Articles of Incorporation to authorize a class of undesignated or “blank check” preferred stock, consisting of 2,500,000 shares at $0.001 par value per share. Shares of preferred stock may be issued in one or more series, with such rights, preferences, privileges and restrictions to be fixed by the Board of Directors. In May 2014, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation which designated 800,000 shares of the Company’s previously authorized preferred stock, par value $0.001, as Class A Convertible Preferred Stock. In February 2015, the Company filed with the Secretary of State of the State of Nevada a Certificate of Designation which designated 400,000 shares of the Company’s previously authorized preferred stock, par value $0.001, as Class B Convertible Preferred Stock. In April 2015, the Company filed with the Secretary of State of the State of Nevada an Amendment to the Certificate of Designation to increase the number shares of Class B Convertible Preferred Stock from 400,000 shares to 585,000 shares.
 
Common Stock Issued for Services
 
During the six months ended June 30, 2017, 12,113 shares of common stock with a fair value of $35,000 were issued to two members of the board of directors as compensation for services.
 
Common Stock Reserved for Future Issuance
 
As of June 30, 2017, approximately 12.1 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options and warrants, as follows:
 
Exercise of stock options
 
5,338,559
 
Exercise of warrants
 
6,730,427
 
Total shares of common stock reserved for future issuances
 
12,068,986
 
 
Common Stock Offering
 
On March 31, 2017, we completed an underwritten public offering (the “Offering”) for gross proceeds of $12.7 million for 6,325,000 shares of our common stock (the “Shares”) pursuant to a registration statement on Form S-3 that was previously filed and declared effective by the SEC. The Shares were issued and sold pursuant to an underwriting agreement (the “Underwriting Agreement”), dated March 28, 2017, by and among the Company and Cowen and Company, LLC and Needham & Company, LLC, as Representatives of the underwriters, at a public offering price per share of $2.00. The Shares include 825,000 shares issued and sold pursuant to the Underwriters’ exercise in full of their option to purchase additional shares of common stock pursuant to the Underwriting Agreement. The Company received net proceeds of approximately $11.4 million from the Offering after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with this offering, the Company incurred $170,300 in offering costs which were offset against the proceeds from this offering.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2017
Stock-Based Compensation [Abstract]  
Stock-Based Compensation
Note 7. Stock-Based Compensation
 
Warrant Activity
 
We typically issue warrants to purchase shares of our common stock to investors as part of a financing transaction or in connection with services rendered by placement agents and consultants. Our outstanding warrants expire on varying dates through November 2021. A summary of warrant activity is as follows:
 
 
 
 
 
 
 
Weighted-
 
 
 
 
 
 
 
Weighted-
 
Average
 
 
 
 
 
 
 
Average
 
Remaining
 
Aggregate
 
 
 
Number of
 
Exercise
 
Contractual
 
Intrinsic
 
 
 
Shares
 
Price/Share
 
Term (Years)
 
Value (1)
 
Outstanding — December 31, 2016
 
 
7,447,478
 
$
4.29
 
 
 
 
 
 
 
Issued
 
 
—
 
 
—
 
 
 
 
 
 
 
Exercised
 
 
(90,000)
 
 
2.04
 
 
 
 
 
 
 
Expired
 
 
(627,051)
 
 
8.36
 
 
 
 
 
 
 
Outstanding — June 30, 2017
 
 
6,730,427
 
$
3.94
 
 
2.7
 
$
8,419,800
 
Vested (exercisable) — June 30, 2017
 
 
6,730,427
 
$
3.94
 
 
2.7
 
$
8,419,800
 
 
(1)
Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of our common stock on June 30, 2017, which was $4.92 per share.
 
During the six months ended June 30, 2017, the Company issued 37,989 shares of common stock in connection with the cashless exercise of warrants to purchase 90,000 shares of common stock. The total intrinsic value of warrants exercised during the six months ended June 30, 2017 was $134,100.
  
Stock Options
 
We have four stock incentive plans: the 2002 Stock Incentive Plan (the “2002 Plan”), the 2009 Stock Incentive Plan (the “2009 Plan”), the 2011 Stock Incentive Plan (the “2011 Plan”) and the 2015 Omnibus Equity Incentive Plan (the “2015 Plan”), (collectively, the “Plans”). The 2002 Plan, the 2009 Plan, and the 2011 Plan (collectively the “Prior Plans”) have been superseded by the 2015 Plan. In October 2015, the stockholders approved the 2015 Plan for 5,000,000 shares. The Prior Plans will remain in effect until all awards granted under such Prior Plans have been exercised, forfeited, cancelled, or have otherwise expired or terminated in accordance with the terms of such awards, but no awards will be made pursuant to the Prior Plans after the effectiveness of the 2015 Plan. As of June 30, 2017, the Company had 1,490,638 shares available for future awards under the 2015 Plan.
 
During the six months ended June 30, 2017, we granted stock options at exercise prices equal to or greater than the quoted market price of our common stock on the grant date. The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:
 
Expected life (years)
5.3 – 6.6
Risk-free interest rate
1.8% - 2.1%
Volatility
112% – 115%
Dividend yield
0%
 
The expected option life assumption is estimated based on the simplified method. Accordingly, the Company has utilized the average of the contractual term of the options and the weighted average vesting period for all options to calculate the expected option term. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected term of our employee stock options. The expected volatility is based on the historical volatility of our stock commensurate with the expected life of the stock-based award. We do not anticipate paying dividends on the common stock in the foreseeable future.
 
We recognize stock-based compensation expense over the vesting period using the straight-line single option method. Stock-based compensation expense is recognized only for those awards that vest. We account for the forfeitures of unvested awards as they occur.
 
Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:
 
 
 
Six Months Ended June 30,
 
Six Months Ended June 30,
 
 
 
2017
 
2016
 
 
 
 
 
 
 
Cost of revenues
 
$
18,523
 
$
9,567
 
General and administrative
 
 
1,217,109
 
 
1,209,591
 
Sales and marketing
 
 
321,075
 
 
312,558
 
Engineering and development
 
 
8,294
 
 
6,423
 
 
 
$
1,565,001
 
$
1,538,139
 
 
A summary of stock option activity is as follows:  
 
 
 
 
 
 
 
Weighted-
 
 
 
 
 
 
 
Weighted-
 
Average
 
 
 
 
 
 
 
Average
 
Remaining
 
Aggregate
 
 
 
Number of
 
Exercise
 
Contractual
 
Intrinsic
 
 
 
Shares
 
Price/Share
 
Term (Years)
 
Value (1)
 
Outstanding — December 31, 2016
 
 
4,512,550
 
$
4.01
 
 
 
 
 
 
 
Granted (weighted-average fair value of $2.98 per share)
 
 
908,500
 
 
3.56
 
 
 
 
 
 
 
Exercised
 
 
(13,125)
 
 
1.94
 
 
 
 
 
 
 
Forfeited
 
 
(17,212)
 
 
2.28
 
 
 
 
 
 
 
Expired
 
 
(52,154)
 
 
8.03
 
 
 
 
 
 
 
Outstanding — June 30, 2017
 
 
5,338,559
 
$
3.90
 
 
8.1
 
$
6,901,200
 
Vested (exercisable) — June 30, 2017
 
 
2,420,322
 
$
4.10
 
 
7.3
 
$
2,805,900
 
Expected to vest after June 30, 2017 (unexercisable)
 
 
2,918,237
 
$
3.74
 
 
2.4
 
$
4,095,300
 
 
(1)
Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on June 30, 2017, which was $4.92 per share.
 
The total intrinsic value of options exercised during the six months ended June 30, 2017 was $34,200.
 
As of June 30, 2017, there was unrecognized compensation expense of $7.8 million related to unvested stock options, which we expect to recognize over a weighted average period of 2.4 years.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Event
 6 Months Ended
Jun. 30, 2017
Subsequent Events [Abstract]  
Subsequent Events
Note 8. Subsequent Event
 
In July 2017, the Company received proceeds of $1.8 million from the exercise of 605,114 supplemental warrants which were issued in connection with the October 2016 tender offer. The warrants were exercisable upon issuance and expired on the earlier of  (i) October 28, 2019 and (ii) the thirtieth (30th) day after the date that the closing price of the Company’s common stock equals or exceeds $4.50 for ten consecutive trading days. 
 
As of June 27, 2017, the closing price of the Company’s common stock was equal to or exceeded $4.50 for ten consecutive trading days. As a result, the supplemental warrants expiration date was accelerated to July 27, 2017 unless exercised prior to that date.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2017
Summary of Significant Accounting Policies [Abstract]  
Principles of Consolidation
Principles of Consolidation
 
The condensed consolidated financial statements include the accounts of Cryoport, Inc. and its wholly owned subsidiary, Cryoport Systems, Inc. All intercompany accounts and transactions have been eliminated. In June 2017, the Company established Cryoport Europe Limited, an English company, as a wholly-owned subsidiary of Cryoport Systems, Inc.
Use of Estimates
Use of Estimates
 
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company’s significant estimates include the allowance for doubtful accounts, recoverability of long-lived assets, allowance for inventory obsolescence, deferred taxes and their accompanying valuations, and valuation of equity instruments and conversion features.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
 
The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, related-party notes payable, accounts payable and accrued expenses. The carrying value for all such instruments, except for related-party notes payable, approximates fair value at June 30, 2017 and December 31, 2016 due to their short-term nature. The difference between the fair value and recorded values of the related-party notes payable is not significant.
Cash and Cash Equivalents
Cash and Cash Equivalents
 
The Company considers highly liquid investments with original maturities of 90 days or less to be cash equivalents.
Customers
Customers
 
The Company grants credit to customers within the United States and to a limited number of international customers and does not require collateral. Revenues from international customers are generally secured by advance payments except for established foreign customers. The Company generally requires advance or credit card payments for initial revenues from new customers. The Company’s ability to collect receivables can be affected by economic fluctuations in the geographic areas and industries served by the Company. Reserves for uncollectible amounts are provided based on past experience and a specific analysis of the accounts, which management believes is sufficient. Accounts receivable at June 30, 2017 and December 31, 2016 are net of reserves for doubtful accounts of $60,000 and $75,000, respectively. Although the Company expects to collect amounts due, actual collections may differ from the estimated amounts. The Company maintains reserves for bad debt and such losses, in the aggregate, historically have not exceeded its estimates.
 
The Company’s customers are in the biotechnology, pharmaceutical and life sciences industries. Consequently, there is a concentration of accounts receivable within these industries, which is subject to normal credit risk. There were no customers that accounted for more than 10% of net accounts receivable at June 30, 2017 and December 31, 2016.
 
The Company has revenue from foreign customers primarily in Europe, Japan, Canada, India and Australia. During the six months ended June 30, 2017 and 2016, the Company had revenues from foreign customers of approximately $714,600 and $508,400, respectively, which constituted approximately 12.7% and 14.6%, respectively, of total revenues. For the six months ended June 30, 2016, there was one customer that accounted for 10.9% of total revenues. No other single customer generated over 10% of total revenues during the six months ended June 30, 2017 and 2016.
Inventories
Inventories
 
The Company’s inventories consist of packaging materials and accessories that are used as part of the solutions provided by the Company to its customers or are sold to customers directly. Inventories are stated at the lower of cost and net realizable value. Cost is determined using the standard cost method which approximates the first-in, first-to-expire method. Inventories are reviewed periodically for slow-moving or obsolete status. The Company writes down the carrying value of its inventories to reflect situations in which the cost of inventories is not expected to be recovered. Once established, write-downs of inventories are considered permanent adjustments to the cost basis of the obsolete or excess inventories. Raw materials and finished goods include material costs less reserves for obsolete or excess inventories. The Company evaluates the current level of inventories considering historical trends and other factors, such as selling prices and costs of completion, disposal and transportation, and based on the evaluation, records adjustments to reflect inventories at net realizable value. These adjustments are estimates, which could vary significantly from actual results if future economic conditions, customer demand, competition or other relevant factors differ from expectations. These estimates require us to make assessments about future demand for the Company’s products in order to categorize the status of such inventories items as slow-moving, obsolete or in excess-of-need. These estimates are subject to the ongoing accuracy of the Company’s forecasts of market conditions, industry trends, competition and other factors.
Property and Equipment
Property and Equipment
 
The Company provides shipping containers, the Cryoport Express® Shippers, to its customers and charges a fee in exchange for the use of the container. The Company’s arrangements are similar to the accounting standard for leases since they convey the right to use the container over a period of time. The Company retains the title to the containers and provides its customers the use of the container for a specific shipping cycle. At the culmination of the customer’s shipping cycle, the container is returned to the Company. As a result, the Company classifies the containers as property and equipment for the per-use container program.
 
Property and equipment are recorded at cost. Cryoport Express® Shippers and data loggers, used as part of the Company’s SmartPak Condition Monitoring Systems, which comprise 52% and 44% of the Company’s net property and equipment balance at June 30, 2017 and December 31, 2016, respectively, are depreciated using the straight-line method over their estimated useful lives of three years. Equipment and furniture are depreciated using the straight-line method over their estimated useful lives (generally three to seven years) and leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease term, whichever is shorter. Equipment acquired under capital leases is amortized over the estimated useful life of the assets or term of the lease, whichever is shorter and included in depreciation and amortization expense.
 
Betterments, renewals and extraordinary repairs that extend the lives of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation and amortization applicable to assets retired are removed from the accounts, and the gain or loss on disposition is recognized in the condensed consolidated statements of operations.
Intangible Assets
Intangible Assets
 
Intangible assets are comprised of patents and trademarks and software development costs. The Company capitalizes costs of obtaining patents and trademarks, which are amortized, using the straight-line method over their estimated useful life of five years once the patent or trademark has been issued. The Company capitalizes certain costs related to software developed for internal use. Software development costs incurred during the preliminary or maintenance project stages are expensed as incurred, while costs incurred during the application development stage are capitalized and amortized using the straight-line method over the estimated useful life of the software, which is five years. Capitalized costs include purchased materials and costs of services including the valuation of warrants issued to consultants.
Long-lived Assets
Long-lived Assets
 
If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the fair value to the carrying value. We believe the future cash flows to be received from the long-lived assets will exceed the assets’ carrying value, and accordingly, we have not recognized any impairment losses through June 30, 2017.
Deferred Financing Costs
Deferred Financing Costs
 
Deferred financing costs represent costs incurred in connection with the issuance of notes payable and equity financings. Deferred financing costs related to the issuance of debt are reported as a direct deduction from the face amount of the related debt, and are amortized over the term of the financing instrument using the effective interest method. Offering costs from equity financings are netted against the gross proceeds received from the related equity financing.
Income Taxes
Income Taxes
 
The Company accounts for income taxes under the provision of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740, Income Taxes, or ASC 740. As of June 30, 2017 and December 31, 2016, there were no unrecognized tax benefits included in the accompanying condensed consolidated balance sheets that would, if recognized, affect the effective tax rates.
 
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Based on the weight of available evidence, the Company’s management has determined that it is more likely than not that the net deferred tax assets will not be realized. Therefore, the Company has recorded a full valuation allowance against the net deferred tax assets. The Company’s income tax provision consists of state minimum taxes.
 
The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on its condensed consolidated balance sheets at June 30, 2017 and December 31, 2016 and has not recognized interest and/or penalties in the condensed consolidated statements of operations for the three months ended June 30, 2017 and 2016. The Company is subject to taxation in the U.S. and various state jurisdictions. As of June 30, 2017, the Company is no longer subject to U.S. federal examinations for years before 2012 and for California franchise and income tax examinations for years before 2011. However, to the extent allowed by law, the taxing authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carry forward amount. The Company is not currently under examination by United States federal or state jurisdictions.
Revenue Recognition
Revenue Recognition
 
The Company provides shipping containers to its customers and charges a fee in exchange for the use of the container. The Company’s arrangements are similar to the accounting standard for leases since they convey the right to use the containers over a period of time. The Company retains title to the containers and provides its customers the use of the container for a specified shipping cycle. At the culmination of the customer’s shipping cycle, the container is returned to the Company.
 
The Company recognizes revenue for the use of the shipper at the time of the delivery of the shipper to the end user of the enclosed materials, and at the time that collectability is reasonably certain. Revenue is based on gross amounts, net of discounts and allowances.
 
The Company also provides logistics support and management to some customers, which may include onsite logistics personnel. Revenue is recognized for these services as services are rendered and at the time that collectability is reasonably certain.
Accounting for Shipping and Handling Revenue, Fees and Costs
Accounting for Shipping and Handling Revenue, Fees and Costs
 
The Company classifies amounts billed for shipping and handling as revenue. Shipping and handling fees and costs are included in cost of revenues in the accompanying condensed consolidated statements of operations.
Engineering and Development Expenses
Engineering and Development Expenses
 
Expenditures relating to engineering and development are expensed in the period incurred.
Stock-Based Compensation
Stock-Based Compensation
 
The Company accounts for stock-based payments to employees and directors in accordance with stock-based payment accounting guidance which requires all stock-based payments to employees and directors, including grants of employee stock options and warrants, to be recognized based upon their fair values. The fair value of stock-based awards is estimated at the grant date using the Black-Scholes Option Pricing Model (“Black-Scholes”) and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. The determination of fair value using Black-Scholes is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.
 
The Company accounts for forfeitures of unvested awards as they occur. The Company’s stock-based compensation plans are discussed further in Note 7.
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services
Equity Instruments Issued to Non-Employees for Acquiring Goods or Services
 
Issuances of the Company’s common stock for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a “performance commitment” which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete. When it is appropriate for the Company to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.
Basic and Diluted Net Income (Loss) Per Share
Basic and Diluted Net Income (Loss) Per Share
 
We calculate basic and diluted net income (loss) per share attributable to common stockholders using the weighted average number of common shares outstanding during the periods presented, and adjust the amount of net income (loss) used in this calculation for deemed preferred stock dividends and cumulative preferred stock dividends, whether they are earned or not during the period. In periods of a net loss position, basic and diluted weighted average shares are the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include dilutive stock options, warrants and shares associated with the conversion of convertible debt and convertible preferred stock outstanding during the periods. As of June 30, 2017 and December 31, 2016, the Company had no cumulative, undeclared, dividends that have not been accrued related to its preferred stock. During the six months ended June 30, 2017 and 2016, undeclared dividends totaling $0 and $75,460, respectively, were added to the net loss on the condensed consolidated statements of operations in order to calculate net loss per share attributable to common stockholders.
 
The following shows the amounts used in computing net loss per share for the six months ended June 30, 2017 and 2016:
 
 
 
 
Six Months Ended June 30,
 
 
 
2017
 
2016
 
Net loss
 
$
(3,649,668)
 
$
(6,644,898)
 
Add:
 
 
 
 
 
 
 
Undeclared cumulative preferred dividends
 
 
—
 
 
(75,460)
 
Net loss attributable to common stockholders
 
$
(3,649,668)
 
$
(6,720,358)
 
Weighted average common shares issued and outstanding - basic and diluted
 
 
20,802,628
 
 
12,428,991
 
Basic and diluted net loss per shareattributable to common stockholders
 
$
(0.18)
 
$
(0.54)
 
 
The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:
 
 
 
Six Months Ended June 30,
 
 
 
2017
 
2016
 
Stock options
 
 
513,746
 
 
58,269
 
Warrants
 
 
875,947
 
 
2,495,464
 
 
 
 
1,389,693
 
 
2,553,733
 
Segment Reporting
Segment Reporting
 
We currently operate in one reportable segment and our Chief Executive Officer is the chief operating decision maker.
Fair Value Measurements
Fair Value Measurements
 
We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following:
 
Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs.
 
Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
 
In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible, as well as consider counterparty credit risk in the assessment of fair value.
 
We have no assets or liabilities that are required to be measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016.
Foreign Currency Transactions
Foreign Currency Transactions
 
We record foreign currency transactions at the exchange rate prevailing at the date of the transaction with resultant gains and losses being included in results of operations. Foreign currency transaction gains and losses have not been significant for any of the periods presented.
Balance Sheet Arrangements
Balance Sheet Arrangements
 
We do not currently have any off balance sheet arrangements.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
 
In May 2014, the FASB issued Accounting Standard Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 supersedes the revenue recognition requirements in FASB Topic 605, “Revenue Recognition”. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. In August 2015, the FASB issued ASU No. 2015-14 which deferred the effective date by one year for public entities and others. The amendments in this ASU are effective for interim and annual periods beginning after December 15, 2017 for public business entities, certain not-for-profit entities, and certain employee benefit plans. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Management has not selected a transition method and is currently assessing the impact the adoption of ASU 2014-09 will have on our consolidated financial statements.
 
In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory”. The amendments in this update apply to inventory that is measured using first-in, first-out (FIFO) or average cost. They do not apply to inventory that is measured using last-in, first-out (LIFO) or the retail inventory method. Other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost and net realizable value for inventory within the scope of this update, there are no other substantive changes to the guidance on measurement of inventory. The amendments in this update more closely align the measurement of inventory in International Financial Reporting Standards (IFRS) and are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2015-11 did not have an impact on our consolidated financial statements.
 
In February 2016, the FASB issued ASU 2016-02, “Leases”, which provides for a comprehensive change to lease accounting. The new standard requires that a lessee recognize a lease obligation liability and a right-to-use asset for virtually all leases of property, plant and equipment, subsequently amortized over the lease term. The new standard is effective for fiscal years beginning after December 15, 2018, with a modified retrospective transition. Management is currently evaluating the impact this standard will have on our consolidated financial statements.
 
In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The amendments in this ASU are effective for the reporting periods beginning after December 15, 2016 and early application is permitted. The Company has adopted this guidance on January 1, 2017 and the adoption of ASU No. 2016-09 did not have an impact on our consolidated financial statements.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2017
Summary of Significant Accounting Policies [Abstract]  
Schedule of Earnings Per Share
The following shows the amounts used in computing net loss per share for the six months ended June 30, 2017 and 2016:
 
 
 
 
Six Months Ended June 30,
 
 
 
2017
 
2016
 
Net loss
 
$
(3,649,668)
 
$
(6,644,898)
 
Add:
 
 
 
 
 
 
 
Undeclared cumulative preferred dividends
 
 
—
 
 
(75,460)
 
Net loss attributable to common stockholders
 
$
(3,649,668)
 
$
(6,720,358)
 
Weighted average common shares issued and outstanding - basic and diluted
 
 
20,802,628
 
 
12,428,991
 
Basic and diluted net loss per shareattributable to common stockholders
 
$
(0.18)
 
$
(0.54)
 
 
The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:
 
 
 
Six Months Ended June 30,
 
 
 
2017
 
2016
 
Stock options
 
 
513,746
 
 
58,269
 
Warrants
 
 
875,947
 
 
2,495,464
 
 
 
 
1,389,693
 
 
2,553,733
 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Tables)
 6 Months Ended
Jun. 30, 2017
Stockholders' Equity [Abstract]  
Schedule of Common Stock Reserved for Future Issuance
As of June 30, 2017, approximately 12.1 million shares of common stock were issuable upon conversion or exercise of rights granted under prior financing arrangements, stock options and warrants, as follows:
 
Exercise of stock options
 
 
5,338,559
 
Exercise of warrants
 
 
6,730,427
 
Total shares of common stock reserved for future issuances
 
 
12,068,986
 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2017
Stock-Based Compensation [Abstract]  
Schedule of Warrant Activity
A summary of warrant activity is as follows:
 
 
 
 
 
 
 
Weighted-
 
 
 
 
 
 
 
Weighted-
 
Average
 
 
 
 
 
 
 
Average
 
Remaining
 
Aggregate
 
 
 
Number of
 
Exercise
 
Contractual
 
Intrinsic
 
 
 
Shares
 
Price/Share
 
Term (Years)
 
Value (1)
 
Outstanding — December 31, 2016
 
 
7,447,478
 
$
4.29
 
 
 
 
 
 
 
Issued
 
 
—
 
 
—
 
 
 
 
 
 
 
Exercised
 
 
(90,000)
 
 
2.04
 
 
 
 
 
 
 
Expired
 
 
(627,051)
 
 
8.36
 
 
 
 
 
 
 
Outstanding — June 30, 2017
 
 
6,730,427
 
$
3.94
 
 
2.7
 
$
8,419,800
 
Vested (exercisable) — June 30, 2017
 
 
6,730,427
 
$
3.94
 
 
2.7
 
$
8,419,800
 
 
(1)
Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of our common stock on June 30, 2017, which was $4.92 per share.
Schedule of Fair Value Assumptions of Stock Options
The fair value of each option grant was estimated on the date of grant using Black-Scholes with the following weighted average assumptions:
 
Expected life (years)
5.3 – 6.6
Risk-free interest rate
1.8% - 2.1%
Volatility
112% – 115%
Dividend yield
0%
Schedule of Share-based Payment Awards
Total stock-based compensation expense related to all of our share-based payment awards is comprised of the following:
 
 
 
Six Months Ended June 30,
 
Six Months Ended June 30,
 
 
 
2017
 
2016
 
 
 
 
 
 
 
Cost of revenues
 
$
18,523
 
$
9,567
 
General and administrative
 
 
1,217,109
 
 
1,209,591
 
Sales and marketing
 
 
321,075
 
 
312,558
 
Engineering and development
 
 
8,294
 
 
6,423
 
 
 
$
1,565,001
 
$
1,538,139
 
Schedule of Stock Option Activity
A summary of stock option activity is as follows:  
 
 
 
 
 
 
 
Weighted-
 
 
 
 
 
 
 
Weighted-
 
Average
 
 
 
 
 
 
 
Average
 
Remaining
 
Aggregate
 
 
 
Number of
 
Exercise
 
Contractual
 
Intrinsic
 
 
 
Shares
 
Price/Share
 
Term (Years)
 
Value (1)
 
Outstanding — December 31, 2016
 
 
4,512,550
 
$
4.01
 
 
 
 
 
 
 
Granted (weighted-average fair value of $2.98 per share)
 
 
908,500
 
 
3.56
 
 
 
 
 
 
 
Exercised
 
 
(13,125)
 
 
1.94
 
 
 
 
 
 
 
Forfeited
 
 
(17,212)
 
 
2.28
 
 
 
 
 
 
 
Expired
 
 
(52,154)
 
 
8.03
 
 
 
 
 
 
 
Outstanding — June 30, 2017
 
 
5,338,559
 
$
3.90
 
 
8.1
 
$
6,901,200
 
Vested (exercisable) — June 30, 2017
 
 
2,420,322
 
$
4.10
 
 
7.3
 
$
2,805,900
 
Expected to vest after June 30, 2017 (unexercisable)
 
 
2,918,237
 
$
3.74
 
 
2.4
 
$
4,095,300
 
 
(1)
Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on June 30, 2017, which was $4.92 per share.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Schedule of Earnings Per Share) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Net loss $ (1,860,457) $ (3,934,714) $ (3,649,668) $ (6,644,898)
Undeclared cumulative preferred dividends 0 0 0 (75,460)
Net loss attributable to common stockholders $ (1,860,457) $ (3,934,714) $ (3,649,668) $ (6,720,358)
Weighted average common shares issued and outstanding - basic and diluted 23,965,825 14,199,742 20,802,628 12,428,991
Basic and diluted net loss per shareattributable to common stockholders $ (0.08) $ (0.28) $ (0.18) $ (0.54)
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Schedule of Antidilutive Shares) (Details) - shares
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 1,389,693 2,553,733
Stock Options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 513,746 58,269
Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 875,947 2,495,464
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Significant Accounting Policies Additional Information [Line Items]          
Allowance for doubtful accounts receivable $ 60,000   $ 60,000   $ 75,000
Preferred Stock Dividends, Income Statement Impact $ 0 $ 0 $ 0 $ 75,460  
Maturity Period Of Highly Liquid Investments     90 days    
Cryogenic Shippers [Member]          
Significant Accounting Policies Additional Information [Line Items]          
Property Plant Equipment Ownership Percentage 52.00%   52.00%    
Data loggers [Member]          
Significant Accounting Policies Additional Information [Line Items]          
Property Plant Equipment Ownership Percentage         44.00%
Foreign Customers [Member]          
Significant Accounting Policies Additional Information [Line Items]          
Revenues     $ 714,600 $ 508,400  
Accounts Receivable [Member]          
Significant Accounting Policies Additional Information [Line Items]          
Concentration risk, percentage     10.00%   10.00%
Sales Revenue, Net [Member]          
Significant Accounting Policies Additional Information [Line Items]          
Concentration risk, percentage     10.00% 10.00%  
Sales Revenue, Net [Member] | Customer One [Member]          
Significant Accounting Policies Additional Information [Line Items]          
Concentration risk, percentage       14.60%  
Sales Revenue, Net [Member] | Foreign Customers [Member]          
Significant Accounting Policies Additional Information [Line Items]          
Concentration risk, percentage     12.70% 10.90%  
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related-Party Transactions (Narrative) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2017
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Mar. 31, 2016
Aggregate principal balances   $ 0   $ 646,700  
Interest Payable   0   $ 11,400  
Related-party interest expense   $ 9,600 $ 30,183    
Common stock exercise price $ 1.88        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   90,000      
Legal Fees $ 5,000        
Amended and Restated Notes [Member]          
Amortization of Debt Discount (Premium)   $ 6,100 $ 8,200    
Debt Instrument, Payment Terms   The Amended and Restated Notes increased the interest rate to 7% per annum, extended the term to April 1, 2017, and modified the repayment provisions to provide for (i) repayment on March 1, 2016 of the outstanding amount of interest accrued through February 29, 2016, (ii) repayment of 10% of the original principal balance and accrued interest of such notes on a quarterly basis commencing April 1, 2016, and (iii) payment of the remaining outstanding balance on April 1, 2017.      
Warrants Not Settleable in Cash, Fair Value Disclosure         $ 26,900
Patrick Mullins, M.D. [Member]          
Aggregate principal balances $ 268,900        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 11,910        
Maryl Petreccia [Member]          
Aggregate principal balances $ 160,000        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 7,088        
Jeffrey Dell, M.D. [Member]          
Aggregate principal balances $ 125,400        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 5,553        
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies (Narrative) (Details)
 1 Months Ended 6 Months Ended
Sep. 16, 2015
USD ($)
Jun. 30, 2017
USD ($)
ft²
Jun. 30, 2016
USD ($)
Property Subject to or Available for Operating Lease [Line Items]      
Consulting Service Fee   $ 115,500 $ 157,270
KLATU Networks, LLC [Member] | Purchase and Sale Agreement [Member]      
Property Subject to or Available for Operating Lease [Line Items]      
Technology Services Costs $ 400,000    
Installment amount of Service costs 200,000    
Minimum [Member] | KLATU Networks, LLC [Member]      
Property Subject to or Available for Operating Lease [Line Items]      
Technology Services Costs $ 25,000    
Irvine, California Facility [Member]      
Property Subject to or Available for Operating Lease [Line Items]      
Estimated Base Rent Under Lease   $ 24,700  
Lease Expiration Date   Feb. 28, 2023  
Land Subject to Ground Leases | ft²   27,600  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Schedule of Common Stock Reserved for Future Issuance) (Details)
Jun. 30, 2017
shares
Class of Stock [Line Items]  
Common Stock Reserved for Future Issuance 12,068,986
Exercise Of Stock Options [Member]  
Class of Stock [Line Items]  
Common Stock Reserved for Future Issuance 5,338,559
Exercise Of Warrants [Member]  
Class of Stock [Line Items]  
Common Stock Reserved for Future Issuance 6,730,427
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stockholders' Equity (Narrative) (Details) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2017
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Nov. 30, 2015
Apr. 30, 2015
Feb. 28, 2015
May 31, 2014
Class of Stock [Line Items]                
Common stock, shares authorized   50,000,000   50,000,000        
Common stock, par value   $ 0.001   $ 0.001        
Preferred stock, par value   $ 0.001   $ 0.001        
Preferred stock, shares authorized   2,500,000   2,500,000        
Common Stock, Capital Shares Reserved For Future Issuance   12,068,986            
Proceeds from Issuance of Common Stock   $ 11,405,924 $ 0          
Director [Member]                
Class of Stock [Line Items]                
Stock Issued During Period, Shares, Issued for Services   12,113            
Stock Issued During Period, Value, Issued for Services   $ 35,000            
Underwritten Public Offering [Member]                
Class of Stock [Line Items]                
Stock Issued During Period, Shares, New Issues 6,325,000              
Stock Issued During Period, Value, New Issues $ 12,700,000              
Proceeds from Issuance of Common Stock $ 11,400,000              
Shares Issued, Price Per Share $ 2.00              
Over-Allotment Option [Member]                
Class of Stock [Line Items]                
Stock Issued During Period, Value, Issued for Services $ 825,000              
Public Offering [Member]                
Class of Stock [Line Items]                
Payments of Stock Issuance Costs $ 170,300              
Minimum [Member]                
Class of Stock [Line Items]                
Common stock, shares authorized         20,833,333      
Class A convertible preferred stock [Member]                
Class of Stock [Line Items]                
Preferred stock, par value   $ 0.001   $ 0.001       $ 0.001
Preferred stock, shares authorized   800,000   800,000       800,000
Class B Convertible Preferred Stock [Member]                
Class of Stock [Line Items]                
Preferred stock, par value             $ 0.001  
Preferred stock, shares authorized             400,000  
Class B Convertible Preferred Stock [Member] | Maximum [Member]                
Class of Stock [Line Items]                
Preferred stock, shares authorized           585,000    
Class B Convertible Preferred Stock [Member] | Minimum [Member]                
Class of Stock [Line Items]                
Preferred stock, shares authorized           400,000    
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Summary of Warrant Activity) (Details) - Warrants [Member]
 6 Months Ended
Jun. 30, 2017
USD ($)
$ / shares
shares
Number of Shares  
Outstanding | shares 7,447,478
Issued | shares 0
Exercised | shares (90,000)
Expired | shares (627,051)
Outstanding | shares 6,730,427
Vested (exercisable) | shares 6,730,427
Weighted-Average Exercise Price/Share  
Outstanding | $ / shares $ 4.29
Issued | $ / shares 0
Exercised | $ / shares 2.04
Expired | $ / shares 8.36
Outstanding | $ / shares 3.94
Vested (exercisable) | $ / shares $ 3.94
Weighted-Average Remaining Contractual Term (Years)  
Outstanding 2 years 8 months 12 days
Vested (exercisable) 2 years 8 months 12 days
Aggregated Intrinsic Value  
Outstanding | $ $ 8,419,800 [1]
Vested (exercisable) | $ $ 8,419,800 [1]
[1] Aggregate intrinsic value represents the difference between the exercise price of the warrant and the closing market price of our common stock on June 30, 2017, which was $4.92 per share.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Schedule of Assumptions Used to Estimate Fair Value of Stock Options) (Details) - Stock Options [Member]
 6 Months Ended
Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Risk-free interest rate, minimum 1.80%
Risk-free interest rate, maximum 2.10%
Volatility, minimum 112.00%
Volatility, maximum 115.00%
Dividend yield 0.00%
Minimum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life (years) 5 years 3 months 18 days
Maximum [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life (years) 6 years 7 months 6 days
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Details) - USD ($)
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Share-based Compensation $ 1,565,001 $ 1,538,139
Cost of Revenues [Member]    
Share-based Compensation 18,523 9,567
General and Administrative Expense [Member]    
Share-based Compensation 1,217,109 1,209,591
Selling and Marketing Expense [Member]    
Share-based Compensation 321,075 312,558
Engineering And Development [Member]    
Share-based Compensation $ 8,294 $ 6,423
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Summary of Stock Option Activity) (Details) - Stock Options [Member]
 6 Months Ended
Jun. 30, 2017
USD ($)
$ / shares
shares
Number of Shares  
Outstanding | shares 4,512,550
Granted | shares 908,500
Exercised | shares (13,125)
Forfeited | shares (17,212)
Expired | shares (52,154)
Outstanding | shares 5,338,559
Vested (exercisable) | shares 2,420,322
Expected to vest after (unexercisable) | shares 2,918,237
Weighted-Average Exercise Price/Share  
Outstanding | $ / shares $ 4.01
Granted | $ / shares 3.56
Exercised | $ / shares 1.94
Forfeited | $ / shares 2.28
Expired | $ / shares 8.03
Outstanding | $ / shares 3.90
Vested (exercisable) | $ / shares 4.10
Expected to vest after (unexercisable) | $ / shares $ 3.74
Weighted-Average Remaining Contractual Term (Years)  
Outstanding 8 years 1 month 6 days
Vested (exercisable) 7 years 3 months 18 days
Expected to vest after (unexercisable) 2 years 4 months 24 days
Aggregated Intrinsic Value  
Outstanding | $ $ 6,901,200 [1]
Vested (exercisable) | $ 2,805,900 [1]
Expected to vest after (unexercisable) | $ $ 4,095,300 [1]
[1] Aggregate intrinsic value represents the difference between the exercise price of the option and the closing market price of our common stock on June 30, 2017, which was $4.92 per share.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Narrative) (Details) - USD ($)
 6 Months Ended
Jun. 30, 2017
Oct. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock Issued During Period, Shares, Cashless Exercise Of Warrants 37,989  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 90,000  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value $ 34,200  
Warrant [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Intrinsic value per share $ 4.92  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Intrinsic Value $ 134,100  
Stock Options [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized compensation cost related to unvested stock options $ 7,800,000  
Weighted average recognition period 2 years 4 months 24 days  
Intrinsic value per share $ 4.92  
Fair Value Assumptions, Exercise Price $ 2.98  
Plan 2015 [Member] | Stock Options [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total shares available for future grant 1,490,638 5,000,000
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Subsequent Event (Narrative) (Details) - USD ($)
 1 Months Ended 6 Months Ended
Jul. 31, 2017
Jun. 30, 2017
Jun. 30, 2016
Subsequent Event [Line Items]      
Proceeds from Warrant Exercises   $ 25,438 $ 0
Class Of Warrant Or Right, Exercisable Term (i) October 28, 2019 and (ii) the thirtieth (30th) day after the date that the closing price of the Company’s common stock equals or exceeds $4.50 for ten consecutive trading days.    
Subsequent Event [Member]      
Subsequent Event [Line Items]      
Proceeds from Warrant Exercises $ 1,800,000    
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 605,114    
EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 43 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 76 186 1 true 35 0 false 5 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.Cryoport.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.Cryoport.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.Cryoport.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 104 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.Cryoport.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 105 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.Cryoport.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 106 - Disclosure - Management's Representation and Basis of Presentation Sheet http://www.Cryoport.com/role/ManagementsRepresentationAndBasisOfPresentation Management's Representation and Basis of Presentation Notes 6 false false R7.htm 107 - Disclosure - Nature of the Business Sheet http://www.Cryoport.com/role/NatureOfBusiness Nature of the Business Notes 7 false false R8.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.Cryoport.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 109 - Disclosure - Related-Party Transactions Sheet http://www.Cryoport.com/role/RelatedpartyTransactions Related-Party Transactions Notes 9 false false R10.htm 110 - Disclosure - Commitments and Contingencies Sheet http://www.Cryoport.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 10 false false R11.htm 111 - Disclosure - Stockholders' Equity Sheet http://www.Cryoport.com/role/StockholdersEquity Stockholders' Equity Notes 11 false false R12.htm 112 - Disclosure - Stock-Based Compensation Sheet http://www.Cryoport.com/role/StockbasedCompensation Stock-Based Compensation Notes 12 false false R13.htm 113 - Disclosure - Subsequent Event Sheet http://www.Cryoport.com/role/SubsequentEvent Subsequent Event Notes 13 false false R14.htm 114 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.Cryoport.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.Cryoport.com/role/SummaryOfSignificantAccountingPolicies 14 false false R15.htm 115 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.Cryoport.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.Cryoport.com/role/SummaryOfSignificantAccountingPolicies 15 false false R16.htm 116 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.Cryoport.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.Cryoport.com/role/StockholdersEquity 16 false false R17.htm 117 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.Cryoport.com/role/StockbasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.Cryoport.com/role/StockbasedCompensation 17 false false R18.htm 118 - Disclosure - Summary of Significant Accounting Policies (Schedule of Earnings Per Share) (Details) Sheet http://www.Cryoport.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEarningsPerShareDetails Summary of Significant Accounting Policies (Schedule of Earnings Per Share) (Details) Details http://www.Cryoport.com/role/SummaryOfSignificantAccountingPoliciesTables 18 false false R19.htm 119 - Disclosure - Summary of Significant Accounting Policies (Schedule of Antidilutive Shares) (Details) Sheet http://www.Cryoport.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSharesDetails Summary of Significant Accounting Policies (Schedule of Antidilutive Shares) (Details) Details http://www.Cryoport.com/role/SummaryOfSignificantAccountingPoliciesTables 19 false false R20.htm 120 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details) Sheet http://www.Cryoport.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies (Narrative) (Details) Details http://www.Cryoport.com/role/SummaryOfSignificantAccountingPoliciesTables 20 false false R21.htm 121 - Disclosure - Related-Party Transactions (Narrative) (Details) Sheet http://www.Cryoport.com/role/RelatedpartyTransactionsNarrativeDetails Related-Party Transactions (Narrative) (Details) Details http://www.Cryoport.com/role/RelatedpartyTransactions 21 false false R22.htm 122 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://www.Cryoport.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) Details http://www.Cryoport.com/role/CommitmentsAndContingencies 22 false false R23.htm 123 - Disclosure - Stockholders' Equity (Schedule of Common Stock Reserved for Future Issuance) (Details) Sheet http://www.Cryoport.com/role/StockholdersEquityScheduleOfCommonStockReservedForFutureIssuanceDetails Stockholders' Equity (Schedule of Common Stock Reserved for Future Issuance) (Details) Details http://www.Cryoport.com/role/StockholdersEquityTables 23 false false R24.htm 124 - Disclosure - Stockholders' Equity (Narrative) (Details) Sheet http://www.Cryoport.com/role/StockholdersEquityNarrativeDetails Stockholders' Equity (Narrative) (Details) Details http://www.Cryoport.com/role/StockholdersEquityTables 24 false false R25.htm 125 - Disclosure - Stock-Based Compensation (Summary of Warrant Activity) (Details) Sheet http://www.Cryoport.com/role/StockbasedCompensationSummaryOfWarrantActivityDetails Stock-Based Compensation (Summary of Warrant Activity) (Details) Details http://www.Cryoport.com/role/StockbasedCompensationTables 25 false false R26.htm 126 - Disclosure - Stock-Based Compensation (Schedule of Assumptions Used to Estimate Fair Value of Stock Options) (Details) Sheet http://www.Cryoport.com/role/StockbasedCompensationScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionsDetails Stock-Based Compensation (Schedule of Assumptions Used to Estimate Fair Value of Stock Options) (Details) Details http://www.Cryoport.com/role/StockbasedCompensationTables 26 false false R27.htm 127 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.Cryoport.com/role/StockbasedCompensationDetails Stock-Based Compensation (Details) Details http://www.Cryoport.com/role/StockbasedCompensationTables 27 false false R28.htm 128 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details) Sheet http://www.Cryoport.com/role/StockbasedCompensationSummaryOfStockOptionActivityDetails Stock-Based Compensation (Summary of Stock Option Activity) (Details) Details http://www.Cryoport.com/role/StockbasedCompensationTables 28 false false R29.htm 129 - Disclosure - Stock-Based Compensation (Narrative) (Details) Sheet http://www.Cryoport.com/role/StockbasedCompensationNarrativeDetails Stock-Based Compensation (Narrative) (Details) Details http://www.Cryoport.com/role/StockbasedCompensationTables 29 false false R30.htm 130 - Disclosure - Subsequent Event (Narrative) (Details) Sheet http://www.Cryoport.com/role/SubsequentEventNarrativeDetails Subsequent Event (Narrative) (Details) Details http://www.Cryoport.com/role/SubsequentEvent 30 false false All Reports Book All Reports cyrx-20170630.xml cyrx-20170630.xsd cyrx-20170630_cal.xml cyrx-20170630_def.xml cyrx-20170630_lab.xml cyrx-20170630_pre.xml true true ZIP 48 0001144204-17-041557-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-041557-xbrl.zip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¿RY3B[@]QRF*:X(HISB^);IDQ8N[4GH\:9 MST=O*6U.I\Q7*>Q"X!EV=NQ36(@6\S.L$/[V-ZU9JHA&]G NUQT9B=_X!".Q M78^ J*>V.G<"ZXQ&VP2U':C$8.1^)J0S\(B4" MDP%+S&#H,((G12Z7B5?UCAT@AF#Y$H^ES_;;>W/7JANO'"C<;1 1 Y;# VD6>C.BS41R)":94\\25]N&GHP#:.?#TI'E+/@'",P+V M)D__FB>24F7Y."8G%YL-:R3M/[A!(#!:H17"&! '8 Y%IT]4'%[KV0LX9.)G M(]PR /YI,1"_XVP 2$,VWYLC@<""1ISV=CJ[[&8H_2$+\MM(*0KJ]X7>B2'! MQ.V*2+")X EQYSB["H'_<4>1DCM4M82DF68AI9$$>,-)'('V*4O M4^L!XCSSD ")C"<"6QA& A\;@Z<#P)SR),3]>#X>PS2:5I(Z(HYDJK>LP$G2 M>2FS_B0OP7LP)/N>86 =(6J,S Z#LB"-S$__V@*%&W'MC('/IG?5E @!U9A: MTSRJ=<9(I,-87ZB"[%QX>CK1FG,_J"@4#,K !KHM"<)HZ\X;&8;:/\3?,E)5 M5()-.UQ]&0$[2D (\&7Z("_16>EU6^G_9.'D04JB4[%SEVC 8*J<6:SJ*F22 MLPAT>QHGDQGC-T*,N+,O$Y7NR,@S?\59REY^ M./MP_@I3SN4E0BJE.2=Y3//P&4(^.\''? +M)H#2"*V!M$SEY@F&C4R5)F62 MC)W 75VPI8@DNZ)BD('$8%15]&+%?3ACPA75*IE=/;.M4OT9Y1BO!D@$V3PT M+=IH:?6:K[!0'K ./QZ;%%:!?Z(_%G_0%K?9UBZVH:]S4(JMG6+1I% JU"_F MO(_D(S)PX$@(U#[(PS/5)O9P^/H9*L>(U# HE@^%BBG*G@N74K&79Q\N+E]I MRS)C=_K@PL![:-">J)]GM#+ 41E6@W\2@R*-)J2329&2@04DV!C\#P?+ 1!V MK#V->9K7DD=PP@)B:Q.@YPK;J>*&JN(/XBHA)M ,-T\=XR\[[6Y%%7\$:1%V M?.,9=XZ\X\!4OW#J[YR((7BXI32C,(?X/M9\F9A,*A8IO.N&B_2OV&!S;WR7$UG MG(U0<$UR .3S- ],+K$!^\X[*I[[S">C:IK,4@!&_I7VT3 Z4P*=(BR[0"95 M10E9F8A!,2A"(&KUOJ/+],9F)GNGS+:&<\:!'R%89RF_Q2 +OND+B5D!$W$A MOV;:^^*W)$MX51&^;"=:JK4BX) IVM;2\9=Q8W+&)U>HR" \,@#5[MRC(S:M MD3A6AR\*#5=G_Y%I5FS_YW[ O_5II2LJC:?6[$8$Z-#I&VQ=_U;?0; 3\@EX MSF_Z\E8$;^]M\5Z,GQ1_!<7*[#^3\L_\9.J/KS.U,^!\_.:RW/\L9>,S( +3 M)U_$;?HNC/VO/__[7__^UX__9V?G0QRGGV)P12^%3M]=]OMWFO\^34^^,(\ MGT[&\#P50P4B>/$S#IX/#\LQ3PT3T?_IQ?]\0"$+_NIV#JNOPX,JB&CG]\OJ,C#[E"6^F%K'AT^PC)^/ M!P-,!]+YMC21$=Y@IF,1D#"][:S3K& X^P(WMT5QGD)OO8O$E\J4#.=JZD:W M-"N$ B,&E$R[5I?VT(GMRQO02+#L4J'<,[H!4?QNMW74+2^V:/WXNH*X!?@\ M3OP*-D"_OV!&%#H%HF*##_,9P[J"4OHK>.\>FI@G7O>!'79*VDP3>B'[=-L/ M99_>8O;Y1G![ZP-W=^^AX.[60UIV5R4MQF T3%AV9[EG=XW#N[3X4W(.5@7NP%'!A45561"L-W__X&H>0;_!_:?W_'U!+ P04 M" #H< E+J:!(#"$, #K<@ $0 &-Y'-D[5U1;^.X M$7X_X/X#ZP+%WH/C.-GL7=+-'9Q-_./PS=G)T=GKHW^2?PW>_YMCH(P8*Q%@Z" M:$K:;2Q'!Q,VI<10-6;F YTR/:,!.V]-C)F==3JH]T[-HUFD#&IUL(S#-\>( M6[ ID^8Z4M-+-J*Q,.>MSS$5?,19V"+@J-1GP5P]5S%FI5<$GXX/(C4&D<-N MY]?WM_<69V96GG;LTTPTUNTQI;.%\(CJH15-']B*:Q]VV\?= M145'L31JONJC9L'!.'KLI _+U&*E( !=>NG3$L60\7(=>(#BKU?%V7,P*9?' M)R7VN7QDVI2K),]0Z7A525(>Z'(=^ZBD',V#<@5X@.+=57$@P,QG3)=28Y^4 ME6%FRE$(/"DI)60SQ0)L^<[X.NU0%:A(,$ 0F#9[G@DJJ8G4_!I^+RHDDC*> MEAL)C>H@X@X(M4&**1XL]#8KI0K0AQ#REDH90><"G9+]C7=F,RY'4?H3;F!\ MGR'@!U G>/'Q[L;=-5C7+J,@QCZF)\,K:;B9WX!)-;4%M0B'VO%*+ K/B@_9 MB$MN878/N] M9NKY2S!%$ELD9^QM9]W"M]^LFX\U"_OR1WL-!&JP9G6QUTCU M4Q&_[K*0;34#*H)8. M-U3HK7.1,[D32NTB&3$(1<*$CP4.,VPLJL.^[GS!F M=$)5!3D_84? TCW4*$L96Q@D>8LD-4D2FPUON_,VH-#[FPDS'/!5)7%5R<_H M\2Z,DE<[LSI M.ZHGUR)ZJDKI4M[/Z,DNC*)Q8JTWC+H8?0]YVSBILCN6=QL2D0NJ.7 TR-U- M:-U6R<_M&\Q_N Y$I&/%X,?2_)_^>'SZ9TU6"R%48J\,Q2#)^8(:FETT?Z & MZK8_NH@UETRGS;-PUT_4]^M$)?K( HR')+/2L.!BX3Z>3JF:]T?W?"SY"!(( MF#L$=G[,Y7@ W5C 6;&55F M_J"HU##E768QSJ=^ID[7F4KMM =HB.0M-]Q/2+71M.0LV M;R")G88++Q>X4@TM83J#=#J7XCF>^3DY*N6D?4&31'UII^'$G2(,-?L<@[-7 MC_ GRP56;_I9."X.^IDZL?I-[>^7H.V2J%5+V+JO=T_8R*OLJEF4VI/@!SH4 MV]&;:OC)/=F'W*2$AMHM,HL5&EU/_905UB9<649#T([I1H$DEX2?J,+:A"OU M:(AZH4X2]T2$L6#]T155$A[H 5/W$ZK8)3.4BZWZS\W&_/3OL=!!7F6%HW!6 M/('RB07P'7F58FA"YL5"I@?W0RYBPQ^9K66]5]"XS?G#IK#JLFO8Y $D8:.; MN'FQN/E %;Z:>]RE9RGH>B/BJ+#.LTU$+,IJN-]C';6<[?LB\2KU^P,C'I@@J%VBV2NK6JG^?B IISDI]+V]*B2%96P_SN MS"]G7- 13F7J[U3$(&-M]!.A*K&QMW%_])2OY95' M3WYJMP1#$ TQ$#7(/< M94#PJ/LY+B[]51D4\DVU&1GV#P-/9K=9UD]P<9'.27"3W>VQU\"URN87\G)W M7+*,_R#+>2.C8@]AGF&)]S.6YI/9P*/;]I[$\5&YRT\S]K.CJW^ M!DX?/$]%)H(E> Z$6L;7ZRDM.#.1'NKS'Q,%(]&,*<.9[F3@6Z3S@HX!(]LZ MMDIB/=T2=+BM6Z#"1'T]@@:PK4=K;>9E_4K:6_[P)_S*'PZUM\ MZ :)+#UN M[CI%G9Q4OXT":\JC@K_:F5X;;[6[1^WC[L&S#I>UOPV(I8_;@\Y\.T#5**67K>7)G8"4G:0 MO@J2O%[V8]]**3V<7PE,7G'Q:U\XA7/\5: LE.S5OA"*9_RK8%AJ)9?[HEC_ M<$ 5#)D.7K27RKN5O_Y-@4H ,B5[M0.$XO<)[& CV1C?[57KN812*UK8?9UB MM]E]LS>,BIUG#H)YD>+]7VFH"BEOY6II9 >$WF]U5(F43 7NS=+O]UA _@]I](8:OQL$\9JD MI?;+-V=PC\OQC6%3G%6U"$VESEM&Q9BT6BE($WD4/EB],%;I^0;)A< ]@)FL MACDI%!KCTY]5%,^R0CB83V;!F/?^5@VEP\7MWG(F&XH?V+.Y$""7^9Y\4>7, M9/?+_!]1H;]0!>SIP\::V;S%^JL'06C.)J"I@GC(;ERU406WP_EWL381M-V^ M9._9=,C4&M5A-*5SS(# UZ8$'T1W_A MXXF8W_+/,0]O;.YNMY*L1E^&\BLWPLI8';[>J$0"W !]FK# MW2: F[N1\KW^->T[7&!=]%F*(Z5[SUS_'BZ%'-#H-.[SM*T"VP3_TD96'<)M M'9$KOF"4XS"JU:W>5W%M %^;6E\'Y,"=[MVHS\"R#LA5W[@%_&+]Q5*SL-O9$87# QMYL,ZI,+?W$'OU#%_@)IP01F M][U'INB8W3$,(:@]W""*!<=4/# U_=^IZ*T==E3\AT@&5$_Z"C=*IS]Z 0Q8 MVKYVN6.!H%K;+!A_P\ VX3.H"NQ>)2X7/$37_!EP:,W6,RF82C!#U?R%,JE$ M=IA\MPT$V9";ZA7^THXZZG.@HH"Q4%^K:)K-F%;F53"3 &_"BPBY'%URQ0*P MOGI2O[:5^"+>5:BY.PQNW1^-&+;,#\ST1]F/=Y$V7[.& L7"7:MHHQNNV:.: M1V,F>9#&8'W&22R!X7^A 9IF',12Q],V$JO:X-C]N M=?6V%)(>H#P6 M*T]V%M?',!U-$9 M8WS-DKM;]<3)!CBS1X!51^IZITP-O8W&XSK-BDHP.=#WX#ID84^&=TSC5ZU# MF[_5QI,-^%SQ%ZM@ J,FJ-U3P7ICQ>SCVKBU">#F\:4WQ?>__5$ZE< F6>?5 MKHW(*W2'M1E1RT!5&YEJXX(#EVLUW+?QH!>&=L62BMP^E5LN[;O(KS]^%5>V M]P'OFE_(,F8AFM>IA-B)T>&:G'$^*&\/D(!Y"+6717AO7-D-T M#@NU]&/5(/IZFYP\0^7\UEX&2/X M9 ]*\KTK_&\;@FF=&F/+3FS-;2O]M7>N[8K<]QJR<+"Q^%9NN/Y6+MGB@:.N MBI/_@8)+<0\3*M/W=1D(?2,3C*LO2&N<2OR.=8(LO>TDFU4M8?\!4$L#!!0 M ( .AP"4LD,@LJK0@ "UT 5 8WER>"TR,#$W,#8S,%]C86PN>&UL M[5U=<^(X%GV?JOD/7N:9 ,E,3R?5F2D2DBZJD@Y%TKM;M;4U)>P+:-J6/))- M8+?VOZ]D<(+!2#*=#A?23R%$5[[GGB/IZLOY\/LT"KT)"$DY.Z^UCIHU#YC/ M \I&Y[7/#]?U]S7O]]]^_.'#W^IU[R,P$"2!P!O,O Y)R(,@_A>9VWNMH];1 MJ:<^--_7V^FH?MQL_>K]J_GN[)?CLY^/_^W]MW?[/^_J_L&K>X^/CT>!JB') M:CCR>>35Z_HY(65?!D2"IQQC\KPV3I+XK-'0Y:<#$1YQ,6H<-YLGC;Q@;5[R M;"IIH?3C25ZVU?CG[B8S^QON MDR0+E=4O;V,)_5L]+U;77]5;Q_63UM%4!C45 \_[('@(?1AZF0-GR2R&\YJD M41QJQ[/OQ@*&YS5_)J99F)OO3IK:_J?[A/M?QCP,%"=7?Z4TF=4\7=OG?K?@ M]*68\9B+1(>^H0LTRBP;RIVO=.B2LP"8A$!]D#RD@1;0!0DU"_=C@$2Z.NA2 MT[=R^%Y)%2)@B;P;WL6Z%2@5?)WGFZI\#0B71(ZO0_[X<@B6:GP"X)/03\,, MUXURMP $I@FH*H,U 6$B\V^R2->;K46#_6GQ]1^?(-'/[PD^H0K7Q>RS\K3+E*\)9:GJ M3YAHG*C/NU).C\RREOK V[X:8 0HD,KS9-93?7C29H$>=F)= MQ*"2*I7@543%UK(JDBI!L NBCD<17:;2LQ$=A-"6,AO1W86P;OMV^%_'7D[[ M,0K:-P3EFC*5RWV#(<2Y8KR">8$AQ#D*=NGLKL,0W <(Y+6*6U?*5.?^*O'C M4<19-H$Q=1AV6[S\5VP;:QV&'3OFQ*'4^W\0(=1H9QPC+(9OC.]GX-^DB:]/ M1/4W!5_ZNG(U51N"4#@4=C7W7?QRR659WE>]BH,CM7H(RND]03'X+P-9"/)J M"L*G$ER;\KK9P7'N!KN=F!@FMT9K0Z69"/J M>!72JGRWP>P0V7%B$LE\/+:T7- MEU"]C!-Q,MZ!6(!/,SCJ!I_XDG6 MZ63 (7C"_9%0IE.2.Y87-XWMV]9XL.K8.B+ENGF'8M:G$E4!JE/KP/QG5WG/ M1@\@HC[X0"=$S5WE92J$>2>W6C4'*Y%J82C7Q:](=:&W.9EZ&C4N[5GLWA#S M!=SE5+]'2G5/0$QHT($A**D&5U.=[H#*9>^2,0CK;OZV%;XA<;@%I%PUIRA4 MDX5('Q6^YJ+#TT$R3,.V;YTOFLT.5@%FV)M6B#!DENO:S?WND9D>S_2"A^\+ ME03=4#*@81:;2KV#6X4'JXUM [)!-2@6%M)8EB8E($ F"ZVK %;,+M?-WY .RN!OX+]DF5$%J+%RL/\US_L7 M[WOLX)R_-9,MR4Q?W3W[Y'NE' +Y%P.[MF!>]!?Q_IANPVKTU3_T*>P)"?7& M?ENU;2%FJLEFBX4&9ASMT3"VHK55XASA("8TSZR>EV-T3VUO84:S?:'/C +Q M/F6^E#*S90?+Q?:%E:+7B+<(%VL6I6L5]B;D9+TOG#F!0;PQN/&*D;F!FI^RE[2L%$D=M,=G1NJ L+B]J[4[DK+VHF@DI*(YSXJ M:9GO-F5^VZ:NI:41D.5.3RD"Q/PLW>"SKBNL%=TK9M;=1YQ\M8. SOWJJ92_ MRRY)3!,2NMU3=3'>*^I< "%.ROJ0$,H@N"*"43:2;=]/HS3;0^G D/K4?*') M;KQ79+H 0CR+==M#Q+9%N&VVX;#'AZ*_7/+3OBI45A@71PYT[,-.ALN1 O=U M<*=:\ M_',W[ZU\OGC]5\VM/RDZ]7<"0Z[??Z7(/9 KREC(NU(PH/^2FDK)B+?,)TRTD8Q[,W\*7-4/S M <+7\P*;S S'"E\O**@E.@>SV-8WRFBE) *J=]# UH6T$A;,[RL]W,O1")2P MU4UJ'"\TS8[RJ#R4YV>UYX&P=PHVP^_*<(D2XIG:7=%E2\Y96OJ[!C:&!O%& MPT>A/.P)/C1N#Q5*(2#:(-=50@JN(\[0[DD(L@\38*GEIM!:202$E,AH[4C) MJMN(R= O.+H;+IPU'E8HE-L/(E:<1IVPY.U\,88Z#4K/91'P4:&G*@& F9OY MO]D*]792$%%&9:*]GSADDU9+3+RM*F]M?+&!0=S-W4,8ZAN;++@EX@LLP34- M/P:C?2+.A /QWED?)*B8Z,MJ'=6%ASP[YF^GS6*W3\Q9H"">9CU-/!;.7JC. MPYQY;[1 0%B%%=@2 )C'MN+YV@[5-]U9(.=8GC;%NE%,?,O%L K58&-T^ZV; M:KC=A5"^&_KAZ9]99@'\/U!+ P04 " #H< E+VVE+RRTY !QY0, %0 M &-Y>ZKR'SI]GKO;LF6W/;4G MI^1;QSENRV5[]N14*L6B25CB'HK4@*2[M5/Y[UF@))N4<",)$$O:\S+CM@%R M?>L#<5E8E[_]^\]9_.&5T"Q*DU\_#CX??/Q DB -HV3RZ\??GJX_G7[\\.__ M_;_^E[_]MT^?/GPC":%^3L(/SXL/EW[N/U$_^"-;]_\P^#SX?/8!?C@X_30J M)I\.#P9?/_SO@Y-?C@]_&1[^GP__]_[[__MP]?CTX=.''S]^? [A"7GYA,]! M.OOPZ1-[3QPE?SS[&?D @B79KQ^G>3[_Y'FQK2"[I(YRG-&5]? M6(,O\F=\ 1$["GF1)B%),A+"#UD:1R$;?^=^S$A\G!*29[JBZCS)@,"/Q6SF MT\7XY3&:)-%+%/B@G2!("U!/,KF'%P<1R=AP#(N8C%^N?)K '[)[0A^G/B67 M)/>C6!N5L= M!G],TSB$=?;JSP)FV?I]9@?O9 MO/R*?X-&3^E5ED>P#2#7?D3_[L<%M"F?,5XV,@.\^^M[V:',_)G 6Q?O<)_VF\A%(^Q]34\ MPD&/E.OE^&4\9V=(]A%V^A)$C^P#PH6?3:_C](S+JLT7/XX_*J$)CM#K$S [.Q^7B,NG=14)?@:8 /)3 M2%[\(LX-"LAYMD%QTYD?)7:D73VZL[#EE.!06&Y3^\JZ7S\.X#'E./XE M@.,X#,NKN%Q;X5L@$_;#^]_C%-:T7S_FM"#]D'=+)GZ\'.NCGY%HF&VT\@;' M9P.+;$EF.B5[;UQL,\='P>?LL!_U+Z6YK*V1&[JO-F$B'UI4O&C9KFN=K\=M M?7,DYRO["*^RO:TMD4VEU[=VAK3^#H&O_9Z7B2=XK&)I8$V\8YLJY^WX3"T, M:^GYVC[N1]LCD"1DTES'_D2@[EH;[V37]+TE/E_A)_T.[WM"HQ1VC^$EG* 5 MX[S6UONZ:P0(8?")^-HO$==1%OCQ?Q*?7L-O5!OHC=;>Z:Z2P0'"I^/4!1W+ MH:)/2*6]=[;;E&Q X9-RUN=.Z(%,HBQGMS)W_DPT5_&:>H.#7>-""$-P9#OH MDX@+@$+]^"8)R<__( LI$QMMO8'-@YA%*G@X!%P,^N'BHJ"T-H'*%W%1=1:^D-;-J4+'XJ7^H6!G6L$#6_.UI<)+W[V7*J]R#Y-?'_.QM#7+R3.L_5O MROO6RF!:_=I[N].572J(&WMG'2<; Y*+[A7X#;U3FT=J[I6"0GWU<2V1&L]% M@@'6+F(_RU8.-()+!F4?[\SFD4/KPD%"EX)7+A@K]P[MV:K**#21BQM[5B^$ MU/<2>CKG\R1 8^6NPB5!..XRC#-E^7ZC V-I\DIH'L$L<0^/)7#("DO1O]>V M1CSZY#T]NY> \OV;XJL1$*F<.CZ6M]H8<^:W!"M7+1U6(#^;LB@@^!\+*WGUXS(N*+_P*5W F;F,/I"M0SK] MO3.'5\=J2@0+DC8R*Q:=.;QZ;DN@ M$I"=BYWVQ-TD+*XAI0N04T)4M9EWYO :NBTQ6P#LW.JT)P(V.7,_"J]^LL ! M I/ .)\26H,IX4>CMW?F\*JZ+6VZN.QDGF:1;")+<64$%9O"& 0 M&"V:$L3#("#$L9%"N2:!\ BL$NT6HZ7L L4[,TG<1OYS%(,&"T(.$V$ V[AL930 T([!PJFN36#FV8@MME9]:/J]D\3A>$K-(K->)8 MV1<@(S"4M&-6$YR 3V=&E+LT)^O1N!+]WJ>EV.Q2*7J)2*AFML%3O(%+I_-N M'#>&*6#;F9&ET>?*&\(NO=2[<2="(Z#(F>7E'(V#)G4O*>PB'TOMDHRD 0F%K:\,/'XN ''@+CJ!U[@SP\L#2XJ8D'"=6WT4!,6L*,^@L"F. M@DBVS*D[ V@$1K5VE.JB$U#JS/:RC;;13@5 (;"6M:-,A$9 $0:#"7?_U>'F M"0 C<"\R?,R3(!50>]1O2*>I4A8[&/9IN&OE9*E TGVW+ M_5?LYV9 V,E7F]O&+L&?)6$*:OEP]BS\\^2KU6V@@?C/4NN"PYD SYY%@ *F M70D!;4P6VB#0.Y+?)+"-(+=I)IO]:NU@7D%Q4&ZRE'$ 6,F :!F]1B%L M [.EU&]@;V9SN>VWR6- #RC.6DV(;(X/67!H;22.7F'?S=;JI[1BJUF=,\[] M+ IT/TKUDT ;"(YF'3Y;78C(0E!_)]%DFI-P]$JH/R%W!5,0+!'LX%7)$%0" M@)/F):NR]W[ZX_#>[H'>X C!=7DS^KL@11;LNGGDUJ=;T1/0(KA8;\:K%B1I M:"M6RXJX3J8#VTI-&!(4M+1F7?T,X@*T< TDL@)%15ZF.-NV"NE89$R]PAL, MW=EQ^.PU1Z.T QE]$7PE-B^$I78DL[0+3!06M+4/UJN.VCA?\!^@L']9?"M0 M8_/FO)D%S<*@$US9VE8H,AL>7UR6Z5II+5)U!;Q6#1+:]CWKG#892IOZ068O MM#P><-D2$0\,M+;)=>Q)I;2M,C6=L \@1> )HO>A"LY,V07DCAPD)D?S=Y]#H8VK[*1[MP4ZD!F?NQZ+S<86O48-W!W6FI=^SJN MQ(/,.&B (US['8-DJ?8G[MR1NTTSHQDS(MH[<2^?#QI$<%?;A[G(H+KDR?EP MF9[OV(Z#86YE9Q8D(Y:^\=W77+,4=-=' BE?6[@SB["][1.D(HELN8V?P0(X M^S;3&M)X_4-KB7P?3*X7:1*4%<$8BH.VS2Y:,^%V MJF6ET4G4!7 BB'/7^]8$FV I,F0VPD<_)B#I*TD*EAY;21NW/2!#$!;=A3,) M+&2VP^_^/U)Z461Y.B-4=6&\W1@P.;_G-;K5$4%$9@%DINOQ2TU8Y0(H[ ,( M<=RUBI3/ITJ!!YD]T#ACN/8J!JFS8!T4%6A:O7NF':M4.I4U-#=$6A2[2"4FBX'$:S>?*E5/0W#NQ6IE:<^G4_I!X&Q<9,'.% M,00L7/JY?YM.)DK];S5DE^,[KGH1)FS5+R0E5,X7RPT;\T90[&$:/ 4T9O,: MH/^]3&/LV.IP2 "\BZ_EC]SP2: .JV9F[;U.8PH;CP0Q?&R5.YR.!ES[(G?# M0KE7A@&2,(U(1ID2SE/.O- N?8C6B8\/U^4&U.M,[^H#T"U>>7DX(0O1XJM M5,:;N*LS!O&S@I)PG#RP: "ZRA.4_9:DSQFAI7/433(OI5>R.ELXKD,48T Q<.RH!5MICWT;>+@6(GPC4+F>.3-BO2W:RQ3E+. I M3244\,F3 <-6WL0< M:;CF9!OLJ695=Q5-*D51%T_43S(_8+)EYXOJ7U3&8>V',&TXSZI@UGS<%#NV M@BE5,94?\79C=@>.PP;3F DUH36(\G(HNTD5:CR0B&O6 MM<6FX U.'-9[L9*"J(T"!.P[LR9M;0GN8?&"7_@3,FBR7ZIT\P9? M'99VLVHC*3@]P6N&P" !R6;K'*6QVB@".'P6X.:JW9W3,YY+JY M&@3CP5PDW'<_9PD@%S!;1&DX?OD?T60:+VZC/XLHO$E>298SD83)"C6[ QBK MMVD..&T.7\"EN7BZ6CC:6RS:^$=":#:-YN\+@HA-[0>PH[S#9$+V"&VJ 0&G M)_TF0%W9J.>;INYN*4^1E"T_^NKL_-&Z;KG50M>-ZY:7&N2O2#S!]R$/J6&_ M?JM5L3L5+A<76%; P997M*M;^%>K66Q,^.XSK0O.;@(\V-*$=N<(ES7-(%EH MLWX^3F&K\$3H[)(\YQH7P=SV@-"Y8V.+&5 ,!5N"STU)E9^7H($#IW/FP^ M)TJ@($OMN27I[U$^+4^Z[&@+A_&G] K._!KN:@V?!-K X?HMX4J37!V@R(H% M.:4=UUS59%?FMO<("AMJSH4^#= MVY)0$0>3+-4(;YGT[=9X!I,5FJRX^MC2=S9.+G2")<=Y0K$3[ M5<&Q)<9LI7]D^Z 61.!-1WV1#?>-)RW:3+) M]>^H>%-NUJ?U1KO5E4*.G-=+[[H]K0#!ED2S+JA6O0-1%V]P>(;C("[4O@Y9 M6X"PI9\T31FN6=$D=S82-PHLNJ-9&>TP2L('DK%I(KQ+7"L^TF&D3-7DS,QT69"GM'+[&I'LHJ"4E,4;[](D6/Y#MA_4>X(W.$5P MS]PP%K 1-FSY*V\2..##KNG>7[!EMB&M&KV]P1F"365#2K5Q84MBN1;\ZN<< M9D-2]9C0H)'3RSNS&L-IESXA'G1I*I>Q<;^SN/,D'].':#(%Z6&S'&7DGD8! M>?MCMOIK)LWET^9YWIE53UX[5'= BB[-)0_*7<'4-7YY9&4EHG)M\>.8A.>+ M351-AX/^D[W!P3$"5SL3(Z,Q:&Q9,T>S%'88__27&U-F*[F,LC*+QSTELZB8 M28:!LB_#O'M3@"XL;$DSZX8NV&J4Q@Y"I9D^Q)W8P<1ALJ^VFV<5'FRY,M?S MQ%V:/Y(\C\FRM,^%GTW?:@*Q\1>GK""0A,EF#P(E'N[>T:@51FS9-&_)Q(^O MB33AWEL;9F[>/9XVQ9>GM.PK/=-%.IM%RTQ@:HP9&A:FW > MB^=_D"!_2L=T] K"L#%^G=(Q_-%G$M\2/R.W&EFL"KF39\,5)J1ED^;Z0C9Q]NGRS-(0L9"$3N.WM1P_W M!J$.&UEFLN8QB(=6*PZUB0$M]2I1?E5P9(G%6JD?V;K6@@?5LN/,-/T==#@K M9DI&:NT D=6D,IK+T.90YS/!D1Q90J^^\S@=#M$D:^[CN-I,+YB3?+7*)#2P M>U=D(P%4282:SAK"O/X^45#W\EX[9C\J$)TK.W6LFP6T_0 M57VO<*H2M&0R6JUSHUQ?9*I3*+D&P7IFKLYJQK$S_;J"4\6 [KE(;&+9D8C;HPS'#VN01;RXRF)Y$?1@./^%#!QR+6!+4L:15ET:1-3'&QP>X+@NEY.@35P-%K;, M8^:IPS7=FN<0;SHQ)NCX9<1\=B=$(WL.MSW#^"_D^"33 ;9,9!4ILV4PH__^ MFZKQ3GGQT_!)S)L1A[U91A>?X'90L64UH X67Q\KSF;$% $,EE(7Q$@A9; MFK1;'Z;K-?)O-"V2L)1>&HLGZ@,8#Q'$L=M@5 $96W:S)Q),DS1.)XO5A)]= MI)DTA8&@!]/*?BV(>H#-)1Q37TN.9BR6GN5,*.40,:73C4F/(,& Z?51#[4\ MJU=?0;5E_?5I&L/+LZL_BPBT$$Q)6+ "F"S@-DW*%@\D P0D!'5<%WE!R4V6 M%>P*P6' ;;6"_*U&/"VWO7=X8NXK>5?=MEI%D:UZ';W#8YMWQ-*(58G>.(-? M$\H^Q)F.?O@TU+B"JK4#^,[#/)H0);" ;$-"%J_Y./4I80>4$*8QEO=K>3-: ML1^<+][;K#*-E+#>L27A?>PG6AFN;;P.](HCJ(3#MN"FPYH6D,5T[LGHPF6( M=3[,+,1]FAEN5[-YG"X(*6?J<2F6TC O[ -($03FV)LJ^&-&H0YDD:.K3$E* MDFOM D":V/?Q')4@"R:]"W[TG)SQ=22)A(?=ZU^@-1Y[=?N^T@-B,AB4S<$ M52[=W/: S*HM6=\E2:U_P70JAH4L>-488;@V2^:94^U^G%G]*W:H"W\>Y7Y< MKA^9T"@E,P(U?99W>(+@WEO;!M,1ISRPU9U1$D."/S/VQL'PP-G:M;%4G^OE MW)/T@D%CTT+1PBRY5*]@LZ$"L@]&27,>\H K!JI@3$"Y#ALU>:=1Q^O $ M1P5N*0/:I%5!83,$FJ8-V2[3,']H+6QOV^GJLJ)[/M_L TAM'N]ZF3KEV)"9 MRZI"*C^_[<;>X5>KCD#-C^-\K0NV^@(\R*Q@!CA"-C>:(TLU+3H[,5RDR2NA M>02SQ3T\EE!*PE)VI65:T=,[.4)0!TSTZ8C.U!J0C%F_1"[C3.3SYKSH=_8& M!P,$3G1ZW#2&9R49-%8DL*DT EAXJNPVVRV(P)C+CZ;2LBI'2JT9 M".>V0+Q(7S*M5D4WE[_,N%YQK,W=%-QC?K&U%Z]LEJBV ?%V]4@AP&(]F]CZ ME?*A7&_E'9ZZ/0D(E"71:%5PZUG VNH4T>S04KG*N6%7LHR?[NIF0X %6VJP MYLFK86.*P_RPH5F)^FN28\O9U8X!'%-4)RJ4>#(CBW#5=_9W <'5H.7>UGVFZ+%EAJK>[)O MJU4+K21I7S*A)K0&$5L>+!/$(=M=6&50F>JFXVU]1H+/D_3U2T@B1N*0_<"X M&U:X@U\MR]A>)7DDG$DYK0#!T:Y.E6(X=O)/Z1*Q%$?XZ6PV 9D=NT>+%;FM M<([DYC(\]:5M'--3)[4K9QUG%H'K*/&3(/+C]\KVBIV=H ?#Z3SHH^,V3@[- M7((G0YE)V.+X0BA+-K:T"4;)9/S" 9$Q1Z>,_R?EIL'D:T"35DU\^OM$.=7\ MX6%!$]B24>WJF,*Q1J :7,HUQVFB]"B,?+I@Z0TU_1E%?1A6-#E\._B"R\!A MRXE5D7)9)K=R3E-[&"L[,]0X"E&HB!'0J8O07&JLW>$5UTQME6#5#'S4PFHD MN/LNLUS^H%&>D^2^>(ZC8/P"BPDL(7*G.U4_;W#\%8$OI/87Q;DNUX0HH,A9 M\,;XE=!1'*)DV^+,%0L^O"8_]KDL 2 MJ-^9[TF[%&B '$WMG9;;21X@ 3GN\H[L09*JP=&!6Y==&>&"G8L]/0A&F+N M\CT98;@VS B&FG);[Y2DEC)6PAJ ML9DSJ-?D"!* C*=V;K,I,$;# ^0W!IH4, G3P9,0)J[O+_&2,.U$-I@3[GL MN M06&CYKPV02>@UIEEJ"Y[@YE6WA' (CA\=*62CTI H3NO)28JRTA+PLN"77[! MB(O2<"G\'?E1_DE^]-!Y@'=XMI/K9Q-T@@QM[OR99+(O?W^=TG7R[RX4K&<$=%N]Z?V\P.-RG&9V+3L"L,SO4/4T#0L+L&O2P'H2U M^J#2W;6B+XL919!>H,T.6P^9@$UG]JCJ)N*>PG*B<>P5]O$&1Z<(W!Y;?(\* M1 +6G-FB5MX;:Y#K :>JE"WKY@V.[0;:6OORU* $]'UU4,GD>=-!Y[&8S7RZ M&+^L:I>-@CQZ91>'[HJ;\#V)-JT&I9]WI8(>\QS*KGX2&D09*3^B,DG+K49U M%#LO]([H7":VQW:^V$;7H$"+A1?#V=)9C1>;@T2P*O2@RWTH,]/.\?MH M@+&DC#6B^4.,HQ)LM6CVP*WW:("C @Z';KT-CCXX,@@:6W$&!^@YGX11,GE(X_@ZI>R/74X#K5X(.D9P@^7 6F91F\B*T!N$ M>E9HL3X^JXHT5]X,Q]C\5AX4;Y*E1\(WFF;-SU&=W@9J M1> &OWOC4ZA*O#^K"Q&;PN1= UO_##/;LPAWO'54E/FRM_AF."N?LXC MNHS377\L%BQ)#^['/*@?@7N]JV'G]"-8JAY;/=/VE];< M0ZJMT6]."J !K3$7[1=@6OW8:LIV5L :H_,/H9$@0,9^&8XQ? LM&,!6S]> M#K8.]NX^B$:B "'[94O$\4FTX !;<67[!@)'1X=N@@%9^V7[1'"B,,$(MIK8 M774R"L-H">8RREB,3,&L(L]93OT@M_AU2-\+JD;K>(S9;J2A5&SUO4L\SVK( MSXUGF ?"6(;?7Z1)J8#"CY\(G1VJ1G6_T@ M>W QH#'R)$/>A<:QU4OOJHC& MBYM(/P.+WXP,;&YW^="H8D/MP$UR'W<_E5_V=H&*'QO[^!I'UBRV>6@4C M=VT?'[JXN%8'!.F;ZKBF(M-\! MGX?-%#$ML@TUIUDPXYA5T;]P$J$AQN*Q)CCE#QP.^K_R!9E^'>@51V$C#MNF M[UQ56O@K7Y -O>**:W<^S"SD"S)4H; /(-V%*Y'64P5_ MS"C4@2P+D4[NH$KRAF.;QGI\NX\-Y,A2\I32*3_/2BM 8=5,K;W.;^A5HORJ MX,@2SK12/ZZ%L T/:-.I? <=SHJ9DI%:.T"$P-]]:ZCSF>!(CBQ1R'?_IQX' MU7: !(&?M2X'VY*CRXAAI73QT;'-+!7XUGX-;6!+-&&F8N[1L547;T-5CDL" M!#MP,2QLN1V,,89K7V&>.M6NPW'R@S8N/&_W2)6;IK<+-5L.7,J7@K+1^NP: MNXVPK+V]25_ P_L097]<4\)N=@DE6?X G_IJ8VKC%K&A"$# +MB=8Y$,YJHN=RZ_0!/TZY7H[VD,CXEA(^5@;I8* M 22@]9-%.: UM+ESR0(,X.]WAI8* 20@,"#N_I"N:G/G O[;X+^,7J.0)"%# MW_=(KKX;5([ ^KJ# WA;B?*8_+X<6R]2Z)"46),LC:,0Y O/_9@5"7V<$I)G M]P UR:02SQ3T\EE!*PE)VY;6]HB>@1F!\%7TZ M NYT(!ESVA-$192\Z'?V3@\0'%/UJ&F*"IE;WN,4MN/L-NB2/.<: M 1[<]M[15SRNEOH;##$49,Y[6Y)JN,9S>\!6VNJ'U:"LH%#WFF15 2'S[3-* M%[(=AT'>5%N.%GZ!@A7K@<3,K'#OTWQQE^8DN_<7;'88YU-"5S_+ERW])WB# M [OUS'5-5)+OA;."-0:(S8]P%,?I#V8UND[I95H\YR]%/ J"M$CR[($$)'I5 MF$#T'@!C'<.E4",C21-DV+P$Z]M<&)YC6H(/2T/G/:&E*51"J]X# #P&NW(C M6IL@P^9*6)=],^N/-IV;'0$LANIT'6CD(\+F1LB3>5F\K"%URTX $D.BYLZT M5=%@+#59F &BYLDRVG!0/Z6^+.4YFQ&8-EJV9E5PIZRKS9D QZGJBMG,IXM:%KI1D$>O4;[X*QF=V$WLU)T5>[>2T9W://A; M3T9W*DZZ;59%^^ MNWG9&? ME:*[7I:BLW&K9ZQ+D E7:T;/PQT@L#KW<'P:JDI9-DDNRH.-/5"HIP5XUM_*A:G-\[; M0*L8?.!V;GH3JA*;BVQ7H)S2[Q9'*.=MH%8,[GT[-T*%JL3F[=L5J+K6E_5# MC:X(0 "&B^B=&\O-](O-[]D2^CY/[;HB>(,C'($P>S+"10K&YAMN4.$;Y:#K M=7^!C)<^;:::PL"\@\&)=E?LJ8VTBLVGOB<]N!_?H/Y=OB3H..R:D\(8'^W4UT<<78%K]V&(X.BM@C='YA]!($"!CO^Y!,'P+ M+1C %AS360<<2ZJK#Z*A*$#(?MW=8/@D6G& +0[)P,2P9;QUMTHT$@4(V:\+ M)0P?12L.L,5XV3<".SI/=Q,,R,*0!V&W/I@>&)$'UNW-Y^/>'-5-,&80WV7; MZRY]/\TH$7Q +>Z9!1G>NJ+

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

7)X+3(P,3"TR,#$W,#8S,%]D M968N>&UL4$L! A0#% @ Z' )2YRU-7)X+3(P,3